var title_f7_45_7888="Laparoscopy surgery instruments";
var content_f7_45_7888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laparoscopic instruments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These instruments are used for grasping, biopsy, and manipulation of tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_45_7888=[""].join("\n");
var outline_f7_45_7888=null;
var title_f7_45_7889="Dopexamine: International drug information";
var content_f7_45_7889=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dopexamine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4323554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dopacard (CH, DE, DK, FR, GB, IE, NL, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1978593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Dopexamine Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sympathomimetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inotropic support and vasodilator therapy in exacerbations of heart failure",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: I.V.: 0.5 mcg/kg/minute, may be increased to 1 mcg/kg/minute and further increased up to 6 mcg/kg/minute in increments of 0.5-1 mcg/kg/minute at intervals of not less than 15 minutes",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution: 10 mg/mL (5 mL)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10371 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-85.214.214.87-D5DBC4741A-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_45_7889=[""].join("\n");
var outline_f7_45_7889=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4323554\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978593\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978595\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978598\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978594\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821206\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978597\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10371\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10371|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_45_7890="Osteoid osteoma xray";
var content_f7_45_7890=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Osteoid osteoma plain radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 483px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Full and B) coned views of the midshaft of the femur demonstrate a dense sclerotic zone of cortical thickening laterally, which contains a small oval lucent nidus (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eisenberg RL. An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_45_7890=[""].join("\n");
var outline_f7_45_7890=null;
var title_f7_45_7891="Necrobiosis lipoidica 4";
var content_f7_45_7891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Necrobiosis lipoidica",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 474px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHaAV8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC9ZoFgTJ5JrRjiGAe5qlapuiT29K2IotwU54ArwWfV2KUUQG/Az1PNNt48RFnGDntV4bQGBXOTinCIbSuO1BZVhgVV5OeM5psKLKcqfl756VdRAUwPlI4yKiEaxKUXgE8Z71QkO2IUPKgEEZ6YpI4hFEGZuF6e9WIIUa3YkdDjkUkkJkjI529DtHJpkjoS8sRKcHtTLqNFTywT5jcj2q5B5NpANwx6A9RUM8ySPxtx69yfQUMSWuiKFzCIlLEnA9DVeNfMILZA6gnrV+6bcAWUFR1C1CoWQgJ1P6VNzRFOS1BVXU5x0GenNQTxqMdMDg57Vbm+QlQQrYqmP3hDcng5yM5pJlWbIGkCKOM4x+VRuw4bcVbqff2NLcwlgCPmXPYdKrQZ88oSSpBxgck9KpFqOly5Eu1SB8ynnLdakcLjA5xzVJZysjR5ZlTg8dKRJEdcxM2Se56VVjNpsdNCB93qvIU9/wAajWWMn7nOcdec09rRmIyzbs8ZPWq0nmRygEnzD90Y647VS1RS13LMh/0VpS24n9Bms9YxcZ2jLnvmrHnmWMwACMHhyecn09qg0otFI4YKxP3BnpQoitZXI4YHjOJMjkjf1zTBb53HII+laF6zJ+6PIA6qOlVYkLTKAxbPbHNXG5la+pmW4lhYDtycVoSsGtgc8f7J5A9KJ41+0gkMvZCexpN24Bxjco5/CrIlEuoW+ybX+8B972qCG8SP5WbcM8E81TuZiWA+YZHBBqGTLDLEAkY49aVg5DXe5WVfLQZzjJBq9Gg8vhTuJ71zNvIYF3Mcj6c1t2uoKxVWIOenFJmbiaLjeVK/w9Qac8Skc856UtuyudoHzH37VJcYVgIl3AVJNiqWKhgFOR39ai8tBg4xu61cVCwbHGT09KgvFCEKpJ9c1SJZUliIbcrY/wBmoZcsCSald8EhQCMflTcK8ZIwa2RzyWhl3CKCSF5rF8QwfaNHu0A5K5ArpLsACs26UPBKFGWKmumDOCqtTxMrg7ewqRByBUl1GY7qVWzlWIxQo71qcw9F6elWEQZ981HGPSrKcnNMCRR0qeNOOKiUZ/CrCfKMUAe9aftEYbOeK1o3XaPU1iaO/m2cTrgbkBxWzABjBPGa8B7n1qs1cnZAQpPbmkVmMy4U7MZJzS5LMuM4Xr71G7bScchvTtTQx6OzSN/dpWxhMgHHPNNt9rSAEDao7+tLEnmvtGeOjcce1UCJJy7Kqx4XB+anTyL8qKGBJ7UgcMW3ncxIAGelCFAz+ZnC9/8APWmKxDeZCMUGDj72aryxmNN0ZwGXHXJJ9qbLOWzz8oPBNJ5gVGycYxgg8g81DZoloMtcljvcbWPBHQ1NHIIHZW+8c7T1/OqCvJFced/yzfhto4FXbhROZCrq0YA5XrUtjsVLyMvmQjAYAVGQUG5zsQjqeK1haCS38ncQp5BPr6Vlz4WVF+aTBPy49KUXrYafQpFkcqQS5Gck/wAI9MVQtZBCH2bgCxB+XOa2ZoSsZKld7tnJ7UlrbRrnCbgD9761oinKyKdurNbtEyMH+82O4p1raLCjnBOT+VXXzGyYGcHgjnA70zLEvgYjHy7u7Gi5FxnlssYbJ3D3rJvZNjbhjJO0ZPOTVyWSUsy+WWi6Zz1qhdWazgoo6/e5/KqiCQy4tmVR8uSSBuBoij242LgLjp2q1EuzTypH7xRt+Y5z/hVWC5yzgbiB1/2q1WplJvoSXF2GkDYIP3RUigpKN+M8E4/pUM0eFVSCJG5/E1Zt4mi5LZAHLY6mhuw47XK9/E5dsgj0qGONhDhsbsdcYwK1vL82OPcc8ZzVO+Bi5A4xn14pKXQRmIftDGM8MFIz/UU2W3YbVbkActT4gTJuUYYccjqKlUsqHzF+XGOD3qmxJFTyiqlSOBxzTUyko2A7T6VamyxCFSAMYY0eWoQbeR1zQmZz0L1rIYmzGDuPXntW0hKwhwSzdcYrCtCHdRnOK2bQEs4Ykk9KGZNliBg5GOSe1Ur/AC5ODtwcZq5bjY+CeAODjHNVpRidmPTOaaIZRdAh+bPPGR61XjdizoT681oSFiwIwwJzjHWq06dXII+laxZhNFK4yoGOeKpuwUglevWtGUKIsEHJ5GTWdLnaCnG010QOKqjybxHCYtauhjA3ZqivQV0HjmIJrO4fxLWAo4GK2OMniGcYqwg4FQxj3xViPqKYEsY5OKsoue1RLwvSrEfSgD2HwLdLd+HrCZcYaMAmuqgXHI5Oa83+DF19o8NRxfxQybTnpXpIUbec5DZ4rxK8eWo0fT4WfPSi/ImONh4xnGahvCECBV6nsakbAVh79qbLtOMgBmGAalHRYYQQmExub19KsIQAzKmXAx7A1Ayhmj4G3GBzjNTHCqRk7iePpVCZHbNnccENnn2plyjOq8tjoOOo/wAashQgyerDpSgGL535RRyvrSBPqZUdmocq7Mec5Peo7m3KknG4cEAdRWpKy8srLjrx61nyyCXOcHGR8p5FQy023coi4QEIzgLnKrnBz71dgKvcMpdck4IA5INNjlinjYKNxA5ZwBj2/wDr1BbxxRXW7cSS2eDSKNlikcbeVlm+6wPTFUPKKuxfoORn3q1LLtif5SmSQNw5+tUI3kJcyEtz8pFJIjVDvk3Zfn2749aS8kVYQ0QyuBwDjNTyWwKKr4UnnmmrbN5TfLwBkH2qgTW5VEga2Y4K9CO9KnPJGSBgen1qRwicHOH/AJ1WkYQgFTgkYyOaVy0uYm8pUVeeTxj39arXNuMsyJkZAwP5066l8tFLAKOxHPFPt5t5IiAUdBnNUmTytK5j37lHSLYZPMbjZ1GKSODMreSQRjBYrjFXr6yRJhdoD8rYYjuKW2jQTSnJYFQ2M9Sc1smRLYqKjbcMc7T1zyTV4ANDgdu4FV7eLE7hUG0/iavPIsaLEOjdKGZRdiHAVQuBtqjJEfmBOcitDbgkZyc8VE0YkGO2COOxpLQ0uZrRBVJJB+lQ5EihTzjJq/JCI7c9CDyTWbCrsSZAAT/Kq3AVMkuDjg/LxVd9y8gt9MVpBAM9PpVaVQJD2Hp6VaRlJjLEhnIfqBnArfsZI2IAHz46YrGhxERu59CO9WUk2srIMtnvxQyHE2JFCsMk5zwKbId+VYbSOQaguLxdw2r7tnt9KBM0qDyeQe560IzsWIoVIw7jP0qlMil3VRnHarUcpK4xyT19KgeMmU4ariYzRlXClwMLtOcYNVZY8KM59wDWldDzCsoGMfLWddbhuIrogcdVHn3xBiHnwSgcn5a5ROvTtXbeP4/9Dtn9GxXFryAfauhbHC9yWMZOasRj5hUEVWEHP0piLSLkcnNTIM1CnSp46BG58BL9vtt/ZMcrs8xR717cp3Icjk180/CS+Nl4ztVBws4MZr6WiA2Lg8gg/WvLxkbTTPfy2d6VuzJ4Y/3Zz171FJEGmXeMADNWI/mLZ+6T0NIMm52lTtAyCK5j0LlVlPmqigsDznHSnlWSVQVYg81ZY7ckY3DoKadzshbOfyqhXGxRmSTLcbeRVm6kVIiG43cDiglUXaCd2eOao6u0b7VZzgDOBUsle80QsPlYEFQev+NU3t23HYq7R0bnp9KlkZpEUcr2xnOKtwCRYcdWAwTjJxUS0Nr2VynbhY5SvloQRnk8jNPWwRQ8pBWNWHHfFJNGDIxVyiqvXOD0q19oh8pETc0xToTjJNTcp36DYoRJCsZy3duetLEm1ZJFPBbGO2BV3TIPIdbggYX5iCcfhWddSvtdVOQc84wOtF7EWu7ISWVmfor47d6bcX5jjXdDt/hJzmq1pcBZZDLHh8goQOtWtSu4o4lChd4I6jpVeo3DW1it94KZPucsM9aJooZFCoRvxuFVri+WWdlBygGM56mo9OKhz5jgMpyP8Km1zbkaVyS7tN6ZcE49+tSWkSlTgYOedxqOa/jNxsyQzdO9ErtCCpJUkZBI45p7IhqT0ZFqTFLEpGSN74/DvVCymY3TCTdggZPf61bSR2n8ybaFzhcjgVXlkAVZV2gj+EdCM4NaRloPk0sW4HWC5lQlju5yfSpAhcAMxK46gZ/Cs8uzSY/gONrY/SpUkdQRICcDAKnrV3uc0qbRZaSPeVDjOOh61AswSeVG6H7uPWoJUaSMSByyd8njFUobho7lAWLDqC5zinYaXc1ZwskCoVwxbG3PoMmqvlD5yOBnA74o84GRieFVCRjvmpoQI7fcThjyBmmtCHoiCToQuN4AGcVIlqJX3k9eNvrRckiESFcrty2D+tZz3xRwRkED5Qx61av0M3qT3MZjkAi5A6+tIjsQobO0U2NzKhLKA3Xg96YrMs24ZkGfu9KtB0NCMbtzY4HarRCqq7cbehyelVJY2nw0WAeM+1S8KmDzzknHIpEtD7eViTnlB0IqaWdQuFwdxqGNldcxHKnmmMh3Bl7deKpGM1oEyKHIU8Ecism4VQCOPxNaTZaXJ59/SqVzGrhznJ9a1izjqLQ47xvAJNH3H/lm2a89XGBivTPFEZbRblOvIrzRK6o7Hnz3Jogatx/eGarJ0FWYj2qiSylTRg7uB2qFBU6ZHSkBx3h66NlrthcA48uZSfpmvrmB1eKKReVYA8V8cRkq4YdQc19YeB73+0vCNjcqcnywCe2RXFjY+6pHqZZO0pROji+WN/XNKFKsGyBzRFzDgjqKYz7ioPQYzXBuezYW4TOGXrnBqyiq0qfICQKaE3yBT90fnQX8qYIcj39KZD10RQ1Tel4qovRck1Tu2kMyqVOcYJAq9qMimThl9eapySgRAsS2DzzxzRexcE2kU57iOP5do35wp9PWnJe4jKsGG3vnp/jVe4jE8i4OM84oCKm1eDJjHpWcmmdKirE7Os4DBiJAMAgdKn01oHYbmzMv3/as+GPzHCDzZMnARe59feun0fQBaGObU444xMfkQtzjGTwKkmpKMVqV5ne5kjhRGKld3BP0/wAaxXTEe0OwQkgODkEehruLlEXTL2Oy8mCNowF5JKnv83XpmuaNqYbTc8kPkY42Hdu+nvQtTOnUVjnLrUzY3QS4xKwxtPXjNO1S+iuwscTqpJDFuyj3qv4htbe9mBikK7UOBjgEVi/Z3ji86NWAcfIMZAAPXB71ajfU7VGL97qb8aQrbARLuZTkyf0FFveBsKI13KfvZ4qv9kdoVZ5mAYA4wA2PwqH7O0Ns8kTMwVSdhG5h6H/61O19B6NallIwt/8AaGG9VPOF/wA4rVvLhJmX5xgDJA6LXKRajL5jLIGCgZx6fXNSx3gyQHOD/B3Jpcr2QnT6st3NwzyMsa/MvTniorOYy3Uq7coM++fpToyrR7yigt1B7VbVR5QeBFBUYkCnHHrRtoD2GQyRmTyMbBnOccVYuYAYWO7DE9u5qnDsLqrh2OfvLyKvwsqOysFWLPBNUzCUdSiGf7P5SjLL096xbsyLKwZlKDkuFzj2rRmuU812wuF4256USRxGMqPnJ7Y4BqlIlxKimUwK8knAGAF7j3rTWQPApQ4XH61nxqyRlW6jkelW0XHIAK9cY5rQ55RsNmlkWMRR8AjrmqH2ZjIhc5A4yDjmrd1K7QuyKSccYHSorSUyIqxjcM8t6VadieUfA8lu2w4IYHbU8LOqFymG449B60eS8k3zldyjjFRNLhSCO/HFNO4mrGvv2II0Vfc4PNEC4ZvMG0jgY6GqFtcbJljkLeuW9a1lkSSHG0M+eT6CjYzYqmEQMwGHJxjFV5GCKTu4bgn3qSRykyrhfmpHiWYBTxg9aaMpIiZdhAOOe/rVC7PlvjHBq7KmyQIxGapX+WkAHQCtYnHURiaym+yuFxkFCa8oxhj9a9fv1zaSgd0NeRsuyVwRyGPFdUdjzprUfF0qzEKrJVhDyB71ZBbWp4zmq61NDnPSgDhIVyRX0X8D7rzvBxhz80UpG32r55gA9a9i+AV7s1S+sWJ/eIHUduKwxMeamzrwUuWsj2wIccHtxUiIgGXODgU5MCMZ70uAUQqByeRXko+gbBkBkyuRu4JqGSEk4HXJqZSfNOT0/Sq01wC7YY/L1waYRTvoUdVQK8RUqTzk+mayinn27RbyrKw6c5Ga0d8k0mH+5jrioeLSQuwHltjrxWMpanVDRWK0yeQEVV+bBJFNlYrGCF3OcKF6HPYU+a5+ctFJlZPmBxgk9wT6VDZXLTalbPHarIyK0gXd8uR3DVJrbS7N+0K6baeXLEEnb777sMfYegqrJqGA3zuOyrmmo8l2sr3HyMHwyHkqaVbUxJujVGJzt68e9VHc53bqNsmnYFBIFAO7J449BXQSLC9miPAjEcYAwD61y2nXk/8AaBM0ZkXsCOtbsuoPJEHWMiT16E1u4oxqXT0Od1S0iJYRKHld1zGBnagPQ+1U9WRopYt0TFm5LHjAroVjWRjIzeXu4PqfxqnrVv51mFwHkU/KBnkelElbY6aNTVXMdAHiWR7lWEfTA4WqN7qLxSfu1BTOFUDj8fWo4ldGYSBlAznjqKuRWr3T7Vj24HDsoGT6VGtzrcUtTJvFkmZpDGySP8/CYU//AFqLK3Cyb2J3YJIU8EmtG/jZmWGThTxk+vpVe0il+aKdCRHwM96uO4SleJKrBFIdN0auCwxz07VZtFEakhnjk/2vukVDIiYKRptfcMAsTu745p1s7SqOdsW8DnliMdqckZXuMmhlN40gBSQZJxxT3F7Cr7kVlbnb0x+NatnERP5chYw/eGe9F3JEJTv3hgOGHP6VjsS5a6HKtCFdnG5C5wQw6H60TF4IUKKxXpwep96t602xSsasQ3TPHWsq1imER3uFyCB3zVxWgSLqXCyYUjqfyxVyOURxnceM9elYdvIYGZHAxntzzUt1dsk4QkeuBWqRzTLaeWrYXzMMe3IarMMMSIxXhgOO1UCRKEOGXJ+U5rTeNHhPznhcZA/lVMjYrmZRII5G2r3Y8Uy7jjhkQxuQDzgc1FLCDJtmYSbccn0qZIVljA3cL0C0xNDQHkO4udq9Bjk1u2ygQqwHQDiufmDoeGBUjjFamkXQCsr85x17VRkzQtmWVjHJnjjjt+NJKQsxAAAHFNgcsku0Dk5BNEWXB8xOexpoykMvQF2uAT6ms26I371GPf1ralUNEBnrwaw735WVR0FawOSoihL8wYHpivJ9QAXULgD++a9ZlPzke1eWasgGp3P++a6YHm1dyuuAasxgdutV1AzViM4Oa0MiwtTxdKgU81NGe1IDjLb9a7v4T3f2Lx1YEthJVMZ964m3UbeK09IuDZ6rZ3S8GKVWz+NKSumioS5ZJn1sDlQO2KkiwFG7sMiquny/aLaKUcCSMMPyqaaTC7VGWOMV4qVnY+p3LEi8EgDaR3rAvZPJc7SAD941qXBf7RFlvkxjbWZqcJKt8u4nke1FjSkrMptdyStuAZUA645J/wAKYwN4VWWQjncAzEDPSq8kpSZAuApHLdhVuBgLtfN2iIJleefrisJKx1uNtUU9SR5E3w/LAo2h24Dnvx+lS6K1zYXjG+TcjREhX+6y49u+e1MuJWlhlQCNhu3Dk8L9KS81OB44WnnPnxfKIlIyOcc9sVKZVm42Ld26pG8qh0QkZjA6DtVm2vFkjcSBiD6jGRWSiv8AZQ8h3EkkLnORmrdoyJEzzEEIBtX1PY1rYxlFWL9rHD56sEwiH5ix7+lWr25STeVMUZTu6k/gKoiNpG6ZdWDbmORuPXipI0edjEzYReAcc9elWpIydO+pBLONqFCcY+bcOD9B2pEmLMcS4HTB7fhVG5byZ9jD5c8Z6irKzqcsMBiOc9TWjaaHyWHT6csqPIUUPuynuf6U0QCBQZQOMHeO9TXTJKkcny5HUZxRcmJ4WhSYbZME5B+XHf61nuNyaSRm64scrqFCqcrkAck4qNAYV25JcnndzkeopZEimRTvPyZ+Y9DUMymSZRC6/LHkgcgnPArRaGid7Jle78t92wfN/CB1qtZzTSqF24bOeeue9XoYpUbGcM+CcLwKjvVaPyyoGWO0kHpnvRctW2LMNycOxklCbsYJ6Y9jSXkq/Z/NDoxVTnjn8qdLaPDbO13tIJCsQcc46D2NZ24faBOOMt0A6AfyrGT1LjFMiM0N4VSQEyYP+sBCiqMFyYpjbzRp+fU+oJrUvYJJZReW5eJG4VSfvfX1rOvXlJwFBcnqAGyR7UR7CauQT28bl5IpAxK7gR39RWcsPnSFyDtJIXceorVF09xbN5ivCgXHyLwD61Vt7JhbvIzlWXP3hziumGi1OOe5etxBjETYYDGO1aFm4eNkZQ2PTtWLYAhiV+ZvQjr71sWqqznOA3ekJodqFsptjwQxyBtHWoLOXagDZ3L7YxWiYgV+cMB654qpNEFkIB3AjrTXYndDJ0Vx8qqe5PanWsSNgxkjB6A1AsTK7bT14HtWlp0BR8lMDuK0SsZy0Llkvzt9OnY1MTt4xjvTTFjBG4c5p4bzU+dSMdPekc8ivdKXVWiJ2/yrJvVJdQOmK3pdiRMAABWLeAFNx4xzxWkWc0zIcncTjvXmuuJs1S4BHO4mvTpo8YYYA7V514qXbrMoA7CuqDPNrKxlLipVqJamTHYnNaGJYTp71LHUKdanj6CgDlYFwg4qVuEPr2pIRlRUm3imI+o/Bd4t14X0qUHObdQfqBWwMFULAK39K4T4M3ZufBkUTHLQSFDz0Hau6JEcbseg9a8eqrTaPqMPLnpRkKu7e0rfdHQfSs+OdZxJzkc9a0kUSxp/dYc+9UryErG44DMfpUHTC1zmpmzcNKThF4Hfdz6elT21wfs+8Rly2dxGASf8Kq3kI83LAAkn61Nk29ptZmUYAJ7t/wDXrKaO7RopX0iMkTMJoyh5LH72egFVr+0jtYWlQoJZBnB5YHrWhdwXF6sU0aB1TAxFwQx9Qe9Vk0/zgrFnPBP7zGMD+XUVlfqaposaSPtMFuZgyKRuOBn8BWlAd77nwpIzt6/LzTtJFu9qI3lZEjyxUDJ+lLFve3uZoNkbjAV5OTs/lmqVQwlqy3pYRfLMshRMEkSdgO9JezRqIpoZ9w5IAPb0rIDy3AmW5jMqg8uinaB7+hp09uke+Fm3ylfMjjjkBxjqf/rU1ZkcmupPqwWV1crtlC5PPWq0zBFVkBJx61W+2yZSG5Z1RiGVsZUDPTHXmrwKsW2RtJFkjKAZz9Cf1q76FOLRXmfdbbmYByOR6+9Rx7ktpVXJYckA1Dq14pEUHlyJMG3MGA4XvyOPwq1YOHiLkcAYx/KqTFKOl2VVcKnOFIHOe9Mjnh2yEup5y2Tg8dKmvo1mySACMk4PGPf0rJSESNl0BBI/h6CteZNEwV9zZsp4ZHwkiF144PWpryD7VLFGhGIF8x/cnIC/1/Kubt41tbxopUUsOVYnAatf7atvCI4EkEJ+aQx5Yg9we+OetRJdS+TXQeZS9pNEoLKi7pHYcKR/CPesWR/MtfNgIw3GB1PtVvUbhDavFDKwUfwFdpx61iQPsZSseQp3EDgVkzohBWNKO5lht4o3jZkxtLqPy4qF4pI3LxqGJOGJ6jPpWkqIdiuQN3OM8Gn3CrAPMk+4TgN2z6UKRlJrYi2KqKrdMjb6VXYBUdXyPm+b396vmEvtKngc49jVAxOSzhjtzyK1i7o5J2uVreAhyMsRncrA8/Q1rWOBIodeo9O9RWjgqVYAnOd2Oa1rZAQxA4HI+tVchizorxGM8HHGRxVJEDcHOfrxWhIm8rubG3tUO0IwwAF74q4slPQitoVkbJAAPHWtC1j4Kjr61HFtjIKjj2qZBsBY5PcVVzCZMkWDyxxjNVZj5e45watbyV3A8DqKq3AEnqBimjBjZXBUZ53c1m3KgoQeMVdcuEKsAcYxjrVC9Duu1mxmriYTMmdjuVSeO1cD4uH/ABOHz6Cu+mAVgucla4Lxef8AibH/AHRXVTPOrmLUqL0NMA6VMAMcVqc49RViCq69KmiyDxQBzsVPOeaIxgZpxpgeufAWfNrrNuT0ZXAr1eTkMu44x+deG/BG4MXiq5gGcTW5OPcV7lksuB1+leXio2qH0GXSvRS7FnzFjtd7HBHHJrKuHea6UEExgZ9+avedvUKQMA4OR1qMRbEZlUYPTisTti1Hc5a9YrcMcZCnt3qu90+5QATuPG7gL/ia3p9MjZcSbgwBx71mTWyvxINuD8v071Moo7IVFYlIjNuqozKzc7h1Puamhs1jwzHzC/IUjBGR1/8ArVUt3jaTYGJHQKx/n6VsR5Do77WUDIUHGSOlc7VgvYpNaYuVhjwDknd0AHp9azdQmmhgM0ylYSxAYdOD0IrSuI5I5PNlY72ySFPHPesS/wDNunjjcbLdfu46jtjHbPXmpSNqbuyBr43MO3Y6EAcDkNUltYuxjnUFHQ5jwM49aZ5Js4Q4bcg644xk9vWt6zsgI3mWaKFfLDBXbDN+FU9DSckloZF8uCuI/JLYyMZB/PkVLDeCFMhGMrKFUlQNtWA+YwEAllbo7DgL61XmhdmVnkARUJGBy1MScXozGvpJpLpGlKlFPzHnjPGTW3AQIFMMsZZRsKHv71H5EbGOJDujzhiTyTjv7d6LFI4l3OjHI4IHDGqe2gSaaLJAaCNWQiM53IR1/Gp4YYW+RyoUrjpnH/1qpXIYQrKpZI8/KnXPPp61n/b7hLth5TtERh84DAn0oV7GXJzF3VZ9NZ2hhh3Erweo3eoB5FZdwxh+QBUDLgr13f4VeS3jmdpImwQcnIwai1CCZASy+YG7sOn0NCk76mqSjoMmcTpCZU81YQP3wHzcDoR3qO9t2kCXAMYzzuVcbfYe1UZLmVY/ICEjqrD09a0Y5D/ZrszHb1xt5I9aqTvsOzSIVKSOhn2CLIYSkYBPpV/UIYZrUqrspI45JDfh61l27vcRMrbRC+PlAycVZ08yQPIq4eMtlFboPXFKxlOPUsQbrdRGW8wBQcnjtU1k6PI4IGH6D0NQtbyR/PGch85U1SQOsrclWQ4OB0rSKOaaTLs6rDcDIHIwM/zq3BIFKDsT1qi7rORuwGGAPU1atgWOTkvitLGWyL0eGmTHQ8E1FfK0eRjOOh71IcqBnHXOKlugzYB/D2pohuxDaOskRYcKOtW7Z0lA54HFUooTAWCltpGOaliIjPy52NgVRjU12J2YrOwxw3NNbBYj8qe+CxJ7cVFINpyOhHFMwZFtBmDnPFUr1QGxjqauPLtdV9aq3O4Y3c81cTGaMS64dgfXINcD4vXGrkjuorvr4kMS3TpXBeLSP7V4H8Arrpnm4gxl6j2p60xalVea1OckWpozk81AO1TRnmgDEXpgUpX1p6/cpMZAFMDpPhndiz8b6axJxITGfxr6JDbZWGehxXzB4dm+zeI9LmIICXCZP419Qhj5kjdiciuDGL3kz2csl7kl5gFxHzgEmprw+WkQU5XvtOcVA78q+C2Bxg96J5S7g9wO1cp6F7sq3UyF1GD5jdPSqbwsQQFILcnp09/pWj8xb5CuCOMjP5UihyZS+0rwcf0p2Gp22Mb7MIXc+UCXOVfHX1ptvK326OEsMlvmyeMdc+wrbuog8Cqq4YfOD6e1YkXnJfefkxjgZHQYqHG50QqXRo6hC91MGAwhzjC8HHT8KyDbjzGQqcYyQeST7V0Dzx+aoLNJnuW6k89Kz7uMGUuflUnIwcioUCoVWtDPNvCSwZSBydrYwB/nvUE8c0c2WBOezDnbWxbDahcOu89eetRCIvI7gbznPHOKfIWq1typO8hiZ2UAhdoCcce1QXhaQK0o8pVAGPQVoFA4QbhtVt7HOc+1JqUKPtcbgoIxlfzqXEqNXUwogwaQsMMSeGHp1qbTI+W80sAeAvoT29qlZGhmLsA3mhjkcgexp8s3myZgVSjJkkdsH/OKLGsql9CNphb3L+XGBvwi57dj9B9KS8jCKGdcHpgCrCQRzXLowGQxkUnvmn6gM2x2Nh8ANu79uPeiJnzqLRiRs0VxFIfvj5X3fd+nuPetS+eQ2wYGMKDggEnHPr+NRxWw3xLn7v7tsnlSO1XJoytsVkYEBSBlevNDRc6ibRzs0AMkex1K/dBAxt/GnRRCa1AD5lztOSf5DtV+ytUnRnZSUI64z09PamwWjxB3jUsCwYkcc0WZTqLYzraLybtYZMKkinaf9rH8q04Fi3D5vnIycjkdqgu5V3upQCRcqdw4/Om2DGSOORd2R8rZ6k1qoX1OedRvcvXJEUTFBk9frSCBZdOMgxuxz7ioppdyESAcH04p4kYW7BQceo7U1Gxk3daGdFCVcjP8X41pWcvlSqDnaR61RhYuA3Qjsa0Y1STG7IGQen9a06GcnqaRjBAODx69aGhDRFg3PrUluVZD0LDpzUscZWJhj5euKRhKRArAAJIBkjgmorlNrIUAxntUq4ZiOMA4OKGUBjzkjsaZLI5AyknHUd6YJg8bY69PpU0xBQ5HbiqhU/MMDNNGb1Ek+WMZ7VXuJBs3HpUu1nQ4OQeCKrSpj5TyKuJjMydQUMzHHFcD4u/5Cg/3BXoF2AVO44A6CvPfF/8AyFf+AiuumebiDFBIzUyk5AqHr0p6glgTWpzE/epEzu4qNelSRdaAM1RwBSOOakAwopjimIYrFJI3H8Dg/r1r6osXMlnbSfe3RKfzFfKzj92TX0x4Rm+2eF9KnBB3wKOPUcVx4xaJnqZXLWSNMyA42nnJ6dqi2M8rM+5U+6Cp/nUvlgMpTAPf3qVgVTBIIPTFcZ6t7EZKoQrcE/xe9K5B2xxMNh4Y4yciql3HczX0CIQIF5IJ5JFaaL5rdPlH3QB0pkvQUkbMAtlRgfX0rHmjjMrlyypjkA9Oa2zsjO37p6ZHP41HPDEqbigZ8jGe3FIFKxlvbMZEKKQCON+M4/CpvKEyxI+EVO3T8jWpaQRvD50gAP8ACOlQ3Koz7ThQDnr6UD9o3oZ3kQh15jDLzs3fMw9c9Km+zMqnMXBHQsCD7kg/pUUZ3KHkh+4SBz15qeB3iDsHLZbO3HGKLFOTKtzFtKkqFjHbHWs++dmHyk4B/GtaeUSBFAYDOSTwRWTczRwXGyTDcA8dM/570cppCTK0g8wOq5Ktxk+vpUOn27RoBtzxxkdOavMjAj5WAbkjHH1FRxoYl3KWA9B0NPlNefQXydp9SOMjuPeo5pAt2qsFaNASFx1z6Z44qGG42s4LBi+RgDmrBiS4AzglBk4Pf1FSo2E209SGMkzMdpLr1Vhzj1qZiJ8nHJXB9/ehsiQkkksACx7H0NEX7tTyck7eP89KHC7uJyZHpwEYkGSqj+EHrTZY0kOVOCpwNnHTqfrUqt8zbFO5uMioHXexB+VSDnBx3xTUROTvcz5FVlIk+ZSxf5hj2zihSInFwx3xFduAOQfpS6mpkgXYMBT0Bp1symMnAG4DG79SKtbBLUREE5fn5iOFI6DHX61FGJFJiZtw6elSL8rspUBemVPAqxDbq8xHJZep7inYXNYW2tf3RZgpHb2p1oCHZNpCnuelW7ZmC4kHJbHT9atrGAm4ADPqKDGU7FWyBWQhgMdK0SOCRwtZ/lOl0G3YAyTxxirpkWSMqv1P1oIl0K4QZbb1JzxTwh3nOM461TRys2QflzU0lxsXOcjNIGht2cHAJ+lQhS2SelWlKyLuPOehFQXgxgA89M00ZvsRj90pAHU9KpzIwkyRxU4fcmW4GePemXDg4A71aMpmLdZ3EcYrgPGI/wCJsB/sCvQrzcr84Arz7xl/yFgR12CuqkediTCWpQOajXg8VKpzWxxjl4GOPwqWL71RipIvvCgZQA+WmkHPSpiOKYRQIjYfKQO4r6C+FUhm8B6WM8ruXjvzXz/3Br2z4K3XmeFHhY4+z3DAY9xmufFL92d2XO1W3dHdyN++dSOQeDU52tg4JOc/So7ldp9eQfwpxyI2JDYzkkdhXAj2W76gCNxP3WPAFWrZfLD7c4P41TdGNwgQYXHWtELtjwuQOgNBEjPkHmTIzAkjoc4/TvTzLGxUctnsehqTygWL5bevOe1U13tOjxqGHOW/u/hQK9zWQEovyqfT2rK1WadUjijjViXw2B0Fa/8AqoRhlKgck+tZxuFLDIIJbqOcUgg9blVFdoNvQdQT1z6U+Nt9qMKVycHNTuAzly4VVGPpUcjxs2yPHmKAQ2atFuVynIvlTEnc7AnhemMVk38G4nOdpYd+APetact5ThXAdjg5PaobaBXk6ZC91PJ/GqsaRlbUpLPJFGUVxkDkdcj2qMGREYJwp4/H2q5eWUTMrIWWQZxg9frUfk+VH8zbSf4SOPoKqxamjLuLZNhcgKVHKj/PNJaT5OyUgDORmrcrrJME8xfU4HQCmtaAIRjg8qepB7f/AKqLF82lmWotvlhCue/Xr70xlDq+3qOhJ/SqdveYvGtn+ZkUHcOcg1enZIlVieG6r1xRYzbsymBulK79jdWAP5UyQndEyqdwPOec/WnvH86SKNyjII/l9aimc4aNm5Pf396OUpsQlNv3Sy5OfX8KrsqqOwCjvwcVDJIY5M5OxuQzHjH1pl3KScsQMdscGpSdxtdi3ESwQKAQTnjtViwdkuyuDyCQDUVk6vAXXcXzk8VqxxEkMAASOx7VVjGUugsq/JvAwR+tLBLvh3jg/wAqcoYJtOCD3qCQFTnGVJ6UrGd77k0jbjjGTjIB70gYeW2O/OTUCsBGSQ2ScUiuohOc5HQUWD0CNASWB5PIFVrxz5LAr04yKnidVRvmwxOaq3r4iYBuSMnFJIpbliFwsaqeAR19KknbdHlcE1m2zsVQyLkeuavE57k9ySKdjOS1ISoZHVuCRwPSo5kCRDnoMfWplQPu3EEn9Kqys5G09B61SMZmdeYKtxzmvPfGX/IUX/cFeg3XCnHSvPPFxzqi/wC4K6aR52JMQfeFTAjpUXenr94VuchJ2qSEHdTKlh6ketAFPtTT0qXbz1zTHFMRGRXrHwOmzY6rbEj5ZFcLjsRXlDCvRPgc7/8ACQ6nAvAa2DgfQ1jXV6bOrBS5a8WeyzjaRwCKkhw1rHk4BPPGar3B3FOScLT7WYjYCceteaj23sWNuyQKWxgjOKLh/KVsnZnJINV5X2MAfmBzn3q15inaowQeB9adiJaEMO4Q8EhiM7c9/epY4wItyLlycjPrUbO2xycAnjB4z9Kck4WPg/cHzA9xQSSsqyQHzSUAGCOtQtGI1+RQR1IJwBUN7fLCjS5yOB+NRae7XQV3zs7Ejr+NIaulcLq0Z4S0ZUF8ZG7g8+lRCJlRkIGD1YdfwrSlZFKptDjOCO9V5U8pumMrgDsPcVSY1IpNGTJszkqvzcd6i04eUD5hALHleuDTmZvNO04A4yT1plznaTyGHTj71aI0v0JmkVW+Zl4O7LdDUQAabCFSATwTx+FZi3gF2YniYMM/N64qdZQf41DP36YOKpIdrAtjEL0zjPp8p4BHqKsswDkkhVb+Kq9swErtE4Y4w2T1qZ2TZtxgE4OO1MTbuVo4QpVymWzyRxkVLKizqVZSwxhcH9aczCOEsuTtHGO9R+YpCOBnsR6igHJvUqx7YVKjOSAQGqokiTs6qMfNz74rTuANvB3HnuB+VUIookaSSMbWblsGmPmKUluwfJHAOD6H61DcgCM7sED7wPOPpWlcRvlVAJLfN9KR7VX6kcjkEYoZaqdw0cKYQ2B16Hg4rXVlK4H0OBWNa+bACAAQRx6irdncebEWO4HOD2pMxnvcvLgNtI6dqrzNtUhskE9MdKZNI8csajJ3HBwOlTTqGTB5wOnepC3UhUqVVcfKBVMyEMVUn19c1ZtEAZxu44JzSDYk5I4zzn2pDWlyB4yyhhw2KSOJWVC/J6f/AF6mm4BAOfbpSlcdsL1oRLkRxRgRleynP1p1wQWCqdpzxinuQIwQATioLhvmUrjJ5x60yb3dyJXw4YAhS3P1qO6OyVlJ5NTKflbgBc5Hpmm3cYPJxuAzn1poxkzKus7T6V534u/5C2PRBXfzyZchyQvYiuA8X/8AIWP+4K6KRwYnYxqcvUUwdTT161uchMKlhB3VCv0qeHrQBXApsgz+FSdqYeTTEQt1rtvg1KIvG7rniS1dfr3ri2610Xw4k8rx1pRBwHLIce4NRUV4tGtB2qxfmfQRwEjLDjGAD64qNAoPmnG7OMU4HMSBh6nntTkCtGFCc9yO9eVE9+WjGGNQ8bZ247ipVONnKlEU4Ge56UyU7ZDgZwMdKZFhdzMOT09OuKozbuPmYlwu7OV6A8miRBGmVyWIwf51nmFmvPNLHZjjn9K0trMG+VcAcFjikN6GdOBIjK6NxgnjrWrZBfIGAQuQwx/KqrOsUhUfOSuV9T9KtSbEVfLJDEjK4psbHhizmSbIxwi46Z71Q1IzNbEKPnzwR1xWjLgKRIAQOp9KozOPN2gEAjg04olMyhE42eaCM8N6tVqXcELKFbouO4qWaBMORkOcfNnuKrI0h8wuQp5GT1+uK1SG53GywCQ5Eahui992epqM2SvGAuFAGTzyauKwQAttZcdRwaVipXY3J+8Wx1qgU2UY48268gleM4qFvMVwzMPLYgbQMfjWpJKmBGceuRxVaWONx8ynaOc0FqXcWJdyd93cE8VFMF8sYwpGe9IuGICEgDIGaZcLuQ4BBAwM0CtqQPIJCVVuM+nT6GolPmAkAqc4PPWnWSeUj7m3EkkgjipSofLKdp74pg3YcUI8soPY+tRXMbBju+70z+FTQS5A3jn61JMdw6Yz+lSTdplG3XcPmIzjgiljhWKV1TOW6r2PvTkIVn2gAY6UCQEqSTnOOnahhq2TY4G4AN2xUTylZNzElMcjvT4mAY7+B0+tQTbyWIA2jv71JcexZjZVYlMKCM49aqxESbmPXpt6c0m9iEIAyy5z70lvtMwyD8pyaQWH5JkCuuAB1qy21hx1PFMZRtY4IpoIJJJNMyeoydhHFgDpxgVUjlVnKfxKOlXygwdx4NUJ3EJGFzn0oGgWLap+ZjuOcUy6f5SMAYHTvTi5Kh+xPrUUw43NxTRlIx7g4LFgOvpXC+MTnVuP7grvLwdTkE5rgfFmTq59CgrppHn4nYxu9SrjtUeOalUADitjkHip4OtV1qzbjJNAyDFN70/nFNccCmIhk71qeFJhbeK9ImY/KLhVP48VnMKSBvLvbRx/DMh4+tJq6sODtJM+nxgykAEqOlSRMvkZzyxxVa2l3KxI5wCPyoSXzJlRRtBQ4+teSj6Sa1Jbld0hUHaSMBh2xQ+Gm2BgEABxnngf/XpyNuWPnfn9c9qSBQ8ruvHynAz+FMyegyU/PuwcB+celSbyyfNjk/N9O9OuQAoU/ex261FDEgdHZgFyW2k+2KB3LKIhnMm1UIGAPT0qjqEyovzbt5YECra4XaQ59SPWqF3ZfbHJkaRQDvHPcU7AnqGn3EkxkjkX7h65+99KseSyy7pGDQsCwyfekt4PJVjGwLEgkmrIwAocjPQmqSJk+xXkj2jK9D0BNQNE3kMy5cDnIGCKml5i5IODnjrWZqUpEPzF92cAKDk1qkZrcmfk4O8jHQ8VIZAUxnG37tUrIuy4lJ8xRkj6471K7eXKMgbAm79aLFlNXc3TrMhxwQelXsK6AliwximzupZiWAIGBnpWfBcP9oOGGwEL6H3pmqvJF2KPDr8w5zgD0onK7WQk5PHPaqctwFmA35Ydv/r1BcXoXDY6nHXtSKUWXLf92ChC7u/vVS9YRzAqTjv35qKK8BVwMbQOp61FJPGyuDkAenOKY+R31NOIr5WRzx1HU5ppnw4BfLCqtnMUQFTwegpjLvl81QM9OBSJcSeckksDz1zVWN3jHzsCQfToKtBxsYZ6ehrNvZgnGCc57d6ljir6Fw3OEA5Bz0HrVmPbImN3LcE1y/nkbRu6Hk+9adjcbl2liWJ4akVKGhopASqkc7c8j0pgUtMCGAT9antCSrKT8wzkjqaiX5GJ28+/WkRcnyzR4P44pjA7lK8jPNIkjbWVuCTUkQxyfXoaDPYUIcMcHOPwqjNHlixGCRir7zKuRj8KzbsbySHIA6e1AISfEcMa4Hy89KhuZAsGOpJ64oeQOgJGCB19agnP7gsvTqKtGUync4Jxz9a4HxZxq+3sEFdzIdxDVwnips6w3U4Uc100zzsQzJHNSdqYpxUg+lanKOTpVq24OaqrV21HIoGVqQ08AU096ZJG1QynaEYdmB/Wpm6VFLs2rvBKAgkA4OKAPozTrhTEmSeY1xn6VNPJtMJUgMh4GawdFu1ltbSQcRyxhkz6AVdnuByW4O7Kkc15OzaPq3HmSZsAPsAjOFH6Vbt3CRFtvBwfxrIMrfZ/lz5gxnnirsUyqEJDbQRkevvTsc0kWZSHkwBg9GPSo9qvGwQZZyAG/ugVXNwr3LIjKxZNxGfvc1YLYlXOwAEjg/XmmkLYYbkG5CHAb3HPpV2GPeVyuXPQE1VhSN5gRxjvVmMkqWkJ3Ebd27qaZMmIYcuN24YPGBjp61Wus+aDGVwRuzzwalEyhiiklsgjJzn8amkKKvy9wwI9DVJCK6/6nBIzgZA/nUJWNoyUk+Y9Dxj6fWpLiQqqrIVVeQW98dKpNMqkgKBtI+Tr+VaoVgKhIlU5yo6Cs+/nEKE7gecbWqbUrlt+6JCVK8hetc/e3CJs88nzWYtwDjBHAFDNacL6lxrvzH2oRk1lveHzi2cY4B9ao3VyTLhOM9OelRxl1JMmCW5XaefrWdztjTsWXvjubJ2k85c43U37aWyp2sPRhWZInmhvNZjzwafCrg4QYyNuSck0Nmqgi+bgI8hQ4ycfSnxylyBvAYjkCqkYIkPmHPb0q2kOZAy7SQck+1K4pKxYWYoFAOMDGKsRXDJGML255xULbCBjqGyCO31qGZwrLxgMenfNTzGPLfcnium8wDrkZIqK7k83JDZIGKY/7hAygZ5yahaZXHJC98+tO4KJGVwilTkdDnsamspD5qr1OcgZqtv2o+CDn396msFzNuHRKVwa0OogkBUEHLYpZ0DSDBziqVu67cEkE81ciwcMckAHJxTOSXusiQFW6hh64q6oBXJAwBUKRcqTwOpFOeTGNv3eOT2oE1dlS63I3Xhhmqa5YMisGQ9xU9+GVy38GMY9M96gQ+UoKA9Oc00hyehHOP3Z2HBz0NVbl8QFckYqd0JYgHjGeagvOYjkcY5NaJHPNlHrg9QelcJ4pI/th8eld0CcY968/wBdfzNVuCR0OK6IHnVmURyKlUCmAe1OBPrWhzki1dth3qitaVoPlHFAyrj5TTDUhPymmkVRJGRUMv3SD6VOaYwz25pAereE5EutD07dsSVIcqzHqBwQa2txW4IzuQAFAwxkEVyPg2ZX0CzKnPkgoSevXp+tdXuby4JizM0Y8p8noP4f615dTSbPrsPrQi/I3NPHmwEMflHyj2+tWJIVZZAGO4njHp0qnpkiyQjYQucZ9zir4wnl4J55bJznmmjlnoytbRBLhQwAbJ/eZ7DtVx1XKAdeuT29qYwVpAEB2uTz2FNnmkMoK7SyED8+v6YqrGTdxfMKldpLfKSexz9KtRSSAlVAKrjhueazorUi6aXcSu8dWzg1rOgZSwOCyk9eaLAzPEDK8gBAVXzycE5xWlsMScbXyrEleMU1FEhfcqMw5zjiqdzdyRIz4VmBKoGbv6/lVILORT1SVpGbYocllKxEd+lY80xgmiWWRy0ZxnPAz2q7czSRxzNG7QvuU4z0wMk47f1rIu4pprY3KHdECSGYjLg+1XY3pxWzLV5c/ZoM5CmQchWHpxj2rnLi4Rwd5yMcDOcH2pJLraoQ52nox5IHTp60LYSpK/nLiNSA3PPIzipep0wpqJE8UkkQKKrMMn5euPU+tTeV90xAhgoDfL1p0a77gJGijB2jHp6UyeOWF90Mh2qcOC3B9qzNh8VjuXKhmJ6qpyR9RSNGsUoVxty3XpVuQC3mSS3yH2hmKHAH196rXkQlZJftDhh2J+alcWrHNDGJN4U89QfX2pVCyIxA2DtUMz4hyHJ2nIBIyT7e1S6fv8jex3FgOvehg1oXFkj3gxgjgAg9jj9agu08ydNwJUg8iqQuZIb6RQF8lyAynpxz19as3EszNuQKoIzgjipeglTa1GyAyRLlvmxzniqUgU9Dz1q1M8QQEsEGBkHt+PpUclvJGDGyhd2CDng/SkmO1jOYFcgnv69Kn0ycpIAe+RUbo7Nxhc9V7imwgrJu28nmrTJmjoxKFiZl52/eBPb1q1Y3HzbV4XO7OeuaxI2YzBjkqwwe46VPFPukRkJGOME/rQckoHRMzdj1qN24Ktgc5qgt2d4DccZ+tWPNDLuYfTNG5naxFM5kcqckDGT7VGzhivZRwKWVAH3kkbhximhQoPJxjIzWiRE2h9yQ0QAI46VnTMzRY4PbNXthODjK1TuAFB2Y561ojmkUsZwOwNec6wCNVuh/tmvSWHb3615pqjZ1K5z/AHzW0DgrblYEinfeGB1plPTI6A1oYkyDnmtS0rMUEYrUsxxQBUP3aaRTieAKaaZJGaY44JzUhqNh8xpgdv4CcHQZg2VIeRF/3uCK7G1dDHszhJlG7I7/AP664XwFMP7NvomxiKYSgfXjiu1XZtURFvu7ST6+1ebXVpn1WXy5sNFGhYSFHEbbQB8uFNb1vtkCNgE44Oc49a5oOzXkewAF0BHTnsa27KVIV2F1IVec96mLCvHqi9JIELZA4JIx3/Cq8uJSAgJdmLE9xVZrvfKVX58HHHrilsWczoXDKcHlug71ZyuNjSjQRsVXk45prmTA2kAlstk44qdh95gyqWwM0gGwNlh7ZpkIpPcvaz+W6ukGOeuT6YqrctDI5jnyfM3MFA5A9ak1KfzGbzSWIA4PU8+npUunostvcXDmCNNvMbsQ8h9iO9UuxqtFcypZEjmYgyMqMpkxgFgQO5681liGa5cPho7dWKr3JGcn6n3qR5nDPvXc4JC4P3RWvonkTyRLePGkEgZHeRsNuA+Xae3uKvR6GyvFXMcxrHC3krDE+NykrkjHv75qgWRtoydxOM5zU9/II3kjiIYElQp54HTp3qmkk2c+WHbG/AHK9qykddOOl2NzGlxICRvKEZNOgc/YXESqxXDPxyFx1HrzTLjCqWZgxOeCOhqOC6+zxRuqjcmQGbuTUM25dNB0kzsiujEEnJzxzTJ2mZSAQ7MQMY6n6+lLLm8ceREW7YUZH4CoPtLiVY7b95MPlPBG2s2VbsWlKqxSQABQFI2cn6UITHGSrNsV9qqOOM9KXfI4LygZU884wcVFDNsiQAAjcSWbkg+gpXFy3HwqJJZHk+dWGNvvUXmCzdUTLpg/L6e9Jch2l3RZIAwcHr+Ap8cTTpnfGFYZOBj2/ClcpRtuULmQTSFgoVTxg1cjmjW1RZZ23plhuOdpHpVd4drkox3ZwEzk5FR7l+0Bpdu89iMZoTKlFNaE9uVnUztIySE/MrLkfgac8K7kZCevAx+tPjILsoUkYzgUyctMiIpK4BOc9qpHJONhqTuPvt8p4zU4k2R8qCQMqcVQcmE4GWXoeeBVojKlQQVXnOatGUlYcZ2IHILDv/StGzuV5B7DGD/SsN/lzu69iO1LpcrGXBboehqkjnq7HRMG3IXJCgcUs9xuYhRwBUTTmUOAu1+MelViG8w8Z4x+PrWiRyt3L7z7oVccADHNUrls4xjmp3wY0UDgDpUFzGrPEV6EciqRjIrnIzn7x9uteY6k2dRuT/00NenXBwCe/QV5dqBzfXH++a2gcNbcjHJo70nfOaK1MSzDzjNa1r93isiA9K2rMHy6QikVphFSGmGqEyNhTD2461IRkUx+tAkdF4BIF9eKxzlEyPUZrtYJ8blYFB5m1uOBiuC8ETeVrrIDhpYHA+o5/wAa9BSLfvZYwEYKyqDweOa4MT8Z9Pk7To2fRljCuZbULuMBaSMg8nuR9MZOPapILkzRKkRwRhenbrVCZ2WVWiO10I2+gYHv7VLGscTvsclGJIOffoKwidtSJ0GnKScHjA+U1pRqcbgRxwM9jWVpkykKGH70cYxnitqIhQRjA44I7/5Fb2PNqPUCfLRRImVYckc4psh2xKRk55596mJXcOCeQOOnNUdRuvJ75A4wKRmtWU7lTcXKJHkKSBgdcd6Na1VtNjNppkaO7JtdyoYKp9/X3prXEZgeXeC0aDGMDJPGPfnvWVpcEl5OZzxbxjbNjoxPAGO5zSS1OhLuQ2VtMY2ZLnySyscEZwM8hh+XNXA29cTqoIUjgDaT3NbqwW9xdm5vWVHx5bsUAGzHBGOAR6ccVgXXkxl4YpxJGcqhxkED0rdR00KjPmZDd6a8q+dawrvfKum8LjHRgD61mzI+nq0Z2mcj5gpzlfanPFPNEBGz70PltG2ee45qrdmK1tGeVZEZCDluoB7H/Cs5ROym/MdbFZlZEYAkkBvUeopGRJrhfKU+XFlFHr6kmkljWVIvnEIWP5hnkjqBUsdpOttG0hCuw+RVP8P+NZSRumt7hHDHC+ANgPRipAJ+tSbIc4UbSTknPLY71owkIka3AJGMIMdahTf9pIVEVWG3Y69RWT3IT3KNzArhdqsiMckkHGKaIonVAApXn6D3rZuFCQqq5DYIAJ4ArFjDtE+9SNrckd6GXCVwuVAAYHgA5C9h0qOzKyRbgoDABee9RpMUiJIdlPRyO3pUwkh8veuFCg5I4z6cVJetiheRtFcvInUgYb1NQSfvpDsB3qclvf0qa7cnIUEngg9qjjcQH5s4l5yT29qDV3SJ4JFRflO+Qjn2+lTzSbkLt8oIyAvSq6xgyAH5VUEgitGCNTYSIGAZRuHsO9WjlqpbmVBvlaQHlc5wOoqwSAxG0YOM+tTWo+zlg3QnGev4UXEgO4oO3PHNM55O7KV2VHTueKgsj+9Y5wR/OlvSVjDuOPY1Dpbn7SS2CP8AaraJw1Wb9sSzDJxx0Aq+qqVTI574rPhCoo7E81dgIKHcRirOe4rOvJHcYB9KrXIxh1xk9MU48qxHQUSkiMFgM/dxVIzlqZ16xWN+cYBNeYXLbriR+7MTXpl8ciQHptP8q8vk/wBc4z3reB59XccDSimDrTxVmZYtuv41uWbDYCcdKwoK2rbhAB0pCKh6U0jOcVJjIPrTCMGqERngVG1THAA9KjfpQIm0eZrfWLORf+egUj2PFesljFKEJ3AwgKfTnivGWZkIdfvIQw+or2PRnFzCbpiSssSMAfcelceLWzPdyWfxx+ZIyGB3BAb+7tPUdz9aryq8kLRkfNE7MNp5x3z69BVkkAI653AnBODj1qvcEQXZlZSFkAycYOf8/wA65Ez2ZK5b0qcZRy2CRxn0FdhBIrwLkjHp61w9oSLghhtAbK7uy11WnSEopbsc4rdPQ4K0OpbndUQkDOCOK5/VrsiMJEgLtIckHoB1rX1BysDlAN3rng1zTIWkZJDuyCWZfU1N7GdOPUgkJmhjjRmLqdzccn0Fb+lRxxoVcoAAOrY+Y+g9axIFdR5mGdZR8joeuD/OtIW895IZI5BCVXJkU4C59jRHc1klY6EyxXenTQQMoeMAtuGFQn19fwrkJmNv+9jtW86Mlt20Y9yO2Oa6/RViCQQTPbiWJGEbyhkjbdznIzz068ZrK8Q6W6QSMiSWswxKyiVWVgeCVI7c9K7+W6uc0Z8srHLiYveSpBIsQKYZWJBLY6g9uar3s1vrUga9ndRGmHhP/Ld8fe4rV1bSnhidTJAwhPARjucADJAI5781htCFuiwCxgMFLkYYn6e1c1W6PRo2lqWv7AvdJhvblU+0JbKrXO0bzEPX8AaTTzvaNoXMuRlRgnYK1Fkvzc+bYTyxXEiMs0X8MinqQTwQe4Nc/YzT6JMxtnExkLxyK2MBcjGKyktmbU3Jpp7nT3M8UahoUd2VPMYngHtis+6vBJYtL5iAN0Rclv8A61ZD6nPcaukM8gg+0scNjgZ9vStqG7t4YQqFQCdm8r0fuKzaHycvqEN1ZmGKRiHJyu5sn5qfIBLuZwGJ44/iHY5Hes67s4oLxbhZJGjBzsXncfenyyPEXc+dbk/NsHBPuPSoY+VbohuJd6bIdqqVPHUj2qpA091FtQDepx8yjnP9KfJcxAPJFG6F3wdq9c88VK1zCIQsK72+9kHGD71J0JWMi9dLVAsgDxMwYFevvxUU0RWZS0imMhWXHYVJcwNvdmJJft7+ntTI4JpWRJW2B1BAAyOPeq0sa9SZZ2JVVy2RyewP+FWrdZYAXQBicjk54NZu2VQ0bZYgY+XjHNXrVjMjK5wsYwAe1NGVVaaFhQJWIQ+WR/ATkZ9jVZmMUmGOWPp0qbTnVzwAecgipbyBBNkYLONwA7c1SOKorOzMa834XjA7U2wJ80YXdnoAa0bmDETHcMDgD1rLA8pxkY961izgqpM345D5mHwCvGD2rQiAKdDnnpWTA5OWwC3B/OtSwXEBVjk561ZxyJYI9yn25ptwAykMOnJFTrtjjPNQXDbos5GBVIhsxtR+5IxAPBx+VeXuwaR8etenXhzFKT0wf5V5g+A7cfxGt4bHDV3FXrTwcEGmDnFPFUZk0Dc1t2h+UVhQkBue9bdmcrTEyIDimOAMCnjkU1/vUySJqZIOKkeo3FAFeX7jfSvW9CQjQrIxuJHktVJ2fwDByD7ivJnHGBznivTvB2658NwtBsMqIQwJ2nauSea58UrwPUyiVqzXdGs5IgTaBtC7fx96pXBZ0czbndSe/T61qeSI7cBMky5+Vz04yKoSqoBwxA9exPYmvPPpJNMWUMbjDfNlQdpP3SBXSaUgkjyc7ycc9O1c7GQ94svLB1VTxgc8dK6fTh5aKcHA5OPTNbROGvsWbrKJgBCBk7SOtc/KAkzqzYlZjvCHv2FdA6tNCCV3MWAz0OK5rUztnl2wtvDZBxnI7j602Y0+xLNFbpJthZ0aOJWdRwSzdh9Ov5Vo6YknmQs0Uv2dX2GRFzkjnv17VlxvEqq83mAZIZYgMk9R/wDq9q0dE03Uru6tJRdz2tuGJdZAdq8biQB04C/nVwV5FT0R2c1ppRt7eVo9TBRd4MabAw53MWPQc+nauS8U3wB0+K1sooNMmkVzcPyVdG+8ee+cEV2s80djaWjS3kRgnmaSS0Ybwykct+A5x0rk7yODWNR1HRtLijlsbqNZLYxRnCTAcjBPygjrniu5p2sjhhLW7KepafqVlayy6jaBI2jugPNyQwG0hge3JBFcfrxSfUJQE2RhiZtvLDnoT2+tettBIugJoeuSCR4owBcI+WV3YqmV/iU4wfTFed2NmtkbiDWDE0ouGjuwM8yYZSPXHQj8KxrU+VHZha1736FDQmuhb3cCymSJDvD5zt6Dgd+tVDaToLhiGcbjuyvOB3q9pscUDYE3kylVePdyGVjyfbGBWrdMHZEiVcmMgtu+9z7fyridz0uflehw9wdzrGYvOmjH3uigHt61ec3EgjlihEI37WToCxHH8qdeIqh2ki39THIuVYDuKkt7jOmPOyN5LN8u5S2CP/r96k2c3ZMpvqksVzE3lyi1jbLqDgE+tbVspuporgB2tx/CRnJ71R02a3vXWR4y4PVBwD/WrMTx7miEU1tbjlI1JXHP601AhyvotySSOGGclJtkRJYBhgg9wKy50knDTrhRK+1Ax61p3EVwJ/JLmSKQgRuy54Pv61DrMGy5hiWdNqoNoBwVx7etZtGlNpNaleztg0RE4dpfmGwdF9zTY428tTIpCJ8oK9/8mrqDyirMSgZeccmri20f2Z03kj7wOKkp1GtzCkj3ybAdksnRm6E/WqkZJEwVyNpwCB1Hr9K3FgQ2rOSFB6Hris1RvjLZBIGP/r00DlzaDYCqIGXfv6HcMCpL52E6sNpVlDLz6DkVCJWFvu2gnGDuqWbElvABj58suBnH+cVpE56iInk37i5A7/SqF0fMkCenetF03I3y7m3AEEVC8ICc9Rxx2rRaHBVQllKpQ8/MODn2rZs5gN249MVyxJjzzxnNbGny7h/jWtjzZbmzK6sgH3VY9aSZNsAXPA61UL7wVGTjpUqyF9oflQOaaJZnXy/uZcf3Sf0ry6QYZh/tGvVLrlJAvJIOPyryycFLmVD2Y1vA4qu4g4xUg6VHnipBVmY+MAnPoa2rE8fhWIpxWvYE4oEx4Ugc0xu9SDgA0jdQaZJAwqN+lSHvUbj0oAhP3feu/wDAsgOhxo+7b5rAjA5GR3rgGBHX616F4DhVvD8UoJVluWyfY4HNY4j4D0cq/wB4XodJkuwEh5DDoeVqhcMDLI6E+WwJwQK0x80n2kHcr5yM9GHHNVoYvNlbdHkZz7Y7156PpW7EdpP5d0ke0hQAG56Meufwrp9PkVIFGcsONp9awxbLJPsj2GVeSAeSMVs2Cudzk8jcoGMnGa1icNZpl9PlSTb8z9QB2OO1ZGpTKjxyuGDxggBTt57fjk9a03bAkBAwp5J9Ky550Zv4Qw5BYAr24NUzCG5mywziW2VFfdOgOCwwW6n6HBNa+m6lFEk/lSTgy5CJcS7lizhSWPueBxWUG2W5k/5aJh1ABYNngk+mKZC7veQwEFcy75CoG4rjJz26dPSrp+RtJKS1PVNGW0uNVcxWn21rX93aWTuPk4+Zgx7Ht1yCK2NX0W21Tw3fW2geTbzeb5uyP5DGwHKn3z1rno520SDyrLzLq4u1wm8jzLdQvHXtTfDniRrfXEsQrQpcs0zSuApUAcj8T1ruutr6nlzpyb5o9Dn9Kddc06+m1O4ls51wI4ZJG2SRqVVVDkZxuDZI9azrqxunuwmp2sNrrOCG+yyl4pSxOyRQ3TCnH4VrXBbWrr7R4e3/AGW0h2rvT5lALM+R03b+MfjVkXdvqkbXt0TIJIPIYl85wwJbHVSR6d6mburHRTbi+b8DhbeB49T+zzvItxFbbFwnzbgD27jqP1rSvofPnmJOASSrx8beOBx3xipfEPkRrFPbQPbyw5jyDk+nzH3BzmsPTbua8RoI1RJAMnAIHAxn6muKVtj1ItzXMSgwXEH2Sdx5gXGzHK+49aivLeFNJnjt9yMq7GTdkEZ6+xpbuW23Izr5N3HyT2FZ0usFWlitY9wbBdiOGwegrDmS3NVCW6G6ND9nSJcFZiu5ecc+uf6VtRWQMTyyyHzAwXD8jnqfpVRZLWXTIpDMYrhGPloy5/WoJtVWDagG/aRkgllI/nRzWHyyk7o23Zo2iSKNZPKUNIG44PpTxbp50LAIUO4bG5OMdiapLrEWoxtbxoHlkAXpgpjoQf6VD50lu+1FMkitg7jwAe4qG0OMHs9GWdXt0eBDGxBYEqe+M9Kraa5aPY7sCq5DEfeHpUk7TT2+6Nwpz9087SOv51jXEzwLHJIdwVTkJwc9qm2ptThePK2al3sBbICDoFH3frWa4LjzWZU3cbQOBjj86S1ujLbYnODx8rdKR2jlLIXxnL4J7CgqMXHQht7fzI3+bI5PXOR04p9sg80RSMUVQcf71XFt2SBGjyWIwqKOpPH5VVlhmN7cbyQUAVsdznB/GrRhUle44W88LFZCBn5lx3H+FVWypKuMhhWvezvMVSTcGEYRcjkKOgrHuMlfmBB6AmtEcE79TLuVCygg5B7elT2MuCfXPFQTH5trZHv61ZtMbDg9K3Wx5tT4jWRsEFOpFDfJyRUEMuNmRyalc5jAPX+dCIZWLfvgc8ZxivO9bj8jVJ1P94mvQ5FLDke9cN4ri26sx/vKD9a3icdRGQG4IqUGoOhxjFSKOlWZkgNallJissDjrirtm2Tg/nQBoDpSEZp2OKRxTIZERgYqNqlYiom60AQtya9E8Cw7PCrOsoYSu2UxjawYcD1+tedv0r0T4fxufDjup6StjnnPescR8B6OVf7x8jeBcWMZBHPPHbvUaSH7NJJxtBzzxznOP0qdV2oExyRj69f8aje3Qwrkbhn1x83WvPR9HO1iTT7hnuJLhVB4KtnpzxiultkETqoJUjHOMc4rF01RHuhDhlkfcozgBVHQ10SK4MaxovA656Dmt4rQ86tLUo36ZVmzkcZPqTzWErB7geZ+88zqAMBcVuahKVjMRYbRwT1GawfNeC5SWLywd3mEY/h/z2oaJpvQu3ECy+WIolLsS338Z4+Un2zUbxtDCZZnjtpG5JzuYdjj29qfYhSZftEjHauGjBxyenTtRFbWDhDc5MUbZ2E4Zsnpn/GnFmidtCC2vNSjIkdmRpTsDEnHltyVwenY1U1S8t5L20+yphrINmXB/etkkhh0q5qWo2yKYbeAxsCNisScfNzz/KrOtalptxYRWlpZNFHE4JmIHmOT6gVXM0tyktVoFtMZJpLpEkCXhNzvicxshP31HbnnFP8AtFva6s8c9sZIEJGzYUPlkbgf96si6vg6xJbAxhV2KuOxz1NVLfWtRiG8XDvGieUQcHK9MEHrVOqmWqDepdkvY/KvRdblS6h8y3LNywJ4J544FYmn3xUv5YPlvkK3QKTUH2VLpQrOQEG0heMD0qTS/O06RwqrLEpBdGGAVzWEndnfTilHTc1otNN7ukklzLt3BSPvdsCqf9niGBmiLmVDnaRjPt/9etd5yqpICoG3G1Bx/wDXqmt79onwYvLcdN3cVjLfQIubfkV7x86ZbLEgRl+8yrgn606zEDQpHwrEF3GctntTLqYo2yVR5SEMCp7jsarOonumEcZyeC3Qn2+lS7mijdG7oVnDKpk3Yd+Qw4AIqzI0G8FYwrIPmHUH2rFsUeNnVZThTwT0GO1W/tixyAyrkKMdMYJ7j1NMzlTble4t5IPPlW2X5uTjPqOn4VzV5NIYZNyFZg25DjB//VWyLeTG4Sru3ZDHqRVDVIpZUUdNi/Mc9fpSOmkoxY2ERxxBJ1+dcbVxnK+1TXBYNE6sGcDGAOvNVTLIyqVO0jB6ZyPWlnfB86NsgHcG9/pTsKS1NeB5JSS0hTbGcY65PH+NQRSeXJIn8JxknoT/AI+9MjYuQsUoDY7DvjPWpHc3Kpv5AHORzVJHLNdxVk3Nk/eBxxzkVHqEQfOTgD2q1CqIpBwMDC8UyfBUggFQOp7mrRwVUc5cRkMSRjPIpLdyImGMHPFaEqeco46Z57VnMDG7bm+mK3iefWXUsRyH5cdcgmrgJKk1nQtznp61oxcqTk4FUYRdxsowQ2Tz2xXHeMogkkMvUlSK7Mt+7II71zni+AtppfGShHTtWkDCqjjVxgZxmnVErDd+tPDcnPStTAfViBsHFVwc05DzwaAOgbpTH9+lP6imt3FMggYcZqNutTnGahamIhbpXo/gJSfDMRBHy3DMa85fGBXo/geMt4XgA5LSscjtz3rDE/AejlX8f5M30TzCFBG4c888U0lIp5FAD5G1O3+eRVh1WMzuPvKmwg9ap3/yhJU+8nPB65rgSPoZO5LaZjuI0Y5YoST7E9K6Jp1+zqEIUY5I6delcvaXsYUs5YyFyCSM+3WtSyXYcSEFWJbPUY7/ANK1icNVak86tJbtKcAMfuntxWYFSdtqrjCjA7cZ6n8K6CZDJabnVOuQcdKo7VjYqqJG+QWctnIPbFXYyTsQOIYoUfdl3H7xMcqvXOfQ0+e2jZHZYtxkTcih+vpk/wCelOMpjV1jcbgrKTIBgg8Dn2zT7YLE2yebbexZiCFQyupB6evHf3pJWNE7Fc2o1C3hlggAcICiq2TngFiD16VUltmKr9oUZUlQxOOa09IslCAmYfaUQs6CTb5ClsKufXqfTGKnt7XyjcM966Ksm0FzkMR94+9NwuNVOXQ51oYzHKrop+X5drHAI9fes2a3UyHZ82evqxro70RK0rrtJ3gDaM7/AHxVaW2t0gRvKb5G2mQcDJ5/OpcDqpVLGLOXhdSyjzUGNwHyuP8AGm3Egk+fa6qRg56ZrXuoWni8+SSMhTsIHH4gVmy24X5skYHDNyCayldHXCaktRsTIsKTbnLKQMD0qxfXSXSxMVUuq7cjg496z12kZjO09WTPX3FLFPEBEiq6zNkOGXIPvmoaNOVblG5UySuvfOSueo9fekt7loW83dlEJBJ6kZq0ioJn8wFiDxx2qnqUEccIZAyjOcY4J96RspJ6Gha6hvT5CcE8KV5/Or1x5j26yM+7+HkdazbdWaMSPhn64JAyMVPDeCScKqBMfw9z+NDZDST0LMHzHyiDzzj7w6c1Qvv3U2E+aM8N8vWtaYRpnb8jD7uRznv0rK1GR5H3LgE8gd8UWCErsowzMu/afu/KCfSlVmaGMMBj0omMsEkUpwySj5gOq1FA6pKNrZjZsqfaqSLcjS0xjCZidu9QxHvSRSHhtxIHQbsYqSFSJkcr8u3a340weWWkUEbsdcelWkccpczZahBZAGbdnn6VZbkbT34HvUdvG5hGUPAGSD1oKblIZ+RyBTscs9Ss8TAsyq2ARn0BrN1CPYq4yqkDcuerdzWvIyRyLJOvmIOqE4DD6jmsu72yiQAkYOQCc8ema1iefW2M9MlSBWhbS/ulx06GsqFiJGB/Cr1o3y4PetDiW5fHzKcdaz9VtxcWE0eMttOPrV9TsAPrUT5BLAZpxYqiujyrayOVcYYcGnCtTxTa/Z9Td1GI5ORWUvStjkJI+9O70zvTwc0wOhT7oNNbrSQNmJSPSg9aZLGtULe9Tt1FQNz3pkshl4Br1LwGm7wra8g5Lnp0GTXls33TXqXgYr/wilkVByd4J69zWGJ+A9HK/wCM/Q3pv9Rku6sybTx1wfWqmYvObzFOTtbAOOn/ANerUMiNIDhfLYDGR71TlUXRwpLDqxHUY71xpHuSla6IxboCzD7iMM9gM9627NSHeNeCwwSfQYqqlsBbNEPmYJgZHPY81biUsI3VsjgbT6Ed61Ssck5XNezO0BZC44yoz39ahnhUyFywHGNoHpSRN5TKSww3yjmpioGTKCCGyAD6d6ZkjIkjSSbymwYpvmIHGcdB9aWLbbHzUAMqtvCMPmJxj8hWjdRGRUbCmUfPuyR19qj+yEPuw27OCpAYMcd8/WqWo29CnAZ4LOS1eyklurhhvdo/vKeDz2xz+datxeWtyLe3s7QlkiI8uJ8AEDLFhznIHX1qSyheKTMzyncOmTlm/r6/hRqePJW1Q3ASOUSSbIlLSNjONy9jWi2Icrs586ZdTSI5LQyGPcA654OdvPv61SmjuYJVS6/e2zqWZnU53L/d9+1d3bzwXNndXTHzrmQxxSRQrtUJj7u3vjHbvVLWtDtbyy82R9QsGtyVAuYXaPI9+2eOKp07o0hiLOzOHupWkYsfuk5Ddzz3qISEoQ4wrfwmn3QubXaFxKcY29fxqIJMyNvQrJnDKRyDXHOPU9OErq5UmhUTq7fcI6Ad6ZqItbcj7NJIwK5IbPDe1WZEcOoIU8dTmoWgaSVQZNz8ggLjAqEje93uZlveRRpy+Zfvbjzk1dEq3IZJAVkTkKRUCwBWYMieSzkemKivPMghbaSRnPByfzqGjS6lsaFo0SIsTwl5Vb7y8nbTDGPODlH2fTBU0y3mHkhVTap59/rTi7qGUE7Tzz3qbCbaZBesyjcJCcHhSM/rUEInuJQsS5wP72MfnWjBHG8jb+GVCRhc89hSRJ5cjOhwAvH9apD57KyM2Zpt7Jj7pO8E8CqyIFkV1j4AzwvAOeo+ta9zEXZCcIjLzjqfrUYVnk2IMRkY6datGbnoX93nW8JjPKn5ufXpVcq3nIygj1UGpIQQhQ5Az0xjpTt3zZxjFVfsc17MsRO0ar168knINSSx8Al/m9B2pkDBApIyT1A61ISGclQNueR60zORSuCZBtBH41kzFVJxySK2biPfIu0dT6dKydRQpKwUBgevqaqLOSqtDPT7xPc1PbthwOPWoWUoF7gjipbc/N+FaXPPa1NLHygdh60SL0NIhLLj05qUjp/tChFtXRzPi60+06b5iD5ovT0rhhnivU7uFZYXjOMOpBrzS+ga0vZYWHKnAraL0OKasyMHgU5elRg+tKOtWQbmnShoQParRFYOn3BUAZGK2I5A65yDTRLFfJbAqNgcU/dzxUbN60yWQy16v8PU3eDbIjHyyyKMH0NeUScV618K8S+DYVbGFupQeO3BrHEfAd2XS5avyZquuFRYztCdAehzkHn8afaWgBEpJUSkLhR0AHOf0qxdxpvYbWAxkAD17VYtwMxlcjA+73//AF1yxPXnMjyYpuR95efpViBDyi8FSSPp2/wpsgxMcbgQvBzU6nbIjAH5jgn0B5FWczY8Id2CoIB/M1LBGcttX7ozhqdEcIwYAKOjGpYMmNhGpyQcnP40ILj4dskkrNnCqNoI6+1AjhEZZMHPJBU9e9LExLBiduBu+aq15cbI/MaUKCcKfr1poRJJONsSwqu4nhlc5Htio3Cy3C+UVYGMIzN8jKazZ7ogbfOHDE7cYH59atQP9pZlihPloQTzuVR3OSM1omJxsIJJ7fcMnl8o4PKn61dlu72RF/0iYzSwFWjbcN7joNwODketVliZCzQlyB8yySEoCe4pGu57O2Z2uJAk6q7lMSFSDgAL6H3q4i3ZjzJay2S3IfzZujRqMCJs/db1+tZM8qNna21ieeM81fNtseV3j2v3XbtI55yKpTmNCTkk9R71z1DvotFeZCsBbduPp0pLeBWiYvuLN3zjNRyqznk5GKiVpAu1Wwo5xWB1LVaDAEW4KcHbkgkcGm3FqC4K9Cc8HtUk6htsiklh3pTkDcD0HIosU5dUOWMJgkE5HApksLxjGAecAg5/SnK5GDjK+/aiRBuRsncOePWlYXO1uN8sKOflbbjj+tNeMeZ83ORgbamPzEgH58YJPeoWZlVQHyvTOOfwpWDmDyWR22EPGRwKaQIbf5omMmcgdAPX61IjfOxTI9NxqVp0EQyQWPrzj1xTIlIzZfOjkyP4sc+tTwlf4myKR3RyVDcmhFDcAnHf3qwlqWy6HO0cY5xSouRkPg56VDGOAAM45xmrETOzkOAPQUzKSBXUth+MVQv03zEjaQxyDjr7VoPAzMXXtySRVG7BWLJ7Zouc0zKugNqkDJ71FZDMwB71NPzET1xUVmT5o9apM45LU2YIjtLNwo7Ux+4HQ81as5A0RD4pDHy/AHce9NSCxnSA8dDiuR8bWLF1vYxwfleu1deCDniqV5brdW0kTjh+9bQdjmqwPLR0BzT8jFLd2z2dzJBICCp71EODWpzFaKUo2QeK2rG4G0Atk1z1TwTFWHOOaAOq3A0xs5Gaq2dwrpgnmrBYEirRDI5eeMZNeufCHEnhGRcAAXkgP5CvIpTxXrHwabPhW5Bx8t62P++RWNf4DqwX8X5HWTgmRODtGRx+lOtVAkkXO18f40s4YgAlgck4x2PvUcY2Hachsc571zI9SWpYRSwGeBnb/wDXq2YgynBGNox9RVe17AghxzjtVzGB8vf1pmLYkJVoxtJAIBwamjGCxBIABGfTNU41IlZcjI5H0qxIB5f7yTAzjimNFhTuhLlvu4UAH+VZEqfa5tzKGhhJHTjd3P4CrEyyQxA26hnzhc9B71JaqFjW3QJgjGW7nOSaaK2Mx45d7oiDyWOCSAcCp0vZEkeGFAY2QAcbA2O//wBarc1qmEYMwb+IA5ANQJbRPPGZgCASx3Z6etWgvcv2V3eS20qzsGt7VCwx1Tj7q+1Zs9t9s0yGeR3umgkEM5UhEXOCOOuR6mtO5trpo5Y7WRLa3Jy7HI3HHasa3MhhntLdAfOI3s38Rz19zWiZC7or6nBcJ58trFeQwyjJ3/MJF9d3ccGuevXV5WMWdh+7ntXT3DXNltt7ppCsTDbEG3AD6Vz2pyKZriSOEDzGLEgcD2HpWc12OmjPWxSjidlOWzkdKhyysc5A6ZParVkm9SpYjI4wM/jUjQqeOM5+91rBo6lUtoV4UVoMc4B4xSLFwx3Zzxj0pzHbKQMA9wDxT42J6gYPOR2p2E5hMuFyp56dKZOHCqoGB0z605wSwx93uKkVt68ZwBSsTzsp4ZkwRzjGKiaN2i/uqvrV6NQucjJH51BKxc/KcKKTiUqhnTzlH6g8Y3YqMk/eDHaRxS3SMm75s91GKjt1L5P4jmhIu+lwVzyE4Y96sxyNnaoPP6VEIXRS2Dt9cVPGp2ZABbrxQDehLE4BBP3setadsA2ADkDr71mJGqNyAR61q2hCrkqOOOKpGUnYvPETHtYAAdx0rHv4eCdo/wD11thyYxuYLkdKzb8bkJIIHXipkczdzmbgYDgnFQ23yzqABz0q1dxfeJAqtbDMw9R0+lCOea1Nq1Xau49CdtaAjBAwPrgVRik3RLF0I6GtOyyqESHjHrTYGdLCpYkHiqmwYJz0rWu0COxj5Ws548udpzk81cWRNXOF8b2vzR3QGP4WrkxXpXiGx+22UsCEBjgj6ivOJongkeOVSrg810Rd0cE1ZmcOlIzBRzVzUYNkm6Jc84NUJQcjcCAO9USW7e5KrweKv294CRmsMNtGByKkV9pBoA6R33KPX61638HWC+FLggEf6a3U/wCyK8Khu2yBnOO1e4fBls+DbiQg83z/APoIqKz9w6MGv3nyO2uMudo4AHbvUML4mOAccZoufOYthkG7HJ9KfCi8OWGe5PeuZHpSLsbjOSfyqcyYHzZyT+NVggKnPDDge9SL7EhhmqRk0MtFYXkrE7gSByfSrzZmmYkYEXBPQM3bj2rPhSRJXkyAA24k1egcxRoWOWJLEA+pzQMnkA2rgjnr9KZEmI1wo4PpnipRlVClgD16U4fu1HXOc4HU0xNi7AxA2kH+HPAP1qvHAouD90berH27Crm9nlOQG9AB3pGHPy/dJzyOlUiblQRRiTcwaUNkn5vlB7DFMMM0hUMY9hOFwAMfSnuyqxVZAcHHHT6UxpgduEbJ4BPGPXirTG7lfUkjtVLBN8v8Ths59j6Vy+turMpUgttGQFxz6V0t4WmDrIry7ifmVsfpWFeWcjqqgj5csSp/Sm3cqm7GPhoPkOVYcZHX/wDVTWBCZBbJHP1rUFlKUOQM53cj9KqlCVIxgN2NZuJuqhBDEWb5gCwPGewq21rsR0DZ9PapLWESHoAUGMk81ZkRVGBy2PzoSM5VXcw5E2udjZOME08bgmVJx/OrF1Cy5YKAncd81HtPyhu3OBU2NFNNXKk2VXA7/nio0LMm0YwevHSpbiIlsg4HU+9OVcRcHoKViuayKM8RZ22kMo6etFtbhQCcAnoCasOpPQYPqKWJOcbe3Q9DSsVz6WIgjIGCghDww9afDGSzbuB2q5BbF+OeRye1TxWzEYGRjjmiwvaFERqXCkEjtnvVxF+QY5461MYVDAYOfXt+FTQwBWUnaPc9qLEuQLkheQSB0FVLoDHzDjofSr77d3A4x1FVpIjuI6jGaiRFzm9QAEbAdccVm2pDzgjI7VraxhQeMCsG1fbMcE4DYpIyqLqdJaBdu4g8ela6lVj3HGMVkWLBcE8jtWnFtVdrfMAO9NkodPhlYKOSPyrNdfK4P0q/xuHXZ1HvWdfKd+c9ySKqImUJfnb096wvEOjLqMAlhAWdTg+9bxwFHHNJbhlQEjqSa2Tscs4XOQfT40Xp+dZl/YRspBXHpXTTgEEVRmg3DNXzEyp9jhbuxeMnYMj1xVRwVPcfWu3ntxtIxWVdacsgyR3qrmTi0c1uIcc/jXvPwSJbwG7Mdxa9kP4bVrxG8sWjY+X29a9w+CwI8AqCDk3k3/stZ1fhOjB/xPkdxLkHAHXv2pYyqIFIz74pGX5uvy0nmbOSOO4rFHfLctRncBxjBqfGxeecCqFux3/Pjg9a0FIeIfic1SIkDESR9DgHketOZlDHaOD+ZpkL7QQ/zDtUERdpXXB4FARRqbiQCDtOMDNTRHMG5yCVOOOp9qr2zDyjvHHdu4o8xmXyx91XzwKAaLBm2nEcY5HQnketI0yYXeWY+i9KhmYbTtAJPdetSwjcVXKnA57VSJaIWKsx4VS3QKKYD5Snb8reuealkIdj5aj5T0AxVZYgVcyYDZwuaoZDcF9uUA6EZxzn2qjwxDuzNgYweufWr0hKjYgBwOPTFVvKLAucgA9KaERufuksCP4sDpWQ6O0xO0nB4J44ramj+YYIKnmq7qzE7vToO9AlKxQhYK2GAAzjPc1K8w4bjLcD1FR3aMhQg5yc8VWDfMAVJJ6Uh7lsoHiznrUJtypJHQ+3WpYmygIGD0NTyHMed3sPWlYnmadjImADN3IqsG8z7oOF681dkB6kcdxVG4Q+aPJPHfjilY6Iu6LKxKud5JI64NJBtFyA54II5PeqyuS/fJqyq+YQR8pOME9sVLKS0NqKDESgHjAzSOhHPbvSRS/KCc++ajeUqWHIHuetBkkyYIqn72fr0FV1dWcrnJxkelRXDHysK455IAqKMbSvTB684zSNFEsT5UA/hUbSDGM89KZcHbMpLZGPrVaRsSY5/CpkgSMfWSX3gct0wa55Ay3IVuCTXUahGwcnIyehrnp0Al3d/WpRM1obdmxKe+OPpVuBz5gUnBYYz7etZVlLmNR6dauxbicjr0I9qoyRdmlEaiMFmI757VXuHyg9DS7WaQLIvI6Uy4HIHb1qkDKZVuMnvjFWJYyAoyflHSpoIhM6D+7yalkQFWzxg9xTuRY5RUDk5+tQyrk4A4q4n3Pwqseh+tWHKU5IgT0qlPFxWk3Wqtx92i5DijDuYA2eK9Y+FKbPBdsnK7riYn8wK8vm+/8AjXqvw948H2eOP30n/oVRN3VjTDxSlc66f7p4yenBqjNKrL5eRuPSpbgDaTgZz1qMKBBwBUROhonDFdqg9RV63YNApAxkYFUYR8x/Cr8wCwjbxz2q0Zy2HIApyO/TNMkkCYlXPo2KH/1DfSnRf6pv92mKJYiZduXBOeQRSyHavVsHrnsKr2JPlLyepqW5JMCnPO6gobEwYk4IXGCe9WldlZUTG8jrmq/Qrimx9/rTQNE5LFdpTr1IqNR5hbexx1zircHKPn0/rUYHJ+lURcpNuXdtH3Scv2IphZCoBOG69cGrA/1Uv1WqYAN6Mj+GmJkUpCoQM5aqc0jnjoR3q6/Ue1VZug/GgnoU5kby+c7ic1AQQoOSD29qskkhcmq833mqrDiyRTsQgfMeuKZLMGXCdT0+tOUDyZTjkAc1Sn4jXHFSUldjtwCoXb5j2ppkR23KTkc4qCT/AFbHvilh6j6VJolYZI2Sojxnr7mrEeGi+Q8ZzzVc8RZHXB5qbT/vH/cFTubJ6EjtIpKuGBzmpWlOOuB3OetRzk7P+BVTQn7FnPO41JSV1ctB9ueSWzwAKkDjYV5JzVSc4MJHXcP5VdAAUYApAxs2SqsO3pUbBtwckknqanXiF8Uw/wCpI7UmSUr1cpznj9a5+/iO52B5xXUTgbv+A1hXPUfQ1HUhlG2J3kKCDjrWrAQGVh2GPrWZF/rD9BV+D/Wr+NaGDNGFn83Dc5457ii7C7uRtUcD3p7Egx4OKhn5xnnANCAtaai/ZS/RmP6VBdArB16nJqeP7qjt5YqG8/1LfhS6iZ//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Yellow-red or yellow-brown plaques with atrophy and telangiectasias are consistent with necrobiosis lipoidica.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_45_7891=[""].join("\n");
var outline_f7_45_7891=null;
var title_f7_45_7892="Natamycin: Patient drug information";
var content_f7_45_7892=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Natamycin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/39/43634?source=see_link\">",
"     see \"Natamycin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Natacyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Natacyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat eye infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702577",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to natamycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699335",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature or in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12087 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-094BD8D684-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_45_7892=[""].join("\n");
var outline_f7_45_7892=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200081\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200082\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013996\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013995\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014000\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014001\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014003\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013998\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013999\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014004\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014005\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/39/43634?source=related_link\">",
"      Natamycin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_45_7893="Chapter 8A: Effective circulating volume and the steady state";
var content_f7_45_7893=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 8A: Effective circulating volume and the steady state",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/45/7893/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/45/7893/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/45/7893/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/45/7893/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/45/7893/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/45/7893/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/45/7893/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/45/7893/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maintenance of adequate tissue perfusion is essential for normal cellular metabolism by providing nutrients and by removing waste products. It is not surprising, therefore, that multiple sensors and multiple effectors are involved in this process. The presence of several levels of control illustrates an important difference between the regulation of volume and the regulation of osmolality or the concentration of a particular solute. Maintenance of concentration can often be achieved with only a single sensor (such as the hypothalamic osmoreceptors), since all tissues are perfused by the same arterial blood. In comparison, there may be marked variability in regional perfusion, necessitating the presence of local sensors.",
"   </p>",
"   <p>",
"    A simple example is changing from the sitting to the standing position which, by gravity, tends to result in hyperperfusion of and fluid accumulation in the lower extremities, and hypoperfusion of the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/1\">",
"     1",
"    </a>",
"    ]. In this setting, activation of the carotid sinus baroreceptors with a subsequent increase in sympathetic activity helps to preserve cerebral perfusion (see below).",
"   </p>",
"   <p>",
"    This chapter will review how the effective circulating volume is regulated, both in the face of changes in dietary Na+ intake and in disease states in which tissue perfusion is altered. In particular, it will show how the neurohumoral influences and the reabsorptive characteristics of the different nephron segments that have been discussed in Chaps. 3 to 5 are integrated in an appropriate fashion to maintain the steady state. The physiologic and clinical importance of the steady state will also be reviewed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <strong>",
"     effective circulating volume",
"    </strong>",
"    refers to that part of the extracellular fluid (ECF) that is in the arterial system (normally about 700 mL in a 70 kg man) and is effectively perfusing the tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/2\">",
"     2",
"    </a>",
"    ]. However, a better physiologic definition is the pressure perfusing the arterial baroreceptors in the carotid sinus and glomerular afferent arterioles, since it is changes in pressure (or stretch) rather than volume or flow that is generally sensed at these sites.",
"   </p>",
"   <p>",
"    The effective circulating volume usually varies directly with the ECF volume. Both of these parameters are typically proportional to total body Na+ stores, since Na+ salts are the primary extracellular solutes that act to hold water within the extracellular space (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12662?source=see_link\">",
"     \"Chapter 7A: Exchange of water between the cells and ECF\"",
"    </a>",
"    ). As a result, the regulation of Na+ balance (by alterations in urinary Na+ excretion) and the maintenance of the effective circulating volume are closely related functions. Na+ loading will tend to produce volume expansion, whereas Na+ loss will lead to volume depletion.",
"   </p>",
"   <p>",
"    In some settings, however, the effective circulating volume may be",
"    <strong>",
"     independent",
"    </strong>",
"    of the ECF volume, the plasma volume, or even the cardiac output (",
"    <a class=\"graphic graphic_table graphicRef82305 \" href=\"UTD.htm?18/62/19435\">",
"     table 1",
"    </a>",
"    ). In congestive heart failure, for example, the effective circulating volume is reduced because a primary decrease in cardiac output lowers the pressure at the baroreceptors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. As will be discussed below, this decline in pressure and flow induces compensatory fluid retention by the kidney, leading to expansion of the extracellular fluid. The net result is effective volume depletion in association with increases in both the plasma and total ECF volumes.",
"   </p>",
"   <p>",
"    The increase in volume in this setting is in part",
"    <strong>",
"     appropriate",
"    </strong>",
"    because the associated rise in intracardiac filling pressure can, by increasing cardiac stretch, improve cardiac contractility and raise the cardiac output and systemic blood pressure toward normal. On the other hand, the elevation in intravascular pressure can also be maladaptive in that it promotes fluid movement out of the vascular space, potentially leading to both pulmonary and peripheral edema.",
"   </p>",
"   <p>",
"    The effective circulating volume may, in some cases, also be independent of the cardiac output. In addition to a reduction in cardiac output, effective volume depletion can occur when perfusion pressure is reduced by a fall in systemic vascular resistance (peripheral vasodilatation) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/2\">",
"     2",
"    </a>",
"    ]. In the presence of an arteriovenous fistula, for example, the cardiac output is elevated by an amount equal to the flow through the fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/4\">",
"     4",
"    </a>",
"    ]. However, this fluid can be considered to be circulating",
"    <strong>",
"     ineffectively",
"    </strong>",
"    , since it bypasses the capillary circulation. Thus, the patient is normovolemic, despite the presence of a cardiac output that may be substantially elevated.",
"   </p>",
"   <p>",
"    The potential dissociation between the effective circulating volume and the cardiac output can also be illustrated by the hemodynamic changes seen in patients with advanced cirrhosis and ascites (",
"    <a class=\"graphic graphic_table graphicRef82305 \" href=\"UTD.htm?18/62/19435\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In this disorder, the ECF volume is expanded because of the ascites, the plasma volume is increased due in part to fluid accumulation in the markedly dilated but slowly circulating splanchnic venous circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/5\">",
"     5",
"    </a>",
"    ], and the cardiac output is often elevated because of multiple arteriovenous fistulas throughout the body such as the spider angiomas on the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite all of these signs suggesting volume expansion, most of the excess fluid is hemodynamically ineffective and these patients behave as if they are volume depleted due to marked peripheral vasodilatation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=see_link\">",
"     \"Hyponatremia in patients with cirrhosis\"",
"    </a>",
"    .) This is exemplified by reductions in systemic vascular resistance and blood pressure, a very low rate of urinary Na+ excretion (often below 10",
"    <span class=\"nowrap\">",
"     meq/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/7\">",
"     7",
"    </a>",
"    ], a reduction in the blood volume in the cardiopulmonary circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/8\">",
"     8",
"    </a>",
"    ], and a progressive increase in the secretion of the hormones typically released in response to hypovolemia: renin, norepinephrine, and antidiuretic hormone (ADH) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, the effective circulating volume is an unmeasured entity that reflects tissue perfusion and may be independent of other hemodynamic parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/2\">",
"     2",
"    </a>",
"    ]. The diagnosis of effective volume depletion is usually made by demonstrating renal Na+ retention as evidenced by a urine Na+ concentration below 15 to 20",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    This relationship is generally true as long as there is neither renal Na+ wasting (most often due to diuretic therapy or underlying renal disease) nor selective renal or glomerular ischemia (as with bilateral renovascular disease or acute glomerular disease). In the latter setting, urinary Na+ excretion may be low without systemic hypoperfusion, whereas obligatory Na+ wasting can prevent the renal Na+ retention that is normally associated with volume depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECTIVE CIRCULATING VOLUME, RENAL SODIUM EXCRETION, AND THE STEADY STATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kidney is the primary regulator of Na+ and volume balance as urinary Na+ excretion responds in an appropriate manner to changes in the effective circulating volume. When there is an increase in volume, as after a Na+ load [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/11\">",
"     11",
"    </a>",
"    ] or closure of an arteriovenous fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/4\">",
"     4",
"    </a>",
"    ], Na+ excretion rises in an attempt to lower the volume toward normal. Conversely, the kidney retains Na+ in the presence of effective volume depletion. This system of volume regulation must be very efficient, since small alterations in Na+ intake necessitate parallel changes in Na+ excretion that involve less than 1 percent of the filtered Na+ load (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6744?source=see_link&amp;anchor=H4#H4\">",
"     \"Chapter 8C: Regulation of renal Na+ excretion\", section on 'Day-to-day regulation'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The time course of the response to variations in Na+ intake is illustrated in Figure 1 (",
"    <a class=\"graphic graphic_figure graphicRef80933 \" href=\"UTD.htm?9/37/9821\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/11\">",
"     11",
"    </a>",
"    ]. If dietary intake is abruptly increased in a patient on a low-sodium diet, only about one-half of the excess intake is excreted on the first day. The remainder is retained, augmenting body Na+ stores. This elevates the plasma osmolality, which stimulates both thirst and the secretion of ADH (see page 000). The increments in water intake and renal water reabsorption produce water retention, resulting in increases in the effective circulating volume and body weight and the return of the plasma osmolality to normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17875?source=see_link\">",
"     \"Chapter 9A: Water balance and regulation of plasma osmolality\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On subsequent days, a progressively greater fraction of the excess intake is excreted (and less retained) until, by three to four days, a new steady state is achieved in which renal Na+ excretion matches intake [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/12\">",
"     12",
"    </a>",
"    ]. This new steady state is characterized by a mild increase in the effective circulating volume due to the Na+ and water retained on the first four days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. The total quantity of Na+ retained is directly related to the increment in Na+ intake above the previous baseline. Thus, the greater the increase in intake, the greater the increase in steady state extracellular volume (",
"    <a class=\"graphic graphic_figure graphicRef80252 \" href=\"UTD.htm?25/12/25805\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The same sequence occurs, in reverse, if Na+ intake is now reduced. Negative Na+ balance occurs until there has been enough loss of volume to lower Na+ excretion to the reduced level of intake.",
"   </p>",
"   <p>",
"    Thus, a high-sodium diet is characterized by increases in volume and Na+ excretion and a low-sodium diet by decreases in volume and Na+ excretion. The changes in volume are essential, since they constitute the signal that allows urinary Na+ excretion to vary appropriately with fluctuations in Na+ intake. Let us assume, for the sake of simplicity, that Na+ excretion in normal subjects is primarily determined by the Na+-retaining hormone aldosterone and the Na+-losing hormone atrial natriuretic peptide (ANP). As Na+ intake rises from 10 to a higher than normal value of 350",
"    <span class=\"nowrap\">",
"     meq/day,",
"    </span>",
"    there must be a fall in the secretion of aldosterone and a rise in that of ANP to result in the necessary reduction in tubular Na+ reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/15\">",
"     15",
"    </a>",
"    ]. Furthermore, the rate of release of these hormones must stay at this new level if Na+ excretion is to remain at 350",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef53243 \" href=\"UTD.htm?0/58/941\">",
"     figure 3",
"    </a>",
"    ). The signal for the continued suppression of aldosterone and stimulation of ANP is the persistent volume expansion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to its role in volume regulation in normal subjects, the steady state also has important implications in the pathogenesis and treatment of disease states. As an example, diuretics inhibit Na+ reabsorption at different sites in the nephron; they are most often given to patients with edema or hypertension to lower the ECF volume. The initial volume loss activates Na+-retaining mechanisms, such as the renin-angiotensin system, that act to limit further losses. These counterregulatory forces are so efficient that, assuming diuretic dose is constant, all of the fluid and electrolyte losses occur in the first 7 to 14 days of therapy, with the maximum natriuretic response being induced by the first dose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6868?source=see_link\">",
"     \"Time course of loop and thiazide diuretic-induced electrolyte complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A steady state is also achieved with changes in intake of other electrolytes. If, for example, K+ intake is increased, the new steady state will be characterized by a limited elevation in body K+ stores and a small rise in the plasma K+ concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7893/abstract/16\">",
"     16",
"    </a>",
"    ]. The latter change will be the stimulus to maintain an increased rate of K+ excretion, a response that is mediated in part by enhanced secretion of aldosterone (see Chap. 12).",
"   </p>",
"   <p>",
"    These observations have important implications for the development of many fluid and electrolyte disorders. The capacity to excrete Na+, K+, HCO3-, and H2O is so great in normal subjects that too much Na+ (edema), too much K+ (hyperkalemia), too much HCO3- (metabolic alkalosis), and too much H2O (hyponatremia) will not persist unless there is an abnormality in the renal excretion of that substance. The excretion of H2O, for example, occurs via the suppression of the release of antidiuretic hormone, resulting in the formation of a dilute urine. Thus, the differential diagnosis of hyponatremia primarily consists of those disorders in which ingested water cannot be excreted normally, usually due to an inability to suppress the release of antidiuretic hormone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This text is continued separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/3/17461?source=see_link\">",
"     \"Chapter 8B: Regulation of the effective circulating volume\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7893/abstract/1\">",
"      Epstein, FH, Goodyer, AN, Laurason, FD, Relman, AS. Studies of the antidiuresis of quiet standing: The importance of changes in plasma volume and glomerular filtration rate. J Clin Invest 1951; 30:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7893/abstract/2\">",
"      Schrier RW. An odyssey into the milieu int&eacute;rieur: pondering the enigmas. J Am Soc Nephrol 1992; 2:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7893/abstract/3\">",
"      Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2). N Engl J Med 1988; 319:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7893/abstract/4\">",
"      EPSTEIN FH, POST RS, MCDOWELL M. The effects of an arteriovenous fistula on renal hemodynamics and electrolyte excretion. J Clin Invest 1953; 32:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7893/abstract/5\">",
"      Lieberman FL, Reynolds TB. Plasma volume in cirrhosis of the liver: its relation of portal hypertension, ascites, and renal failure. J Clin Invest 1967; 46:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7893/abstract/6\">",
"      KOWALSKI HJ, ABELMANN WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953; 32:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7893/abstract/7\">",
"      Arroyo V, Bosch J, Gaya-Beltr&aacute;n J, et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 1981; 94:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7893/abstract/8\">",
"      Henriksen JH, Bendtsen F, Gerbes AL, et al. Estimated central blood volume in cirrhosis: relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor. Hepatology 1992; 16:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7893/abstract/9\">",
"      P&eacute;rez-Ayuso RM, Arroyo V, Camps J, et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 1984; 26:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7893/abstract/10\">",
"      Miller TR, Anderson RJ, Linas SL, et al. Urinary diagnostic indices in acute renal failure: a prospective study. Ann Intern Med 1978; 89:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7893/abstract/11\">",
"      Strauss, MB, Lamdin, E, Smith, WP, Bleifer, DJ. Surfeit and deficit of sodium: A kinetic concept of sodium excretion. Arch Intern Med 1958; 102:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7893/abstract/12\">",
"      Walser M. Phenomenological analysis of renal regulation of sodium and potassium balance. Kidney Int 1985; 27:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7893/abstract/13\">",
"      Bonventre JV, Leaf A. Sodium homeostasis: steady states without a set point. Kidney Int 1982; 21:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7893/abstract/14\">",
"      Simpson FO. Sodium intake, body sodium, and sodium excretion. Lancet 1988; 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7893/abstract/15\">",
"      Sagnella GA, Markandu ND, Buckley MG, et al. Hormonal responses to gradual changes in dietary sodium intake in humans. Am J Physiol 1989; 256:R1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7893/abstract/16\">",
"      Rabelink TJ, Koomans HA, Hen&eacute; RJ, Dorhout Mees EJ. Early and late adjustment to potassium loading in humans. Kidney Int 1990; 38:942.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7255 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-E2FE460E4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_45_7893=[""].join("\n");
var outline_f7_45_7893=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECTIVE CIRCULATING VOLUME, RENAL SODIUM EXCRETION, AND THE STEADY STATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7255\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7255|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/37/9821\" title=\"figure 1\">",
"      Steady state sodium balance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/12/25805\" title=\"figure 2\">",
"      Na intake and Na balance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/58/941\" title=\"figure 3\">",
"      Hormonal response to Na load",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7255|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/62/19435\" title=\"table 1\">",
"      Potential independence of effective arterial blood volume from other hemodynamic measures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12662?source=related_link\">",
"      Chapter 7A: Exchange of water between the cells and ECF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/3/17461?source=related_link\">",
"      Chapter 8B: Regulation of the effective circulating volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6744?source=related_link\">",
"      Chapter 8C: Regulation of renal Na+ excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17875?source=related_link\">",
"      Chapter 9A: Water balance and regulation of plasma osmolality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=related_link\">",
"      Hyponatremia in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6868?source=related_link\">",
"      Time course of loop and thiazide diuretic-induced electrolyte complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_45_7894="Normal BP boys";
var content_f7_45_7894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Blood pressure levels for boys by age and height percentile",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"16\" width=\"6%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Age",
"        <br/>",
"        (year)",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        BP",
"        <br/>",
"        (percentile)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Systolic BP (mmHg)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Diastolic BP (mmHg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"7\">",
"        Percentile of height",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"7\">",
"        Percentile of height",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        5",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        10",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        25",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        75",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        5",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        10",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        25",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        75",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        1",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        66",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        2",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        71",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        3",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        4",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        5",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        82",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        6",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        57",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        84",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        7",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        78",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        86",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        8",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        61",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        88",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        9",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        77",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        89",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        10",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        82",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        90",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        11",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        78",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        82",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        90",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        12",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        83",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        91",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        13",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        83",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        137",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        91",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        14",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        84",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        139",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        92",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        15",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        66",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        93",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        16",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        82",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        137",
"       </td>",
"       <td>",
"        137",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        87",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        137",
"       </td>",
"       <td>",
"        139",
"       </td>",
"       <td>",
"        141",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        144",
"       </td>",
"       <td>",
"        145",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        94",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        17",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        84",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        139",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        89",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"        <sup>",
"         th",
"        </sup>",
"       </td>",
"       <td>",
"        139",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        141",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        145",
"       </td>",
"       <td>",
"        146",
"       </td>",
"       <td>",
"        147",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        97",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The 90",
"    <sup>",
"     th",
"    </sup>",
"    percentile is 1.28 standard deviation, 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile is 1.645 standard deviation, and the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile is 2.326 over the mean.",
"    <div class=\"footnotes\">",
"     BP: blood pressure.",
"    </div>",
"    <div class=\"reference\">",
"     From: the Fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. National Heart, Lung and Blood Institute. National Institutes of Health. May 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_45_7894=[""].join("\n");
var outline_f7_45_7894=null;
var title_f7_45_7895="Vitamin D2 (ergocalciferol): Drug information";
var content_f7_45_7895=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vitamin D2 (ergocalciferol): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/13/36052?source=see_link\">",
"    see \"Vitamin D2 (ergocalciferol): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/10/27814?source=see_link\">",
"    see \"Vitamin D2 (ergocalciferol): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Calciferol&trade; [OTC];",
"     </li>",
"     <li>",
"      Drisdol&reg;;",
"     </li>",
"     <li>",
"      Drisdol&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F166128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Drisdol&reg;;",
"     </li>",
"     <li>",
"      Ostoforte&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F166157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin D Analog",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F166131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     1 mcg = 40 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Vitamin D:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults 19-70 years: RDA: 600 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Female: Pregnancy/Lactating: RDA: 600 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoporosis prevention (unlabeled use):",
"     </b>",
"     Adults &ge;50 years: 800-1000 units/day (NOF guidelines, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin D deficiency treatment (unlabeled dose):",
"     </b>",
"     Oral:  50,000 units once per week for 8 weeks, followed by 50,000 units every 2-4 weeks thereafter for maintenance of adequate levels (Holick, 2007)",
"     <b>",
"      or",
"     </b>",
"     50,000 units twice per week for 5 weeks (Stechschulte, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin D deficiency/insufficiency",
"     </b>",
"     in patients with CKD stages 3-4 (K/DOQI guidelines):",
"     <b>",
"      Note:",
"     </b>",
"     Dose is based on 25-hydroxyvitamin D serum level (25[OH]D): Oral (treatment duration should be a total of 6 months):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum 25(OH)D &lt;5 ng/mL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     50,000 units/week for 12 weeks, then 50,000 units/month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum 25(OH)D 5-15 ng/mL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     50,000 units/week for 4 weeks, then 50,000 units/month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum 25(OH)D 16-30 ng/mL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     50,000 units/month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypoparathyroidism:",
"     </b>",
"     Oral: 625 mcg to 5 mg/day (25,000-200,000 units) and calcium supplements",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nutritional rickets and osteomalacia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adults with normal absorption:",
"     </i>",
"     25-125 mcg/day (1000-5000 units)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adults with malabsorption:",
"     </i>",
"     250-7500 mcg (10,000-300,000 units)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin D",
"     </b>",
"     <b>",
"      <i>",
"       -dependent",
"      </i>",
"     </b>",
"     <b>",
"      rickets:",
"     </b>",
"     Oral: 250 mcg to 1.5 mg/day (10,000-60,000 units)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin D",
"     </b>",
"     <b>",
"      <i>",
"       -resistant",
"      </i>",
"     </b>",
"     <b>",
"      rickets:",
"     </b>",
"     Oral: 12,000-500,000 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Familial hypophosphatemia:",
"     </b>",
"     Oral: 10,000-60,000 units plus phosphate supplements",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F166147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/10/27814?source=see_link\">",
"      see \"Vitamin D2 (ergocalciferol): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     1 mcg = 40 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Vitamin D:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0-12 months: Adequate intake: 400 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-18 years: RDA: 600 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Adequate intake:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Breast-fed (fully or partially) Infants:",
"     </i>",
"     Oral: 10 mcg/day (400 units/day) beginning in the first few days of life; continue supplementation until infant is weaned to &ge;1 L/day or 1 quart/day of vitamin D-fortified formula or whole milk (after 12 months of age)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Nonbreast-fed Infants, Older Children ingesting &lt;1000 mL of vitamin D-fortified formula or milk:",
"     </i>",
"     Oral: 10 mcg/day (400 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children with increased risk of vitamin D deficiency (chronic fat malabsorption, maintained on chronic antiseizure medications):",
"     </i>",
"     Oral: Higher doses may be required; use laboratory testing (25 [OH]D, PTH, bone mineral status) to evaluate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin D deficiency/insufficiency",
"     </b>",
"     in patients with CKD stages 3-4 (K/DOQI guidelines):",
"     <b>",
"      Note:",
"     </b>",
"     Dose is based on 25-hydroxyvitamin D serum level (25[OH]D): Oral (treatment duration should be a total of 3 months):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum 25(OH)D &lt;5 ng/mL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     8000 units/day for 4 weeks, then 4000 units/day for 2 months",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     50,000 units/week for 4 weeks, then 50,000 units twice a month for 2 months",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Serum 25(OH)D 5-15 ng/mL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4000 int units/day",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     50,000 int units every other week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum 25(OH)D 16-30 ng/mL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2000 units/day",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     50,000 units every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypoparathyroidism:",
"     </b>",
"     Oral: 1.25-5 mg/day (50,000-200,000 units) and calcium supplements",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nutritional rickets and osteomalacia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children with normal absorption:",
"     </i>",
"     25-125 mcg/day (1000-5000 units)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children with malabsorption:",
"     </i>",
"     250-625 mcg/day (10,000-25,000 units)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin D",
"     </b>",
"     <b>",
"      <i>",
"       -dependent",
"      </i>",
"     </b>",
"     <b>",
"      rickets:",
"     </b>",
"     Oral: 75-125 mcg/day (3000-5000 units); maximum: 1500 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin D",
"     </b>",
"     <b>",
"      <i>",
"       -resistant",
"      </i>",
"     </b>",
"     <b>",
"      rickets:",
"     </b>",
"     Oral: 12,000-500,000 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Familial hypophosphatemia:",
"     </b>",
"     Oral: 40,000-80,000 units plus phosphate supplements; dose may be reduced once growth is complete",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F166132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     1 mcg = 40 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Vitamin D:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &le;70 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;70 years: RDA: 800 units/day",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15822439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15822440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F166109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 50,000 units [1.25 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Drisdol&reg;: 50,000 units [contains soybean oil, tartrazine; 1.25 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral: 50,000 units [1.25 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [drops]: 8000 units/mL (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calciferol&trade;: 8000 units/mL (60 mL) [contains propylene glycol; 200 mcg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Drisdol&reg;: 8000 units/mL (60 mL) [contains propylene glycol; 200 mcg/mL, OTC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 400 units",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F166094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F166112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of refractory rickets, hypophosphatemia, hypoparathyroidism; dietary supplement",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5075481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of vitamin D deficiency in patients with chronic kidney disease (CKD); osteoporosis prevention",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F166164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Calciferol&trade; may be confused with calcitriol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Drisdol&reg; may be confused with Drysol&trade;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ergocalciferol may be confused with alfacalcidol, cholecalciferol",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Liquid vitamin D preparations have the potential for dosing errors when administered to infants. Droppers should be clearly marked to easily provide 400 international units. For products intended for infants, the FDA recommends that accompanying droppers deliver no more than 400 international units per dose.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F166155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Endocrine &amp; metabolic: Hypervitaminosis D (signs and symptoms include hypercalcemia, resulting in headache, nausea, vomiting, lethargy, confusion, sluggishness, abdominal pain, bone pain, polyuria, polydipsia, weakness, cardiac arrhythmias [eg, QT shortening, sinus tachycardia], soft tissue calcification, calciuria, and nephrocalcinosis)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F166116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ergocalciferol or any component of the formulation; hypercalcemia; malabsorption syndrome; hypervitaminosis D or abnormal sensitivity to the toxic effects of vitamin D",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F166098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment or diseases that may impair vitamin D metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rickets: The range between therapeutic and toxic doses is narrow in vitamin D-resistant rickets; adjust dose based on clinical response to avoid toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tartrazine: Products may contain tartrazine, which may cause allergic reactions in certain individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Adequate calcium supplementation is required; calcium and phosphorous levels must be monitored during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Toxicity: Effects of vitamin D can last &ge;2 months after therapy is discontinued.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Vitamin D Analogs. More specifically, orlistat may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with orlistat.  If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after orlistat.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F166105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (manufacturer); A/C (dose exceeding RDA recommendation; per expert analysis) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5075482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Abnormalities have been observed in animal studies with maternal doses causing hypervitaminosis D. Doses larger than the RDA should be avoided during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F166135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5075484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small quantities of vitamin D are found in breast milk following normal maternal exposure via sunlight and diet. The amount in breast milk does not correlate with serum levels in the infant. Therefore, vitamin D supplementation is recommended in all infants who are partially or exclusively breast fed. Hypercalcemia has been noted in a breast-feeding infant following maternal use of large doses of ergocalciferol; high doses should be avoided in lactating women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5075487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vitamin D is found in fish, fortified milk, fortified cereal, and infant formulas; it is also produced by exposure to sunlight. Multivitamin supplements containing vitamin D may be required for breast fed infants, those ingesting &lt;1000 ml/day of vitamin D-fortified formula or milk, adolescents who do not obtain 400 units/day through vitamin D-fortified milk (100 int units/8 ounce serving), and children at increased risk of vitamin D deficiency.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Supplemental calcium and/or phosphorous may be required depending on the indication for therapy. Alternately, a low phosphate diet and/or the use of a nonaluminum-binding agent may be required.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5686151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Drisdol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50000 unit (50): $154.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Ergocalciferol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50000 unit (50): $95.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Calcidol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8000 units/mL (60 mL): $99.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Calciferol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8000 units/mL (60 mL): $170.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Drisdol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8000 units/mL (60 mL): $208.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ergocalciferol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8000 units/mL (60 mL): $100.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vitamin D Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 unit (1): $0.05",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F166107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum calcium, creatinine, BUN, and phosphorus every 1-2 weeks; x-ray bones monthly until stabilized; signs and symptoms of vitamin D intoxication",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Children at increased risk of vitamin D deficiency (chronic fat malabsorption, chronic antiseizure medication use) require serum 25(OH)D, PTH, and bone mineral status to evaluate.  If vitamin D supplement required, then 25(OH)D levels should be repeated at 3-month intervals until normal. PTH and bone mineral status should be monitored every 6 months until normal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Vitamin D deficiency/insufficiency in patients with CKD stages 3-4: Measure serum 25(OH)D levels after 3 months of treatment in children or after 6 months in adults. Discontinue ergocalciferol (or any vitamin D supplements) if the corrected total serum calcium level is &gt;10.2 mg/dL.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F166110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum calcium times phosphorus should not exceed 70 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"     to avoid ectopic calcification",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D deficiency: There is no clear consensus on a reference range for total serum 25(OH)D concentrations or the validity of this level as it relates clinically to bone health. In addition, there is significant variability in the reporting of serum 25 (OH)D levels as a result of different assay types in use. However, the following ranges have been suggested:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults (NAS, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &lt;30 nmol/L (12 ng/mL): At risk for deficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     30-50 nmol/L (12-20 ng/mL): Potentially at risk for inadequacy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;50 nmol/L (20 ng/mL): Sufficient levels in practically all persons",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;125 nmol/L (50 ng/mL): Concern for risk of toxicity",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;margin-right:4em;\">",
"     Children (Misra, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &lt;37.5 nmol/L (15 ng/mL): At risk for deficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     37.5-50 nmol/L (15-20 ng/mL): Potentially at risk for inadequacy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;50 nmol/L (20 ng/mL): Sufficient levels in practically all children",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;250 nmol/L (100 ng/mL): Concern for risk of toxicity",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F166120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adekon (MX);",
"     </li>",
"     <li>",
"      Aderowest (MX);",
"     </li>",
"     <li>",
"      AFI-D2 forte (NO);",
"     </li>",
"     <li>",
"      Aquasol AD (MX);",
"     </li>",
"     <li>",
"      Axed (MX);",
"     </li>",
"     <li>",
"      Biocatines D2 (ES);",
"     </li>",
"     <li>",
"      Calciferol (CZ);",
"     </li>",
"     <li>",
"      Calciferol BD (TH);",
"     </li>",
"     <li>",
"      D-forte (FI);",
"     </li>",
"     <li>",
"      Devitol (AT, FI);",
"     </li>",
"     <li>",
"      Endo-D (IT);",
"     </li>",
"     <li>",
"      Ergosterina Irradiata (IT);",
"     </li>",
"     <li>",
"      Farmobion D2 (IT);",
"     </li>",
"     <li>",
"      Infadin (CZ);",
"     </li>",
"     <li>",
"      Jekovit (FI);",
"     </li>",
"     <li>",
"      One-Alpha (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PR, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Ostelin (AU, IT);",
"     </li>",
"     <li>",
"      Pharmaton Complex (MX);",
"     </li>",
"     <li>",
"      Raquiferol (AR);",
"     </li>",
"     <li>",
"      Raquiferol D2 (PE);",
"     </li>",
"     <li>",
"      Sterogyl (BE, LU);",
"     </li>",
"     <li>",
"      Sterogyl-15 (FR);",
"     </li>",
"     <li>",
"      Uvesterol D (FR);",
"     </li>",
"     <li>",
"      Vigantol (ES);",
"     </li>",
"     <li>",
"      Vigantolo (IT);",
"     </li>",
"     <li>",
"      Vitamina D2 Salf (IT);",
"     </li>",
"     <li>",
"      Vitaminol (GR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F166097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates calcium and phosphate absorption from the small intestine, promotes secretion of calcium from bone to blood; promotes renal tubule phosphate resorption",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F166115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect:~1 month following daily doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Readily; requires bile",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Inactive until hydroxylated hepatically and renally to calcifediol and then to calcitriol (most active form)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cardella CJ, Birkin BL, and Rapoport A, &ldquo;Role of Dialysis in the Treatment of Severe Hypercalcemia: Report of Two Cases Successfully Treated With Hemodialysis and Review of the Literature,&rdquo;",
"      <i>",
"       Clin Nephrol",
"      </i>",
"      , 1979, 12(6):285-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/45/7895/abstract-text/160852/pubmed\" id=\"160852\" target=\"_blank\">",
"        160852",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holick MF, &ldquo;Vitamin D Deficiency,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(3):266-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/45/7895/abstract-text/17634462/pubmed\" id=\"17634462\" target=\"_blank\">",
"        17634462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Calcium and Vitamin D",
"      </i>",
"      , Washington, DC: The National Academies Press, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Children With Chronic Kidney Disease.&rdquo; Available at  file://www.kidney.org/professionals/KDOQI/guidelines_pedbone/index.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Guideline 7. Prevention and Treatment of Vitamin D Insufficiency and Vitamin D Deficiency in CKD Patients.&rdquo; Available at  file://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide7.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Letsou AP and Price LS, &ldquo;Health Aging and Nutrition: An Overview,&rdquo;",
"      <i>",
"       Clin Geriatr Med",
"      </i>",
"      , 1987, 3(2):253-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/45/7895/abstract-text/3555761/pubmed\" id=\"3555761\" target=\"_blank\">",
"        3555761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Misra M, Pacaud D, Petryk A, et al, \"Vitamin D Deficiency in Children and Its Management: Review of Current Knowledge and Recommendations,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 122(2):398-417.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/45/7895/abstract-text/18676559/pubmed\" id=\"18676559\" target=\"_blank\">",
"        18676559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Myrianthopoulos M, &ldquo;Dietary Treatment of Hyperlipidemia in the Elderly,&rdquo;",
"      <i>",
"       Clin Geriatr Med",
"      </i>",
"      , 1987, 3(2):343-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/45/7895/abstract-text/3581018/pubmed\" id=\"3581018\" target=\"_blank\">",
"        3581018",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Osteoporosis Foundation, &ldquo;Clinician&rsquo;s Guide to Prevention and Treatment of Osteoporosis,&rdquo; Washington, DC, 2010. Available at  file://www.nof.org/files/nof/public/content/file/344/upload/159.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pettifor JM, Bikle DD, Cavaleros M, et al, &ldquo;Serum Levels of Free 1,25-Dihydroxyvitamin D in Vitamin D Toxicity,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1995, 122(7):511-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/45/7895/abstract-text/7872586/pubmed\" id=\"7872586\" target=\"_blank\">",
"        7872586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riggs BL and Melton LJ, &ldquo;The Prevention and Treatment of Osteoporosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 327(9):620-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/45/7895/abstract-text/1640955/pubmed\" id=\"1640955\" target=\"_blank\">",
"        1640955",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stechschulte SA, Kirsner RS, and Federman DG, &ldquo;Vitamin D: Bone and Beyond, Rationale and Recommendations for Supplementation,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 2009, 122(9):793-802.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/45/7895/abstract-text/19699370/pubmed\" id=\"19699370\" target=\"_blank\">",
"        19699370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thomas MK, Lloyd-Jones, DM, Thadhani RI, et al, &ldquo;Hypovitaminosis D in Medical Inpatients,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(12):777-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/45/7895/abstract-text/9504937/pubmed\" id=\"9504937\" target=\"_blank\">",
"        9504937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner CL, Greer FR, and the Section on Breastfeeding and Committee on Nutrition, &ldquo;Prevention of Rickets and Vitamin D Deficiency in Infants, Children, and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 122(5):1142-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/45/7895/abstract-text/18977996/pubmed\" id=\"18977996\" target=\"_blank\">",
"        18977996",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10150 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_45_7895=[""].join("\n");
var outline_f7_45_7895=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166127\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166128\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166157\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166131\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166147\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166132\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822439\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822440\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166109\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166094\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166112\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5075481\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166164\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166155\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166116\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166098\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299278\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166103\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166105\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5075482\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166135\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5075484\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5075487\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5686151\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166107\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166110\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166120\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166097\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166115\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10150\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10150|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/13/36052?source=related_link\">",
"      Vitamin D2 (ergocalciferol): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/10/27814?source=related_link\">",
"      Vitamin D2 (ergocalciferol): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_45_7896="Clinical manifestations and diagnosis of fibromyalgia in children and adolescents";
var content_f7_45_7896=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of fibromyalgia in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/45/7896/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/45/7896/contributors\">",
"     Yukiko Kimura, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/45/7896/contributors\">",
"     Gary A Walco, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/45/7896/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/45/7896/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/45/7896/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/45/7896/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/45/7896/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibromyalgia is one of a group of chronic soft tissue pain disorders that are poorly understood. The etiology and pathogenesis of this disorder are unknown, although data indicate a significant central sensitization component is at the root of the syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is characterized by chronic and diffuse musculoskeletal pain, severe fatigue, and non-restorative sleep. Initially described in adults, this disorder is often seen in children and adolescents and is also referred to as juvenile primary fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31031?source=see_link\">",
"     \"Pathogenesis of fibromyalgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of fibromyalgia in children and adolescents will be reviewed here. The treatment and outcome of juvenile fibromyalgia, and the clinical features, diagnosis, and treatment of the disease in adults are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19350?source=see_link\">",
"     \"Treatment and prognosis of fibromyalgia in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link\">",
"     \"Initial treatment of fibromyalgia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic criteria for fibromyalgia in children and adolescents are controversial.",
"   </p>",
"   <p>",
"    In adults, although several different classification schema have been proposed, the most frequently used diagnostic criteria were published by the American College of Rheumatology (ACR) in 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/7\">",
"     7",
"    </a>",
"    ]. The ACR criteria include widespread pain for at least three months duration and the presence of at least 11 tender points at 18 potential sites (",
"    <a class=\"graphic graphic_table graphicRef79179 \" href=\"UTD.htm?26/31/27132\">",
"     table 1",
"    </a>",
"    ). These criteria were based on the evaluation of 293 adult patients (mean age of 44.7 years). The application of these criteria to children, however, has not been validated.",
"   </p>",
"   <p>",
"    In 1985, criteria for diagnosing fibromyalgia in children were published based upon a review of 33 children (mean age 14.7 years, range 9 to 17 years) (",
"    <a class=\"graphic graphic_table graphicRef69755 \" href=\"UTD.htm?39/1/39963\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/3\">",
"     3",
"    </a>",
"    ]. These criteria (referred to as the Yunus criteria) differ from those of the ACR in requiring fewer tender points (5 versus 11) as well as clinical findings beyond diffuse pain. The other major clinical findings include the absence of another underlying condition or cause, and normal laboratory test results.",
"   </p>",
"   <p>",
"    In our clinical practice, we use the Yunus criteria to diagnose children with fibromyalgia, because children can often have all the cardinal symptoms of fibromyalgia but may not necessarily have the number of tender points required by the ACR criteria. In fact, it is generally thought that fibromyalgia in children may occur with fewer tender points.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that the prevalence of fibromyalgia syndrome in children and adolescents is between 1 and 2 percent.",
"   </p>",
"   <p>",
"    Three illustrative examples that used the ACR criteria for diagnosis are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based study of 2408 Israeli children aged 8 to 21 years, 1.2 percent met the criteria for fibromyalgia [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study of 548 Mexican children aged 9 to 17 years found fibromyalgia in 1.3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 1756 third- and fifth-graders in Finland, the prevalence of fibromyalgia was 1.3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective cohort study of 2595 cases (both adults and children) identified by ICD-9 diagnoses from a large, stable health insurance claims database [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/11\">",
"     11",
"    </a>",
"    ], the estimated rates of fibromyalgia among males and females based upon age were 0.5 and 1 percent for zero to four year olds; 1 and 1.4 percent for 5 to 9 year olds; 2 and 2.6 percent for 10 to 14 year olds; and 3.5 and 6.2 percent for 15 to 19 year olds, respectively. These data should be viewed with some skepticism, however, as the rigor of the diagnosis was not evaluated. In addition, the data regarding children less than four years of age is much higher than what would be expected, as fibromyalgia is thought to be almost non-existent in this age group.",
"   </p>",
"   <p>",
"    The age of onset of fibromyalgia is typically in the early adolescent years. Several studies have noted a mean age of onset ranging from 11.5 to 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/3,12-15\">",
"     3,12-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with fibromyalgia account for about 7 percent of all cases referred to tertiary pediatric rheumatology centers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. There is a strong female predominance in the pediatric population, similar to that seen in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/12,17\">",
"     12,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the etiology of fibromyalgia remains unknown, it is currently considered to be a disorder of pain regulation, classified often under the term \"central sensitization\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/1\">",
"     1",
"    </a>",
"    ]. One widely accepted hypothesis is that fibromyalgia is a disorder of pain regulation due to neuroendocrinologic changes in the central and peripheral nervous systems, which occurs in genetically susceptible individuals possibly in response to environmental triggers. This results in heightened pain perception and hypersensitivity to numerous stimuli.",
"   </p>",
"   <p>",
"    The following is a summary of the data that support this mechanism of central sensitization. They are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31031?source=see_link\">",
"     \"Pathogenesis of fibromyalgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The increased incidence of fibromyalgia in first degree relatives of patients with this condition supports genetic susceptibility.",
"     </li>",
"     <li>",
"      Alterations in pain processing with increased levels of pain mediators and increased activation of pain-sensitive areas of the brain as detected by magnetic resonance imaging are observed in patients with fibromyalgia.",
"     </li>",
"     <li>",
"      Neurohumoral abnormalities are observed in the hypothalamic-pituitary-adrenal axis at baseline and after provocative testing in patients with fibromyalgia.",
"     </li>",
"     <li>",
"      Sleep and mood disturbances are noted in the majority of patients, suggesting underlying central nervous system dysfunction.",
"     </li>",
"     <li>",
"      Autonomic nervous system dysfunction (eg, orthostatic hypotension) is seen more frequently in patients with fibromyalgia compared to the normal population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Comorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several comorbid psychological conditions are associated with fibromyalgia in both children and adults. As discussed above, if the underlying pathogenesis of fibromyalgia is related to neuroendocrine changes in the central and peripheral nervous systems in response to environmental triggers in genetically susceptible individuals, it would not be surprising that other neuropsychological conditions are more prevalent in children with fibromyalgia. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vestibular difficulties [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Depression [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Temperamental instability and increased vulnerability to stress [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sleep disturbances (eg, sleep and periodic limb movements, restless sleep, nocturnal arousals, and motor activity) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/15,23,24\">",
"       15,23,24",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The interactions among these conditions may contribute to the breadth and the severity of symptoms seen in children with fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/22\">",
"     22",
"    </a>",
"    ]. However, it is unclear whether there is a causal relationship between fibromyalgia and any of these disorders, and if so, whether fibromyalgia is a cause or an effect [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/20,25\">",
"     20,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed previously, fibromyalgia is characterized by chronic widespread pain and the presence of tender points. Other common symptoms include fatigue, headache, depressed mood, and disturbed sleep. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following case series illustrate these findings and their frequency:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case series from the United States of 59 children with juvenile fibromyalgia diagnosed at a mean age of 15.5 years, the following symptoms and their frequency were reported [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/26\">",
"       26",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Diffuse pain - 97 percent",
"     </li>",
"     <li>",
"      Headaches - 76 percent",
"     </li>",
"     <li>",
"      Sleep disturbances - 69 percent",
"     </li>",
"     <li>",
"      Stiffness - 29 percent",
"     </li>",
"     <li>",
"      Subjective joint swelling - 24 percent",
"     </li>",
"     <li>",
"      Fatigue - 20 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In another case series from the United States of 45 patients, similar rates of diffuse pain (&gt;90 percent) and headaches (71 percent) were reported [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/12\">",
"       12",
"      </a>",
"      ]. However, there was a higher incidence of sleep disturbances (&gt;90 percent), fatigue (62 percent), and morning stiffness (53 percent) than in the above cohort.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardinal manifestation of fibromyalgia is diffuse musculoskeletal pain involving the arms, legs, back, and neck. Not all parts of the body may be affected simultaneously, but it is important to recognize that this is not a local phenomenon. Affected patients frequently say, \"I hurt all over.\"",
"   </p>",
"   <p>",
"    The pain may be described as an ache or an achy feeling, but terms as varied as \"dull,\" \"sharp,\" \"shooting,\" \"excruciating,\" and \"burning\" also are used by patients to describe the pain. It is usually constant and chronic, not intermittent, and may vary in intensity. It may wake patients from sleep, but as a rule, the disturbed sleep characteristic of fibromyalgia is not caused by pain.",
"   </p>",
"   <p>",
"    Although patients may describe joint pain and stiffness, they will also complain of pain and aching in the muscles, one characteristic that distinguishes fibromyalgia from arthritis. In addition, patients with fibromyalgia do not have swollen or inflamed joints on physical examination, although many will describe subjective perception of joint swelling. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In both Yunus' [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/3\">",
"     3",
"    </a>",
"    ] and ACR [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/7\">",
"     7",
"    </a>",
"    ] criteria for fibromyalgia, chronic pain is a required finding, with the ACR definition specifying a minimum duration of three months (",
"    <a class=\"graphic graphic_table graphicRef79179 \" href=\"UTD.htm?26/31/27132\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef69755 \" href=\"UTD.htm?39/1/39963\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Tender points",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second major finding in patients with fibromyalgia is the presence of multiple tender points. These are highly localized areas of the body (\"points\") that are consistently sensitive to pressure. Palpation of these specific tender points in patients with fibromyalgia usually elicits pain causing a significant reaction in the patient, such as wincing and a withdrawal response. Palpation of \"control\" points should also be included. These points should not be tender, or at least should be less tender than the fibromyalgia tender points. Patients are usually not aware of the presence of the tender points as areas that are particularly painful. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although a total of 24 tender points have been identified, only 18 have been found to be reliable for use in the ACR criteria (",
"    <a class=\"graphic graphic_figure graphicRef79397 \" href=\"UTD.htm?25/4/25671\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Yunus and other investigators have found that the diagnosis of fibromyalgia in children requires fewer tender points than the number needed to diagnose adults according to the ACR definition [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/3,25,27-30\">",
"     3,25,27-30",
"    </a>",
"    ]. Another set of criteria for the clinical diagnosis of fibromyalgia that do not require a tender point examination was approved by the ACR in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/31\">",
"     31",
"    </a>",
"    ]. These criteria, which require a widespread pain index &gt;7 and a score of &gt;5 on a symptom severity (SS) scale, recognize the limitations of the 1990 ACR criteria and present a simple but preliminary case definition that was able to correctly classify 88 percent of cases identified by the ACR classification criteria. These criteria have not been tested in children.",
"   </p>",
"   <p>",
"    The optimal threshold for the number of tender points needed to diagnose both children and adults with fibromyalgia remains uncertain. The ACR criteria were based upon the greatest differentiation of cumulative tender points between the 293 adult patients with fibromyalgia and 265 controls. This number was not validated in a subsequent prospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/7\">",
"     7",
"    </a>",
"    ], and, in fact, reports in adults using fewer tender points than the ACR criteria have demonstrated greater diagnostic sensitivity without a significant loss of specificity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of tender points in the absence of chronic pain does not appear to be predictive of later development of fibromyalgia in children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, the exact number of tender points present in a child with possible fibromyalgia is probably not as important in making the diagnosis of juvenile fibromyalgia as whether the child's constellation of symptoms is consistent with the diagnosis (ie, persistent chronic pain), provided that no other disease process is evident. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is a common and key complaint in children with fibromyalgia, which is similar to adults with this disorder. In the previously mentioned case series, Yunus found that 91 percent of his patients suffered from fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/3\">",
"     3",
"    </a>",
"    ]. The prevalence of fatigue in other series of children with fibromyalgia has ranged from as little as 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/26\">",
"     26",
"    </a>",
"    ] to 80 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/12,13,21\">",
"     12,13,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frequent headaches occur in a majority of patients with fibromyalgia. The reported incidence ranges from 55 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/3,22,24,27\">",
"     3,22,24,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression is common among patients with fibromyalgia. Studies in children have noted a prevalence of depression ranging from as little as 7 percent, when depression was defined by the need for treatment by a psychiatrist [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/26\">",
"     26",
"    </a>",
"    ], to 55 to 61 percent when less stringent criteria were employed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/3,12\">",
"     3,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sleep disturbance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disturbed or interrupted sleep occurs in at least two-thirds of children with fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/12,23,25,28,29\">",
"     12,23,25,28,29",
"    </a>",
"    ]. Patients most often describe difficulty in falling asleep. Despite complaints of severe fatigue, these children often take an hour or more to fall asleep. Even when they do fall asleep, many have difficulty maintaining sleep and wake up during the night. There may be overlap with restless legs syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/24\">",
"     24",
"    </a>",
"    ]. Non-restorative sleep (feeling tired or exhausted even after getting a full night's sleep) is a common complaint in children with fibromyalgia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Psychosocial impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children often suffer from fibromyalgia for many months, sometimes years, before the diagnosis is made. As a consequence, their day-to-day life may be greatly disrupted, often with inconsistent or poor school attendance or a switch to home schooling. Some sleep during the day after not being able to sleep at night because of sleep disturbances. Getting these dysfunctional children to improve adaptive functioning and to attend school regularly should be primary goals for the family and the health care provider.",
"   </p>",
"   <p>",
"    In addition, dietary habits may deteriorate, and many patients fail to participate in any form of exercise and become de-conditioned. This may perpetuate the cycle of pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19350?source=see_link\">",
"     \"Treatment and prognosis of fibromyalgia in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other symptoms in children with fibromyalgia include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Numbness, stiffness, and a subjective sense of soft tissue swelling",
"     </li>",
"     <li>",
"      Feeling cognitively impaired (eg, a perception that they are in a \"fog\")",
"     </li>",
"     <li>",
"      Irritable bowel syndrome, which may be quite severe",
"     </li>",
"     <li>",
"      Anxiety, mood, and behavioral disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Dizziness, postural orthostatic tachycardia syndrome (POTS), or neurocardiogenic orthostatic hypotension have been reported in adults with fibromyalgia [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/27,32,33\">",
"       27,32,33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Joint hypermobility [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of fibromyalgia is made clinically and is based upon the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of chronic, generalized pain and associated features, including fatigue, sleep disturbances, headache, irritable bowel syndrome, and depression.",
"     </li>",
"     <li>",
"      A thorough physical examination that excludes other diagnoses, such as infections, connective tissue disorders, or neurologic conditions. Of note, arthritis and other autoimmune disorders may coexist with so-called \"secondary\" fibromyalgia [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/35,36\">",
"       35,36",
"      </a>",
"      ], but these disorders must be ruled out prior to making a diagnosis of primary fibromyalgia.",
"      <br/>",
"      <br/>",
"      The examination also includes measurement of tender points, which should always be done in the same fashion by applying pressure equivalent to about 4",
"      <span class=\"nowrap\">",
"       kg/cm2",
"      </span>",
"      to selected anatomic locations (",
"      <a class=\"graphic graphic_figure graphicRef79397 \" href=\"UTD.htm?25/4/25671\">",
"       figure 1",
"      </a>",
"      ). Applying enough pressure to whiten the examiner's fingernail bed generates approximately 4",
"      <span class=\"nowrap\">",
"       kg/cm2",
"      </span>",
"      of pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/37\">",
"       37",
"      </a>",
"      ]. The pressure should be applied gradually over a few seconds and to both right and left sides of the body. Control locations, such as over the thumbnail or the mid-forearm, should also be examined and should not be as tender as the predefined tender points.",
"     </li>",
"     <li>",
"      Negative or normal conventional laboratory tests and imaging studies with the possible exception of polysomnography. A small percentage of patients may have a positive test for antinuclear antibodies (ANA), but this likely reflects the underlying presence of incidental positive ANA tests in the general population. Although it is not necessary to perform any of the following studies, normal results of complete blood counts, urinalyses, and chemistry profiles, as well as ANA, rheumatoid factor, acute phase reactants, and serum immunoglobulins, are reassuring and supportive of the diagnosis of fibromyalgia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our practice, we utilize the Yunus diagnostic criteria (",
"    <a class=\"graphic graphic_table graphicRef69755 \" href=\"UTD.htm?39/1/39963\">",
"     table 2",
"    </a>",
"    ), which includes multiple common signs and symptoms seen in children with fibromyalgia and less emphasis upon the specific number of tender points [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for juvenile fibromyalgia includes other pain syndromes, chronic fatigue syndrome, and rheumatic diseases. Differences in clinical features distinguish fibromyalgia from these other disorders, which also present with musculoskeletal pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Complex regional pain syndrome type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex regional pain syndrome type 1 (CRPS; also known as reflex sympathetic dystrophy, posttraumatic sympathetic dystrophy, and Sudeck's atrophy) typically presents with moderate to severe pain that is usually localized to an extremity. This pain is usually accompanied by allodynia (severe pain with even light stroking of the skin of the affected area), edema, and changes in color or temperature of the affected limb. These changes may be subtle early in the disease process, or extreme, with severe atrophy and trophic changes of the skin, hair and nails, and significant dysfunction of involved muscles and joints. Like fibromyalgia, CRPS occurs more frequently in females than males, and is much more common in adolescents.",
"   </p>",
"   <p>",
"    Patients with CRPS are easily distinguished from patients with fibromyalgia because they have localized pain (compared to the vague diffuse pain that occurs in many parts of the body in fibromyalgia), and they usually do not have tender points. In addition, sleep disturbance, fatigue, headaches, and other features of fibromyalgia are not cardinal features of CRPS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37768?source=see_link\">",
"     \"Complex regional pain syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Growing pains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growing pains are common in children, but they are usually seen in school-aged children and not adolescents, as is the case with fibromyalgia. Growing pains typically affect both legs and sometimes the arms and other areas of the body, almost always occur at the end of an active day or in the middle of the night, and may wake a child at night.",
"   </p>",
"   <p>",
"    Children with growing pains are easily distinguished from patients with fibromyalgia because they have localized rather than diffuse pain; their pain is intermittent, only occurs at night, is self-limited rather than chronic and persistent, and is not characterized by tender points; and they do not have other associated symptoms. Growing pains are also far more likely to be relieved by non-steroidal anti-inflammatory drugs (NSAID). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20902?source=see_link\">",
"     \"Growing pains\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Chronic fatigue syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic fatigue syndrome (CFS) is not a pain syndrome. However, at times patients with CFS can have diffuse pain in addition to severe fatigue, indicating possible overlap between CFS and fibromyalgia. In one study of 27 adolescents with CFS, 8 patients also fulfilled diagnostic criteria for fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/38\">",
"     38",
"    </a>",
"    ]. Not surprisingly, patients with fibromyalgia also had more muscle pain, neurologic symptoms, and sleep disturbances than the other patients in the study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Rheumatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE), and other rheumatic diseases are usually easily differentiated from fibromyalgia because of the presence of objective physical findings and laboratory abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=see_link\">",
"     \"Pauciarticular onset juvenile idiopathic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=see_link\">",
"     \"Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=see_link\">",
"     \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35717?source=see_link\">",
"     \"Classification of juvenile arthritis (JRA/JIA)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=see_link\">",
"     \"Systemic lupus erythematosus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rheumatic disease most commonly confused with fibromyalgia is JIA, because the symptoms of musculoskeletal pain and joint stiffness are quite similar in the two diseases. Patients with fibromyalgia will often have joint tenderness and pain on motion of the joint, which may be confused with the inflammatory synovitis of JIA. However, they will also have tenderness of the muscles in areas away from the joints, have tender points, and will lack the objective signs of synovitis that occur in patients with arthritis. In addition, the presence of back pain is not as common in most children with JIA, although it can occur in children with certain types of arthritis, specifically enthesitis related arthritis (or spondyloarthropathy).",
"   </p>",
"   <p>",
"    As a note of caution, fibromyalgia can occur or develop in children with rheumatic diseases such as JIA and SLE, so it is possible for patients to have both [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7896/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In such cases, differentiating pain due to a flare of the underlying disease from pain due to fibromyalgia may be particularly challenging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibromyalgia is one of a group of chronic soft tissue pain disorders that is characterized by chronic and diffuse musculoskeletal pain, severe fatigue, nonrestorative sleep, and the presence of tender points. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the etiology of fibromyalgia is unknown, the proposed mechanism that is currently most widely accepted is that it is a disorder of pain regulation due to neuroendocrinologic changes in the central and peripheral nervous systems, which occurs in genetically susceptible individuals, possibly in response to environmental triggers. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31031?source=see_link\">",
"       \"Pathogenesis of fibromyalgia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In children with fibromyalgia, clinical features include diffuse pain, headache, sleep disturbances, fatigue, depression, and the presence of tender points. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of juvenile fibromyalgia is made clinically and is based upon a history of chronic, generalized pain and associated features (eg, fatigue, sleep disturbances, headache, and depression), a physical examination that demonstrates the presence of tender points and excludes other diagnoses, and negative or normal laboratory tests. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis for juvenile fibromyalgia includes other pain disorders (eg, complex regional pain syndrome type 1), growing pains, chronic fatigue syndrome, and rheumatic diseases. Differences in clinical features usually distinguish fibromyalgia from these other disorders, which also present with musculoskeletal pain. However, there may be considerable overlap and more than one condition may co-exist in individual patients. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/1\">",
"      Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011; 152:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/2\">",
"      Yunus MB. Role of central sensitization in symptoms beyond muscle pain, and the evaluation of a patient with widespread pain. Best Pract Res Clin Rheumatol 2007; 21:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/3\">",
"      Yunus MB, Masi AT. Juvenile primary fibromyalgia syndrome. A clinical study of thirty-three patients and matched normal controls. Arthritis Rheum 1985; 28:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/4\">",
"      Buskila D. Fibromyalgia in children--lessons from assessing nonarticular tenderness. J Rheumatol 1996; 23:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/5\">",
"      Breau LM, McGrath PJ, Ju LH. Review of juvenile primary fibromyalgia and chronic fatigue syndrome. J Dev Behav Pediatr 1999; 20:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/6\">",
"      Anthony KK, Schanberg LE. Juvenile primary fibromyalgia syndrome. Curr Rheumatol Rep 2001; 3:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/7\">",
"      Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/8\">",
"      Buskila D, Press J, Gedalia A, et al. Assessment of nonarticular tenderness and prevalence of fibromyalgia in children. J Rheumatol 1993; 20:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/9\">",
"      Clark P, Burgos-Vargas R, Medina-Palma C, et al. Prevalence of fibromyalgia in children: a clinical study of Mexican children. J Rheumatol 1998; 25:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/10\">",
"      Mikkelsson M, Salminen JJ, Kautiainen H. Non-specific musculoskeletal pain in preadolescents. Prevalence and 1-year persistence. Pain 1997; 73:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/11\">",
"      Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol 2006; 12:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/12\">",
"      Siegel DM, Janeway D, Baum J. Fibromyalgia syndrome in children and adolescents: clinical features at presentation and status at follow-up. Pediatrics 1998; 101:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/13\">",
"      Romano TJ. Fibromyalgia in children; diagnosis and treatment. W V Med J 1991; 87:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/14\">",
"      Malleson PN, al-Matar M, Petty RE. Idiopathic musculoskeletal pain syndromes in children. J Rheumatol 1992; 19:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/15\">",
"      Moldofsky H, Fung K, Lue FA, et al. Sleep and symptoms in children and adolescents with fibromyalgia (fibrositis syndrome). Sleep Res 1993; 22:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/16\">",
"      Bowyer S, Roettcher P. Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. Pediatric Rheumatology Database Research Group. J Rheumatol 1996; 23:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/17\">",
"      Eraso RM, Bradford NJ, Fontenot CN, et al. Fibromyalgia syndrome in young children: onset at age 10 years and younger. Clin Exp Rheumatol 2007; 25:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/18\">",
"      Rusy LM, Harvey SA, Beste DJ. Pediatric fibromyalgia and dizziness: evaluation of vestibular function. J Dev Behav Pediatr 1999; 20:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/19\">",
"      Masi AT, White KP, Pilcher JJ. Person-centered approach to care, teaching, and research in fibromyalgia syndrome: justification from biopsychosocial perspectives in populations. Semin Arthritis Rheum 2002; 32:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/20\">",
"      Mikkelsson M, Sourander A, Piha J, Salminen JJ. Psychiatric symptoms in preadolescents with musculoskeletal pain and fibromyalgia. Pediatrics 1997; 100:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/21\">",
"      Vandvik IH, Forseth KO. A bio-psychosocial evaluation of ten adolescents with fibromyalgia. Acta Paediatr 1994; 83:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/22\">",
"      Conte PM, Walco GA, Kimura Y. Temperament and stress response in children with juvenile primary fibromyalgia syndrome. Arthritis Rheum 2003; 48:2923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/23\">",
"      Roizenblatt S, Tufik S, Goldenberg J, et al. Juvenile fibromyalgia: clinical and polysomnographic aspects. J Rheumatol 1997; 24:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/24\">",
"      Tayag-Kier CE, Keenan GF, Scalzi LV, et al. Sleep and periodic limb movement in sleep in juvenile fibromyalgia. Pediatrics 2000; 106:E70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/25\">",
"      Reid GJ, Lang BA, McGrath PJ. Primary juvenile fibromyalgia: psychological adjustment, family functioning, coping, and functional disability. Arthritis Rheum 1997; 40:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/26\">",
"      Gedalia A, Garc&iacute;a CO, Molina JF, et al. Fibromyalgia syndrome: experience in a pediatric rheumatology clinic. Clin Exp Rheumatol 2000; 18:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/27\">",
"      Raj SR, Brouillard D, Simpson CS, et al. Dysautonomia among patients with fibromyalgia: a noninvasive assessment. J Rheumatol 2000; 27:2660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/28\">",
"      Sherry DD. Pain syndromes in children. Curr Rheumatol Rep 2000; 2:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/29\">",
"      Pellegrino MJ, Waylonis GW, Sommer A. Familial occurrence of primary fibromyalgia. Arch Phys Med Rehabil 1989; 70:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/30\">",
"      Kashikar-Zuck S, Parkins IS, Graham TB, et al. Anxiety, mood, and behavioral disorders among pediatric patients with juvenile fibromyalgia syndrome. Clin J Pain 2008; 24:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/31\">",
"      Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010; 62:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/32\">",
"      Kelemen J, L&aacute;ng E, B&aacute;lint G, et al. Orthostatic sympathetic derangement of baroreflex in patients with fibromyalgia. J Rheumatol 1998; 25:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/33\">",
"      Cohen H, Neumann L, Alhosshle A, et al. Abnormal sympathovagal balance in men with fibromyalgia. J Rheumatol 2001; 28:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/34\">",
"      Sendur OF, Gurer G, Bozbas GT. The frequency of hypermobility and its relationship with clinical findings of fibromyalgia patients. Clin Rheumatol 2007; 26:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/35\">",
"      Kimura Y, Walco GA. Pain in children with rheumatic diseases. Curr Rheumatol Rep 2006; 8:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/36\">",
"      Coury F, Rossat A, Tebib A, et al. Rheumatoid arthritis and fibromyalgia: a frequent unrelated association complicating disease management. J Rheumatol 2009; 36:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/37\">",
"      Okifuji A, Turk DC, Sinclair JD, et al. A standardized manual tender point survey. I. Development and determination of a threshold point for the identification of positive tender points in fibromyalgia syndrome. J Rheumatol 1997; 24:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7896/abstract/38\">",
"      Bell DS, Bell KM, Cheney PR. Primary juvenile fibromyalgia syndrome and chronic fatigue syndrome in adolescents. Clin Infect Dis 1994; 18 Suppl 1:S21.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6426 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E0FBF310BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_45_7896=[""].join("\n");
var outline_f7_45_7896=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Comorbidity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Tender points",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sleep disturbance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Psychosocial impact",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Complex regional pain syndrome type 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Growing pains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Chronic fatigue syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6426\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6426|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/4/25671\" title=\"figure 1\">",
"      Manual tender point survey",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6426|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/31/27132\" title=\"table 1\">",
"      ACR fibromyalgia classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/1/39963\" title=\"table 2\">",
"      Juvenile fibromyalgia criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35717?source=related_link\">",
"      Classification of juvenile arthritis (JRA/JIA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37768?source=related_link\">",
"      Complex regional pain syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20902?source=related_link\">",
"      Growing pains",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=related_link\">",
"      Initial treatment of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31031?source=related_link\">",
"      Pathogenesis of fibromyalgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=related_link\">",
"      Pauciarticular onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19350?source=related_link\">",
"      Treatment and prognosis of fibromyalgia in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_45_7897="Tissue Doppler echocardiography";
var content_f7_45_7897=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tissue Doppler echocardiography",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/45/7897/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/45/7897/contributors\">",
"     John Gorcsan, III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/45/7897/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/45/7897/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/45/7897/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/45/7897/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/45/7897/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue Doppler echocardiography (TDE) has become an established component of the diagnostic ultrasound examination; it permits an assessment of myocardial motion using Doppler ultrasound imaging, often with color coding. The technique uses frequency shifts of ultrasound waves to calculate myocardial velocity; this is similar to routine Doppler ultrasound to assess blood flow, but its technological features focus on lower velocity frequency shifts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15365?source=see_link\">",
"     \"Principles of Doppler echocardiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although Doppler ultrasound has been in widespread clinical use to assess intracardiac blood flow and noninvasive hemodynamics for many years, interest in TDE increased significantly when the color-coded TDE method was introduced [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Routine echocardiographic assessment of regional left ventricular (LV) wall motion is subjective because it is determined by visual determination of endocardial excursion and wall thickening. TDE offers the promise of an objective measure to quantify regional and global LV function through the assessment of myocardial velocity data.",
"   </p>",
"   <p>",
"    Two techniques are used to assess myocardial function: pulsed-TDE and color-coded TDE, which is an extension of the pulsed-Doppler technique. This modality has been applied in several clinical settings, particularly in the assessment of global and regional left ventricular systolic function. Other uses include assessment of left ventricular diastolic function, estimation of left ventricular filling pressures, determination of LV dyssynchrony for cardiac resynchronization therapy (CRT), and the distinction of different cardiac diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNICAL ASPECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue Doppler ultrasonography utilizes modifications of blood flow Doppler technology and calculates velocity from frequency shifts in received ultrasound data in a similar manner. Thus, the fundamental units are velocity observed from the echocardiographic transducer as a frame of reference. A primary advantage of TDE is that Doppler shifts of tissue motion are of high amplitude, being approximately 40 dB higher than Doppler signals from blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. An instrumentation feature common to both pulsed and color-coded TDE involves removal of the high-pass filter used for routine Doppler to assess blood flow in order to focus on the lower velocity values of myocardial motion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/1,2,7\">",
"     1,2,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pulsed-TDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulsed-TDE is available on most commercial echocardiography systems. The details of TDE set-up are unique to each system, but TDE is generally executed though a system preset feature. Operation is then very similar to routine pulsed-Doppler, with adjustments of the scale and sweep speed to optimize the spectral display, similar to pulsed-Doppler of blood flow. The gate of the sample volume is usually opened to 1 cm and directed to assess the region of interest. Routine color flow instrumentation uses the autocorrelator technique to calculate and display multigated points of color-coded blood velocity along a series of ultrasound scan lines within a two-dimensional sector [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/8\">",
"     8",
"    </a>",
"    ]. Color-coded blood velocity data are then superimposed on conventional gray scale two-dimensional images in real time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Color-coded TDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Color-coded tissue velocities can be superimposed on conventional M-mode and two-dimensional images (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66770 \" href=\"UTD.htm?28/47/29426\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59526 graphicRef58091 \" href=\"UTD.htm?5/43/5815\">",
"     image 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef79915 \" href=\"UTD.htm?23/0/23553\">",
"     figure 1",
"    </a>",
"    ). Pulse repetition frequencies can be increased to enhance temporal resolution. As an example, TDE measurements can be made at 40 Hz with a 60 degree two-dimensional sector at approximately 15 cm depth setting and at over 300 Hz using color M-mode scanning with a commercially available ultrasound system.",
"   </p>",
"   <p>",
"    The operation of color-coded TDE is similar to operation of routine color flow Doppler instrumentation. Variables include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Color gain &mdash; TDE color gain should be maximized to below the level of color noise artifact.",
"     </li>",
"     <li>",
"      Velocity range &mdash; Since the most common application of TDE is to interrogate myocardial velocities, a velocity range should be selected to maximize the sensitivity of displaying lower velocity values, without limiting the ability to measure higher velocity values. Velocities that exceed the upper limits of the selected range can be displayed as a saturated value at that highest velocity value in some systems. Selected velocity ranges of &plusmn; 9 to &plusmn; 20",
"      <span class=\"nowrap\">",
"       cm/sec",
"      </span>",
"      appear to be useful to assess myocardial velocity by TDE.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent applications of TDE are in the evaluation of left ventricular systolic and diastolic function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Assessment of global and regional left ventricular systolic function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of TDE to assess regional left ventricular function has been well documented [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. One study of 12 patients with heart disease and 20 normal subjects found that, by comparing TDE velocity values to estimates of velocity from digitized routine M-modes scans, TDE was able to measure endocardial velocity; peak velocity, measured by color-coded TDE, correlated closely with peak velocity by digitized M-modes (r = 0.99) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66770 \" href=\"UTD.htm?28/47/29426\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59526 graphicRef58091 \" href=\"UTD.htm?5/43/5815\">",
"     image 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef79915 \" href=\"UTD.htm?23/0/23553\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/5\">",
"     5",
"    </a>",
"    ]. In 16 subjects who could be adequately analyzed, posterior wall endocardial velocities throughout the cardiac cycle on TDE correlated with the velocity estimated from digitized M-modes (r = 0.88).",
"   </p>",
"   <p>",
"    In a canine model, color-coded TDE objectively quantified a wide range of alterations in regional contractility induced by inotropic modulation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/6\">",
"     6",
"    </a>",
"    ]. Using myocardial length crystals as a reference standard to assess regional left ventricular function, and high fidelity pressure and conductance catheters to assess global left ventricular performance by pressure-volume relations, mid-ventricular M-mode and two-dimensional color TDE images were recorded during control and inotropic stimulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"     esmolol",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    produced significant increases in peak systolic endocardial velocity, systolic time velocity integral (TVI), and diastolic TVI; after an infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"     esmolol",
"    </a>",
"    , there were significant decreases in these indices of myocardial contractility. Changes in TDE peak systolic velocity were correlated with changes in fractional shortening (r = 0.88) and shortening velocity (r = 0.87) by sonomicrometry. Changes in TDE peak velocity from multiple mid-left ventricular sites also correlated significantly with maximal elastance obtained from pressure-volume relations (r = 0.85).",
"   </p>",
"   <p>",
"    Pulsed TDE can also quantify regional left ventricular function as demonstrated in an animal model of ischemia and reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/9\">",
"     9",
"    </a>",
"    ]. Peak septal velocities, obtained from pulsed TDE, were calculated during systole, isovolumic relaxation, and early and late diastole; regional myocardial blood flow and systolic and diastolic function were assessed by radioactive microspheres and ultrasonic crystals, respectively. Ischemia, produced by coronary artery occlusion, resulted in a significant rapid reduction of systolic velocities and abnormalities in diastolic function; these changes were detected by pulsed TDE within five seconds of occlusion. The decrease in systolic velocity on pulsed TDE correlated significantly with both systolic shortening (r = 0.90) and regional myocardial blood flow (r = 0.96) during the reduction in coronary blood flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Strain and strain rate imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important refinement in the assessment of regional left ventricular function has been calculation of the myocardial velocity gradient or strain rate imaging. Strain, which is a change in length corrected for the original length or the fractional or percentage change from the original or unstressed dimension, reflects deformation of a structure and therefore directly describes the",
"    <span class=\"nowrap\">",
"     contraction/relaxation",
"    </span>",
"    pattern of the myocardium; strain rate is the rate of this deformation and is a strong index of left ventricular contractility (",
"    <a class=\"graphic graphic_figure graphicRef83923 \" href=\"UTD.htm?37/20/38215\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/10-14\">",
"     10-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strain rate imaging involves mathematical subtraction of the whole heart or translational motion from regional thickening velocity using a transmural data set from color-coded TDE [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/13,15,16\">",
"     13,15,16",
"    </a>",
"    ]. This quantification of the spatial distribution of intramural velocities across the myocardium has improved the ability of TDE to reflect directional and incremental alterations in regional and global left ventricular contractility in patients with cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/13,17\">",
"     13,17",
"    </a>",
"    ]. The technique can also identify regional diastolic asynchrony due to postsystolic shortening during ischemia, thereby defining the extent of ischemic myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/18\">",
"     18",
"    </a>",
"    ]. When used with low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    it is also a useful method for assessing the degree of myocardial viability [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=see_link\">",
"     \"Evaluation of hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Use during dobutamine stress echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    stress echocardiography is a technique for evaluating regional wall motion abnormalities due to ischemia that is induced by pharmacologic stress; it is useful for the diagnosis of coronary heart disease or determining the viability of dysfunctional myocardium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=see_link\">",
"     \"Dobutamine stress echocardiography in the evaluation of hibernating myocardium\"",
"    </a>",
"    .) A major limitation of this approach is that diagnostic criteria are based on the somewhat subjective visual assessment of wall motion, with segments scored in a semi-quantitative manner.",
"   </p>",
"   <p>",
"    Color-coded TDE has the potential to objectively measure myocardial velocity as a means of more accurately assessing regional left ventricular function by echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In one report of 60 patients, the normal and abnormal segmental endocardial velocity response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress was evaluated with color-coded TDE and compared to routine visual inspection of segmental function with two-dimensional gray scale images; echocardiographic images were obtained from the parasternal long and short-axis and apical four and two chamber views [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/20\">",
"     20",
"    </a>",
"    ]. Wall motion abnormalities at peak stress occurred in 19 patients while 22 patients who reached their target heart rate and had normal wall motion at peak stress served as a control group. Segmental peak endocardial velocities by TDE increased significantly in all segments in the control group, while endocardial velocity was significantly lower at peak stress in those who developed abnormal segments motion. In a second study of 114 patients who underwent coronary angiography within two months of dobutamine stress TDE, the sensitivity, specificity, and overall accuracy of TDE was 83, 72, and 80, percent, respectively; these values were equivalent to those obtained with expert wall motion scoring [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strain and strain rate imaging have limitations because tissue Doppler strain is derived from relative changes in velocity along a single ultrasound scan line and myofiber orientation is three-dimensionally complex. It may accurately assess shortening or thickening only when this principal vector is aligned with the ultrasound beam, which is affected by the angle of incidence in the Doppler equation. Accordingly, TDE cannot reliably assess apical segments from apical windows. After excluding apical segments from analysis, a TDE measured peak velocity of &lt;5.5",
"    <span class=\"nowrap\">",
"     cm/sec",
"    </span>",
"    with peak stress had an average sensitivity, specificity, and accuracy of 96, 81, and 86 percent, respectively, for identifying abnormal segments at peak stress as defined by routine two-dimensional criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TDE strain and strain rate imaging can also be used as an adjunct to visual wall motion analysis to assess myocardial viability. A study of 55 patients applied strain and strain rate imaging to the standard apical four-chamber, two-chamber, and long axis views along with routine visual wall motion scoring during a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echo viability study [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients were reassessed nine months after percutaneous revascularization or coronary bypass surgery. Of the 42 percent of patients with improvements in LV function after revascularization, strain and strain rate imaging combined with visual assessment increased sensitivity from 73 to 83 percent, compared with visual assessment alone. Although specificity was unaffected, strain imaging has potential to assist in determining myocardial viability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Mitral annular velocity to assess LV function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral annular motion assessed by M-mode echocardiography can be used as an index of global left ventricular systolic function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/24\">",
"     24",
"    </a>",
"    ]. This motion can be easily viewed from the apical windows in most patients (",
"    <a class=\"graphic graphic_figure graphicRef78304 \" href=\"UTD.htm?3/6/3170\">",
"     figure 3",
"    </a>",
"    ). Mitral annular descent reflects the longitudinal shortening of the left ventricular chamber and correlates with other global measures of left ventricular function, such as stroke volume [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Although two-dimensional echocardiography has become the standard to assess left ventricular function and ejection fraction, an advantage of using mitral annular motion to determine left ventricular function is that an adequate endocardial tracing is not necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=see_link\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TDE, obtained from the apical windows, offers an advantageous ultrasound beam angle of incidence for Doppler calculations, which accordingly have favorable signal-to-noise ratios (",
"    <a class=\"graphic graphic_figure graphicRef78304 \" href=\"UTD.htm?3/6/3170\">",
"     figure 3",
"    </a>",
"    ). Mitral annular descent velocity, as determined by color-coded TDE, is a rapidly acquired index of global left ventricular function (",
"    <a class=\"graphic graphic_figure graphicRef64924 \" href=\"UTD.htm?19/37/20062\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In one study of 55 patients, color-coded TDE was compared to radionuclide ventriculography, which served as a standard of reference of left ventricular ejection fraction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/27\">",
"     27",
"    </a>",
"    ]. TDE color M-modes echocardiograms were obtained from six mitral annular sites, including inferoseptal and lateral images from apical 4-chamber views, anterior and inferior images from apical 2-chamber views, and anteroseptal and posterior images from apical long axis views (",
"    <a class=\"graphic graphic_figure graphicRef52117 \" href=\"UTD.htm?11/6/11362\">",
"     figure 5",
"    </a>",
"    ). The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean left ventricular ejection fraction, based upon the peak annular descent velocity was 49 percent, which had excellent linear correlation with the ejection fraction obtained from the radionuclide ventriculogram (r = 0.86)",
"     </li>",
"     <li>",
"      Peak mitral annular descent velocity average &gt;5.4",
"      <span class=\"nowrap\">",
"       cm/sec",
"      </span>",
"      had a sensitivity and specificity of 88 and 97 percent for an ejection fraction greater than 50 percent.",
"     </li>",
"     <li>",
"      Peak mitral annular descent velocity from the apical 4-chamber view correlated most closely with radionuclide ejection fraction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mitral annular velocity is also a sensitive indicator of alterations in left ventricular contractility induced by inotropic stimulation using low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    . This was illustrated in a report of 12 healthy subjects in which the myocardial response to low dose dobutamine infusion was quantified using a new semiautomated color-coded TDE analysis system [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/28\">",
"     28",
"    </a>",
"    ]. Mitral annular velocity was obtained from the apical four-chamber view using the medial site and the results were compared to routine two-dimensional echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/29\">",
"     29",
"    </a>",
"    ]. Mitral annular peak systolic velocity increased significantly at the lowest dose of dobutamine (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per min), with further incremental increases with each increase in dobutamine dose; in contrast, routine measures of left ventricular ejection fraction did not detect an increase until the dose of dobutamine was 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per min. These data support the use of mitral annular velocity by TDE as a means of assessing left ventricular function, especially when endocardial definition is suboptimal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Use in evaluating chronic aortic regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;TDE may be helpful for identifying subclinical left ventricular dysfunction in patients with chronic severe aortic regurgitation who are asymptomatic but may be candidates for surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link\">",
"     \"Course and management of chronic aortic regurgitation in adults\"",
"    </a>",
"    .) In one study of 21 asymptomatic patients, reduced long axis contraction, as measured by mitral annular excursion and systolic velocity, were indicators of subclinical left ventricular dysfunction established by impaired exercise capacity and a reduction in ejection fraction with exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/30\">",
"     30",
"    </a>",
"    ]. A systolic annular excursion &lt;12 mm and a resting mitral annular velocity &lt;9.5",
"    <span class=\"nowrap\">",
"     cm/sec",
"    </span>",
"    were the best indicators of subclinical left ventricular dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Use in heart failure and resynchronization therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;TDE is useful for assessing the severity of LV interventricular dyssynchrony in patients with heart failure who typically have an intraventricular conduction delay [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. TDE may have a role for evaluating the effect of CRT or biventricular pacing on LV function and reverse remodeling and documenting an improvement in heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Color-coded TDE may quantify the degree of LV regional mechanical delay, which is a marker of response to CRT. The opposing wall delay may be determined as the difference in the TDE time-to-peak systolic velocity, measured during the ejection interval. An opposing wall delay &ge;65 ms may predict acute hemodynamic improvement, clinical response, and reverse remodeling following CRT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]. A slightly longer baseline opposing wall delay of &ge;80 ms has been associated with long-term survival after CRT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/36\">",
"     36",
"    </a>",
"    ]. Initially described using the basal segments from the 4-chamber view, a 12-segment model using basal and mid segments from apical 4-chamber, 2-chamber, and apical long axis views is often used for a more complete assessment (",
"    <a class=\"graphic graphic_waveform graphicRef73677 \" href=\"UTD.htm?37/41/38550\">",
"     waveform 1",
"    </a>",
"    ). The standard deviation of time-to-peak systolic velocity from these same 12-segments, known as the Yu Index (or mechanical dyssynchrony index), &ge;33 ms also predicts clinical outcome and reverse remodeling following CRT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/32,36\">",
"     32,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since most patients with wide QRS have mechanical dyssynchrony, TDE may be particularly useful to identify the subset of patients with wide QRS who lack mechanical dyssynchrony because they have a low probability of response and poor prognosis following CRT. Although other reasons for non-response to CRT exist, such as LV scar that will not reverse remodel or suboptimal lead placement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/34\">",
"     34",
"    </a>",
"    ], the absence of dyssynchrony is one factor that may potentially be identified prospectively by TDE and other echo-Doppler methods, such as speckle tracking [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Comparison with speckle tracking'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Current CRT guidelines use a widened electrocardiographic QRS as a marker for dyssynchrony and echo-Doppler methods have not yet been established for routine patient selection for CRT. TDE dyssynchrony analysis has been investigated as an adjunct in patients who may be borderline or ambiguous by the routine CRT selection criteria and assist with clinical decision-making. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Assessment of diastolic function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peak negative myocardial velocity can provide a quantitative assessment of diastolic dysfunction. In one study of 43 patients with and without impaired left ventricular systolic and diastolic function, peak negative myocardial velocity was significantly depressed in those with diastolic dysfunction due to hypertensive heart disease or a dilated cardiomyopathy compared to normals (",
"    <a class=\"graphic graphic_waveform graphicRef54765 \" href=\"UTD.htm?5/33/5652\">",
"     waveform 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/37\">",
"     37",
"    </a>",
"    ]. Compared to transmitral flow velocity, myocardial velocity gradient (MVG), which is defined as the slope of the regression line for the transmural velocity profile between the endocardium and epicardium cross the myocardial wall and reflects myocardial thickening and thinning dynamics, was less affected by changes in preload produced by leg raising or diuretic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=see_link&amp;anchor=H5#H5\">",
"     \"Echocardiographic evaluation of left ventricular diastolic function\", section on 'Tissue Doppler imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Use of mitral annular velocity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The longitudinal expansion of the left ventricle during early diastole, as assessed by mitral annular velocity, is an interesting and useful application of TDE [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. One study used the early diastolic mitral annular velocity (Ea), obtained by pulsed-TDE in 128 patients undergoing cardiac catheterization; the magnitude of Ea (in",
"    <span class=\"nowrap\">",
"     cm/s)",
"    </span>",
"    was blunted in patients with diastolic dysfunction, established by other means, such as the time constant of relaxation by high-fidelity pressure catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/37\">",
"     37",
"    </a>",
"    ]. The Ea appeared to be less influenced by alterations of loading, such as an increased volume with a saline infusion or preload reduction by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    , than mitral inflow velocity. However, the load-independence of Ea is still uncertain and this is undergoing more careful study.",
"   </p>",
"   <p>",
"    Despite this limitation, there are several important clinical applications of Ea. These include an assessment of left ventricular filling pressures, differentiating constrictive pericarditis from restrictive cardiomyopathy, and differentiating hypertrophic cardiomyopathy from left ventricular hypertrophy as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Estimation of LV filling pressures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determination of left ventricular filling pressure is important for the optimization of left ventricular function in patients with cardiovascular disease. Since this usually requires the invasive placement of a pulmonary artery catheter, a noninvasive estimation of left ventricular filling pressures would be clinically useful. TDE is a possible solution, particularly in patients with a reduced left ventricular ejection fraction. However, the reliability of transmitral flow variables is reduced in patients with a left ventricular ejection fraction &ge;50 percent. A review of technical issues in such patients with a systematic approach for the ultrasonographer was published in early 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been proposed that the mitral inflow to annular velocity ratio is a possible application of TDE to noninvasively assess left ventricular filling pressures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55656 \" href=\"UTD.htm?39/33/40464\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/38,41,42\">",
"     38,41,42",
"    </a>",
"    ]. This approach uses measures of transmitral peak inflow velocity of early rapid diastolic filling (E), obtained by routine pulsed-Doppler echocardiography, and measures of Ea, obtained by pulsed-TDE sample volume placed in the lateral annulus imaged from the apical four chamber view. The unitless index of",
"    <span class=\"nowrap\">",
"     E/Ea,",
"    </span>",
"    used an indicator of left ventricular filling pressures, correlated significantly with invasively derived mean pulmonary capillary wedge pressure (r = 0.87) and showed better correlation with left ventricular end-diastolic pressure (a measure of left ventricular filling pressure) than did other Doppler variables [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/38,41\">",
"     38,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     E/Ea",
"    </span>",
"    estimates of filling pressures can be made in patients with arrhythmias, such as sinus tachycardia, and also in patients with heart failure. As a general clinical guideline, an",
"    <span class=\"nowrap\">",
"     E/Ea",
"    </span>",
"    &gt;10 is predictive of a mean pulmonary capillary wedge pressure above 15 mmHg with a sensitivity and specificity of 92 and 80 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Differentiation of constrictive pericarditis from restrictive cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differentiation between suspected constrictive pericarditis or restrictive cardiomyopathy is often difficult and the invasive evaluation may yield ambiguous data. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Distinction between these two entities is of great importance because constrictive pericarditis may be cured with surgical pericardiectomy and is often lethal without intervention, while restrictive cardiomyopathy, as with advanced amyloid heart disease, does not have a known cure and is associated with a poor prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23207?source=see_link\">",
"     \"Idiopathic restrictive cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A Doppler echocardiographic assessment of mitral inflow velocities, pulmonary venous velocities, and hepatic vein flow patterns can be used to make this distinction; however, their value is limited in some patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TDE assessment of Ea is another noninvasive measure that can be combined with the routine Doppler echocardiogram and provides complementary information. In one study, Ea obtained by pulsed-TDE distinguished eight patients with constrictive pericarditis from seven patients with restrictive cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/43\">",
"     43",
"    </a>",
"    ]. Since restrictive cardiomyopathy is a disease of the myocardium, Ea is blunted, whereas constrictive pericarditis is a disease of the pericardium and Ea velocity is preserved.",
"   </p>",
"   <p>",
"    Although experience is limited to a small number of patients, general guidelines are that an Ea less than 10",
"    <span class=\"nowrap\">",
"     cm/s",
"    </span>",
"    by pulsed-TDE and less than 7",
"    <span class=\"nowrap\">",
"     cm/s",
"    </span>",
"    by color-coded TDE are supportive of restrictive pathophysiology (",
"    <a class=\"graphic graphic_figure graphicRef59160 \" href=\"UTD.htm?5/15/5374\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/44\">",
"     44",
"    </a>",
"    ]. Measurement of early mitral annular velocity (E', also called Ea) more be more helpful. In a series of 75 patients, an E' of more than 8",
"    <span class=\"nowrap\">",
"     cm/s",
"    </span>",
"    had a 95 percent sensitivity and 96 percent specificity for the diagnosis of constrictive pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulsed-TDE can also distinguish between restrictive cardiomyopathy and constrictive pericarditis by measuring the myocardial velocity gradient. One study evaluated this approach in 15 patients with restrictive cardiomyopathy, 10 with constrictive pericarditis, and 30 age-matched normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/46\">",
"     46",
"    </a>",
"    ]. The Doppler myocardial velocity gradient, as measured from the left ventricular posterior wall in early diastole and during ventricular ejection, was significantly lower in patients with a restrictive cardiomyopathy compared to those with constrictive pericarditis and normal controls (",
"    <a class=\"graphic graphic_figure graphicRef64453 \" href=\"UTD.htm?17/37/18008\">",
"     figure 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef59316 \" href=\"UTD.htm?35/18/36142\">",
"     figure 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef58771 \" href=\"UTD.htm?22/35/23093\">",
"     waveform 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Differentiation of hypertrophic cardiomyopathy from left ventricular hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the echocardiographic findings of systolic anterior movement of the mitral valve and asymmetrical septal hypertrophy are useful for diagnosing hypertrophic cardiomyopathy, these findings may also be present in patients with left ventricular hypertrophy secondary to hypertension or vigorous exercise. TDE may help to distinguish among these disorders as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15562?source=see_link\">",
"     \"Echocardiographic recognition of cardiomyopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link&amp;anchor=H2599233#H2599233\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Criteria to distinguish HCM from athlete's heart'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TDE together with Doppler mitral inflow velocity can be used to determine whether left ventricular filling pressures are elevated in patients with HCM (",
"    <a class=\"graphic graphic_figure graphicRef58942 \" href=\"UTD.htm?12/50/13092\">",
"     figure 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     COMPARISON WITH SPECKLE TRACKING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A speckle is a unique acoustic pattern generated from ultrasound interrogation of tissue. Speckle tracking is a semiautomated means of measuring myocardial strain and strain rate [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/47\">",
"     47",
"    </a>",
"    ]. This method can detect longitudinal, circumferential, or radial displacement, although radial measurements are less reproducible [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/48\">",
"     48",
"    </a>",
"    ]. Advantages of speckle tracking over TDE include lack of dependence upon the angle of the incident ultrasound beam and lack of requirement for specialized imaging since speckle analysis is performed on routine B-mode images [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/14\">",
"     14",
"    </a>",
"    ]. Disadvantages include significant signal noise and signal drifting as well as lower frame rates (40 to 90",
"    <span class=\"nowrap\">",
"     frames/s",
"    </span>",
"    as compared to &gt;100",
"    <span class=\"nowrap\">",
"     frames/s",
"    </span>",
"    for TDE) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7897/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. In addition, fewer data are available on the utility of speckle tracking imaging for clinical applications including evaluation of diastolic function and assessment of ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=see_link\">",
"     \"Echocardiographic evaluation of left ventricular diastolic function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41048?source=see_link&amp;anchor=H10#H10\">",
"     \"Stress echocardiography: Indications, imaging techniques and safety\", section on 'Strain imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       \"Patient information: Echocardiogram (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;TDE is a rapidly evolving and expanding noninvasive technique to assess left ventricular physiology. Further refinements in signal processing and quantitative analysis will likely expand the clinical applications of this technique.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical applications of TDE include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Evaluation of global and regional left ventricular systolic function at rest and with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Assessment of global and regional left ventricular systolic function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of left ventricular diastolic function including estimation of left ventricular filling pressures. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Assessment of diastolic function'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specific applications of TDE in distinguishing clinical entities include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Differentiation of constrictive pericarditis from restrictive cardiomyopathy (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Differentiation of constrictive pericarditis from restrictive cardiomyopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Differentiation of hypertrophic cardiomyopathy from left ventricular hypertrophy secondary to hypertension or exercise. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Differentiation of hypertrophic cardiomyopathy from left ventricular hypertrophy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Speckle tracking offers an alternative means of measuring myocardial strain and strain rate. The relative clinical utilities of speckle tracking and TDE are not well defined.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/1\">",
"      Sutherland GR, Stewart MJ, Groundstroem KW, et al. Color Doppler myocardial imaging: a new technique for the assessment of myocardial function. J Am Soc Echocardiogr 1994; 7:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/2\">",
"      Miyatake K, Yamagishi M, Tanaka N, et al. New method for evaluating left ventricular wall motion by color-coded tissue Doppler imaging: in vitro and in vivo studies. J Am Coll Cardiol 1995; 25:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/3\">",
"      Pellerin D, Cohen L, Larrazet F, et al. Preejectional left ventricular wall motion in normal subjects using Doppler tissue imaging and correlation with ejection fraction. Am J Cardiol 1997; 80:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/4\">",
"      Palka P, Lange A, Fleming AD, et al. Doppler tissue imaging: myocardial wall motion velocities in normal subjects. J Am Soc Echocardiogr 1995; 8:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/5\">",
"      Gorcsan J 3rd, Gulati VK, Mandarino WA, Katz WE. Color-coded measures of myocardial velocity throughout the cardiac cycle by tissue Doppler imaging to quantify regional left ventricular function. Am Heart J 1996; 131:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/6\">",
"      Gorcsan J 3rd, Strum DP, Mandarino WA, et al. Quantitative assessment of alterations in regional left ventricular contractility with color-coded tissue Doppler echocardiography. Comparison with sonomicrometry and pressure-volume relations. Circulation 1997; 95:2423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/7\">",
"      Isaaz K, Thompson A, Ethevenot G, et al. Doppler echocardiographic measurement of low velocity motion of the left ventricular posterior wall. Am J Cardiol 1989; 64:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/8\">",
"      Sahn DJ. Instrumentation and physical factors related to visualization of stenotic and regurgitant jets by Doppler color flow mapping. J Am Coll Cardiol 1988; 12:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/9\">",
"      Derumeaux G, Ovize M, Loufoua J, et al. Doppler tissue imaging quantitates regional wall motion during myocardial ischemia and reperfusion. Circulation 1998; 97:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/10\">",
"      Mirsky I, Parmley WW. Assessment of passive elastic stiffness for isolated heart muscle and the intact heart. Circ Res 1973; 33:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/11\">",
"      Abraham TP, Nishimura RA. Myocardial strain: can we finally measure contractility? J Am Coll Cardiol 2001; 37:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/12\">",
"      Greenberg NL, Firstenberg MS, Castro PL, et al. Doppler-derived myocardial systolic strain rate is a strong index of left ventricular contractility. Circulation 2002; 105:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/13\">",
"      Sutherland GR, Di Salvo G, Claus P, et al. Strain and strain rate imaging: a new clinical approach to quantifying regional myocardial function. J Am Soc Echocardiogr 2004; 17:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/14\">",
"      Gorcsan J 3rd, Tanaka H. Echocardiographic assessment of myocardial strain. J Am Coll Cardiol 2011; 58:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/15\">",
"      Uematsu M, Miyatake K, Tanaka N, et al. Myocardial velocity gradient as a new indicator of regional left ventricular contraction: detection by a two-dimensional tissue Doppler imaging technique. J Am Coll Cardiol 1995; 26:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/16\">",
"      Uematsu M, Nakatani S, Yamagishi M, et al. Usefulness of myocardial velocity gradient derived from two-dimensional tissue Doppler imaging as an indicator of regional myocardial contraction independent of translational motion assessed in atrial septal defect. Am J Cardiol 1997; 79:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/17\">",
"      Edvardsen T, Skulstad H, Aakhus S, et al. Regional myocardial systolic function during acute myocardial ischemia assessed by strain Doppler echocardiography. J Am Coll Cardiol 2001; 37:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/18\">",
"      Pislaru C, Belohlavek M, Bae RY, et al. Regional asynchrony during acute myocardial ischemia quantified by ultrasound strain rate imaging. J Am Coll Cardiol 2001; 37:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/19\">",
"      Hoffmann R, Altiok E, Nowak B, et al. Strain rate measurement by doppler echocardiography allows improved assessment of myocardial viability inpatients with depressed left ventricular function. J Am Coll Cardiol 2002; 39:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/20\">",
"      Katz WE, Gulati VK, Mahler CM, Gorcsan J 3rd. Quantitative evaluation of the segmental left ventricular response to dobutamine stress by tissue Doppler echocardiography. Am J Cardiol 1997; 79:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/21\">",
"      Nishino M, Tanouchi J, Tanaka K, et al. Dobutamine stress echocardiography at 7.5 mg/kg/min using color tissue Doppler imaging M-mode safely predicts reversible dysfunction early after reperfusion in patients with acute myocardial infarction. Am J Cardiol 1999; 83:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/22\">",
"      Cain P, Baglin T, Case C, et al. Application of tissue Doppler to interpretation of dobutamine echocardiography and comparison with quantitative coronary angiography. Am J Cardiol 2001; 87:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/23\">",
"      Hanekom L, Jenkins C, Jeffries L, et al. Incremental value of strain rate analysis as an adjunct to wall-motion scoring for assessment of myocardial viability by dobutamine echocardiography: a follow-up study after revascularization. Circulation 2005; 112:3892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/24\">",
"      Feigenbaum H, Zaky A, Nasser WK. Use of ultrasound to measure left ventricular stroke volume. Circulation 1967; 35:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/25\">",
"      Jones CJ, Raposo L, Gibson DG. Functional importance of the long axis dynamics of the human left ventricle. Br Heart J 1990; 63:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/26\">",
"      Pai RG, Bodenheimer MM, Pai SM, et al. Usefulness of systolic excursion of the mitral anulus as an index of left ventricular systolic function. Am J Cardiol 1991; 67:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/27\">",
"      Gulati VK, Katz WE, Follansbee WP, Gorcsan J 3rd. Mitral annular descent velocity by tissue Doppler echocardiography as an index of global left ventricular function. Am J Cardiol 1996; 77:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/28\">",
"      Gorcsan J 3rd, Deswal A, Mankad S, et al. Quantification of the myocardial response to low-dose dobutamine using tissue Doppler echocardiographic measures of velocity and velocity gradient. Am J Cardiol 1998; 81:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/29\">",
"      Shimizu Y, Uematsu M, Shimizu H, et al. Peak negative myocardial velocity gradient in early diastole as a noninvasive indicator of left ventricular diastolic function: comparison with transmitral flow velocity indices. J Am Coll Cardiol 1998; 32:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/30\">",
"      Vinereanu D, Ionescu AA, Fraser AG. Assessment of left ventricular long axis contraction can detect early myocardial dysfunction in asymptomatic patients with severe aortic regurgitation. Heart 2001; 85:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/31\">",
"      Bax JJ, Bleeker GB, Marwick TH, et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 2004; 44:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/32\">",
"      Yu CM, Chau E, Sanderson JE, et al. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation 2002; 105:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/33\">",
"      Gorcsan J 3rd, Kanzaki H, Bazaz R, et al. Usefulness of echocardiographic tissue synchronization imaging to predict acute response to cardiac resynchronization therapy. Am J Cardiol 2004; 93:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/34\">",
"      Ansalone G, Giannantoni P, Ricci R, et al. Doppler myocardial imaging to evaluate the effectiveness of pacing sites in patients receiving biventricular pacing. J Am Coll Cardiol 2002; 39:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/35\">",
"      Suffoletto MS, Dohi K, Cannesson M, et al. Novel speckle-tracking radial strain from routine black-and-white echocardiographic images to quantify dyssynchrony and predict response to cardiac resynchronization therapy. Circulation 2006; 113:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/36\">",
"      Gorcsan J 3rd, Oyenuga O, Habib PJ, et al. Relationship of echocardiographic dyssynchrony to long-term survival after cardiac resynchronization therapy. Circulation 2010; 122:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/37\">",
"      Sohn DW, Chai IH, Lee DJ, et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 1997; 30:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/38\">",
"      Nagueh SF, Middleton KJ, Kopelen HA, et al. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/39\">",
"      Rodriguez L, Garcia M, Ares M, et al. Assessment of mitral annular dynamics during diastole by Doppler tissue imaging: comparison with mitral Doppler inflow in subjects without heart disease and in patients with left ventricular hypertrophy. Am Heart J 1996; 131:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/40\">",
"      Hill JC, Palma RA. Doppler tissue imaging for the assessment of left ventricular diastolic function: a systematic approach for the sonographer. J Am Soc Echocardiogr 2005; 18:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/41\">",
"      Ommen SR, Nishimura RA, Appleton CP, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation 2000; 102:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/42\">",
"      Nagueh SF, Lakkis NM, Middleton KJ, et al. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation 1999; 99:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/43\">",
"      Garcia MJ, Rodriguez L, Ares M, et al. Differentiation of constrictive pericarditis from restrictive cardiomyopathy: assessment of left ventricular diastolic velocities in longitudinal axis by Doppler tissue imaging. J Am Coll Cardiol 1996; 27:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/44\">",
"      Rajagopalan N, Garcia MJ, Rodriguez L, et al. Comparison of new Doppler echocardiographic methods to differentiate constrictive pericardial heart disease and restrictive cardiomyopathy. Am J Cardiol 2001; 87:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/45\">",
"      Ha JW, Ommen SR, Tajik AJ, et al. Differentiation of constrictive pericarditis from restrictive cardiomyopathy using mitral annular velocity by tissue Doppler echocardiography. Am J Cardiol 2004; 94:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/46\">",
"      Palka P, Lange A, Donnelly JE, Nihoyannopoulos P. Differentiation between restrictive cardiomyopathy and constrictive pericarditis by early diastolic doppler myocardial velocity gradient at the posterior wall. Circulation 2000; 102:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/47\">",
"      Perk G, Tunick PA, Kronzon I. Non-Doppler two-dimensional strain imaging by echocardiography--from technical considerations to clinical applications. J Am Soc Echocardiogr 2007; 20:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/48\">",
"      Langeland S, D'hooge J, Wouters PF, et al. Experimental validation of a new ultrasound method for the simultaneous assessment of radial and longitudinal myocardial deformation independent of insonation angle. Circulation 2005; 112:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/49\">",
"      Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009; 22:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7897/abstract/50\">",
"      Abraham TP, Pinheiro AC. Speckle-derived strain a better tool for quantification of stress echocardiography? J Am Coll Cardiol 2008; 51:158.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5298 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_45_7897=[""].join("\n");
var outline_f7_45_7897=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNICAL ASPECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pulsed-TDE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Color-coded TDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Assessment of global and regional left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Strain and strain rate imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Use during dobutamine stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Mitral annular velocity to assess LV function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Use in evaluating chronic aortic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Use in heart failure and resynchronization therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Assessment of diastolic function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Use of mitral annular velocity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Estimation of LV filling pressures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Differentiation of constrictive pericarditis from restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Differentiation of hypertrophic cardiomyopathy from left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COMPARISON WITH SPECKLE TRACKING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5298\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5298|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/47/29426\" title=\"diagnostic image 1\">",
"      Tissue Doppler normal LV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/35/22066\" title=\"diagnostic image 2A\">",
"      Color coded tissue Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/57/6033\" title=\"diagnostic image 2B\">",
"      Tissue Doppler echocardiogram LV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/33/40464\" title=\"diagnostic image 3\">",
"      Mitral inflow annular ratio",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5298|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/0/23553\" title=\"figure 1\">",
"      MVG calculation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/20/38215\" title=\"figure 2\">",
"      Tissue Doppler echo with velocity and strain plots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/6/3170\" title=\"figure 3\">",
"      Mitral annular dynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/37/20062\" title=\"figure 4\">",
"      Mitral annular time velocity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/6/11362\" title=\"figure 5\">",
"      Mitral annular sample sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/15/5374\" title=\"figure 6\">",
"      Time velocity CM pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/37/18008\" title=\"figure 7\">",
"      TDE pericarditis restrictive CM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/18/36142\" title=\"figure 8\">",
"      MVG restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/50/13092\" title=\"figure 9\">",
"      Doppler echo for LV pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5298|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?37/41/38550\" title=\"waveform 1\">",
"      TDE LV dyssynchrony",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?5/33/5652\" title=\"waveform 2\">",
"      Echo MVG normal HHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?22/35/23093\" title=\"waveform 3\">",
"      TDE constriction v restriction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=related_link\">",
"      Course and management of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=related_link\">",
"      Differentiating constrictive pericarditis and restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=related_link\">",
"      Dobutamine stress echocardiography in the evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=related_link\">",
"      Echocardiographic evaluation of left ventricular diastolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15562?source=related_link\">",
"      Echocardiographic recognition of cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=related_link\">",
"      Evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23207?source=related_link\">",
"      Idiopathic restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15365?source=related_link\">",
"      Principles of Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41048?source=related_link\">",
"      Stress echocardiography: Indications, imaging techniques and safety",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_45_7898="Diagnosis and staging of esophageal cancer";
var content_f7_45_7898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and staging of esophageal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/45/7898/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/45/7898/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/45/7898/contributors\">",
"     Michael K Gibson, MD, PhD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/45/7898/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/45/7898/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/45/7898/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/45/7898/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/45/7898/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/45/7898/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell carcinoma (SCC) and adenocarcinoma account for over 95 percent of esophageal malignant tumors. For most of the twentieth century, SCC has predominated. In the 1960s, SCC accounted for more than 90 percent of all esophageal tumors in the United States, and adenocarcinomas were considered so uncommon that some authorities questioned their existence. For the past two decades, however, the incidence of esophageal adenocarcinoma has increased dramatically in Western countries, such that the two tumors now occur with almost equal frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Esophageal SCC and adenocarcinomas differ in a number of features, including tumor location and predisposing factors (",
"    <a class=\"graphic graphic_table graphicRef78167 \" href=\"UTD.htm?6/11/6331\">",
"     table 1",
"    </a>",
"    ). Smoking and alcohol are major risk factors for SCC while Barrett's esophagus with specialized intestinal metaplasia (a complication of gastroesophageal reflux disease [GERD]), obesity, smoking, and possibly GERD itself are the risk factors for adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=see_link\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There seems little doubt that esophageal SCCs and adenocarcinomas represent two different diseases with characteristic pathogenesis, epidemiology, tumor biology, and outcomes. In acknowledgement of these differences, the most recent 2010 TNM staging system provides separate stage groupings (but similar definitions for tumor, nodal and metastasis categories) for SCCs and adenocarcinomas of the esophagus and esophagogastric junction (EGJ, (",
"    <a class=\"graphic graphic_table graphicRef62895 \" href=\"UTD.htm?13/38/13934\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"UTD.htm?4/24/4494\">",
"     table 3",
"    </a>",
"    ))&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/4\">",
"     4",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"local\" href=\"#H6\">",
"     'TNM staging criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In clinical practice, there is controversy as to whether and how histology should influence the therapeutic approach. This issue is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link&amp;anchor=H2#H2\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\", section on 'Squamous cell versus adenocarcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of histology, approximately 50 to 60 percent of patients with esophageal cancer present with incurable locally advanced or metastatic disease. Prolonged progression-free survival is possible in only a few of such patients while palliation is the goal of treatment for the majority. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30106?source=see_link\">",
"     \"Management of locally advanced unresectable esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44202?source=see_link\">",
"     \"Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with localized, potentially resectable disease, median survival strongly correlates with disease stage. A minority of patients have disease that is limited to the mucosa or submucosa (ie, T1N0), with a high cure rate from surgical (and for selected patients, endoscopic) therapy alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20426?source=see_link\">",
"     \"Management of superficial esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, most have tumors that invade through esophageal wall (T3, (",
"    <a class=\"graphic graphic_table graphicRef62895 \" href=\"UTD.htm?13/38/13934\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"UTD.htm?4/24/4494\">",
"     table 3",
"    </a>",
"    )) or are node-positive, and long-term survival is uniformly poor. Only approximately 15 percent of these patients can be cured using multimodality therapy.",
"   </p>",
"   <p>",
"    The optimal treatment for these patients is controversial. However, in many institutions, initial chemoradiotherapy or perioperative chemotherapy is preferred over upfront surgery for patients with T2 tumor stage or higher or regional nodal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39738?source=see_link&amp;anchor=H12480581#H12480581\">",
"     \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\", section on 'Multimodality approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, the appropriate selection of patients for palliative therapy, chemoradiotherapy, or",
"    <span class=\"nowrap\">",
"     surgery/endoscopic",
"    </span>",
"    therapy alone is highly dependent upon accurate preoperative assessment of disease stage. The diagnosis and staging of esophageal cancer will be reviewed here. The epidemiology, and clinical manifestations, treatment approaches, and the role of largely palliative endoscopic techniques in the treatment of esophageal cancer are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    studies may suggest the presence of esophageal cancer, but the diagnosis is established with endoscopic biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/5\">",
"     5",
"    </a>",
"    ]. Early esophageal cancers appear endoscopically as superficial plaques, nodules, or ulcerations (",
"    <a class=\"graphic graphic_picture graphicRef55091 \" href=\"UTD.htm?3/16/3343\">",
"     picture 1",
"    </a>",
"    ). Advanced lesions appear as strictures (",
"    <a class=\"graphic graphic_picture graphicRef55542 \" href=\"UTD.htm?4/43/4799\">",
"     picture 2",
"    </a>",
"    ), ulcerated masses (",
"    <a class=\"graphic graphic_picture graphicRef78958 \" href=\"UTD.htm?9/15/9471\">",
"     picture 3",
"    </a>",
"    ), circumferential masses (",
"    <a class=\"graphic graphic_picture graphicRef67522 \" href=\"UTD.htm?43/25/44447\">",
"     picture 4",
"    </a>",
"    ), or large ulcerations. Although often considered clinically unimportant, a study of 209 esophageal cancer patients suggests that the length of an esophageal tumor may be an independent predictor of long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the endoscopic visualization of a large mucosal mass is nearly pathognomonic of esophageal cancer, biopsy must be performed to confirm the diagnosis (",
"    <a class=\"graphic graphic_picture graphicRef68324 \" href=\"UTD.htm?39/54/40807\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63363 \" href=\"UTD.htm?37/60/38853\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Early studies found that the greater the number of biopsies taken (up to seven), the higher the diagnostic accuracy. As an example, in a series of 202 consecutive patients, 47 of whom had gastric or esophageal carcinoma, the percentage of correct diagnoses of esophageal carcinoma were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      First biopsy &mdash; 93 percent",
"     </li>",
"     <li>",
"      Four biopsies &mdash; 95 percent",
"     </li>",
"     <li>",
"      Seven biopsies &mdash; 98 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The addition of brush cytology specimens to seven biopsies increased the accuracy to 100 percent. Seventeen percent of lesions thought to be benign endoscopically were subsequently proven to be malignant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     In vivo staining",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vivo staining of the esophageal mucosa (chromoendoscopy) can direct the area of biopsy and determine the extent of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/8\">",
"     8",
"    </a>",
"    ]. Lugol's iodide reacts with the glycogen components of normal squamous mucosa to produce a greenish brown color, while neoplastic tissue is depleted of glycogen and squamous carcinoma remains unstained. Although the role of in vivo staining in the diagnosis of and screening for esophageal cancer is not established, limited data suggest that it may help in some high-risk settings. This topic is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=see_link\">",
"     \"Chromoendoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREOPERATIVE STAGING EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the prognosis of esophageal cancer is strongly associated with its stage. Accurate clinical staging is critical for estimating prognosis and selecting the appropriate treatment strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     TNM staging criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TNM staging system of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) for esophageal cancer is used universally [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/4\">",
"     4",
"    </a>",
"    ]. A major change between the 2002 and the 2010 editions was the development of separate stage groupings according to histology (",
"    <a class=\"graphic graphic_table graphicRef62895 \" href=\"UTD.htm?13/38/13934\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"UTD.htm?4/24/4494\">",
"     table 3",
"    </a>",
"    ). This change was based upon an analysis of worldwide data on 4627 patients with cancer of the esophagus or EGJ who underwent surgery alone, and which showed that among patients with lymph node-negative tumors, prognosis was dependent on T-stage as well as histology, grade, and tumor location [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the separate stage groupings for SCC and adenocarcinoma, other major differences from the 2002 classification include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A simplification of tumor location and inclusion of tumors at the esophagogastric junction and proximal 5 cm of the stomach that extend into the EGJ or esophagus as esophageal cancers (the so-called Siewert III EGJ tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/10\">",
"       10",
"      </a>",
"      ]). All other tumors with an epicenter in the stomach &gt;5 cm from the EGJ, or those within 5 cm or the EGJ without extension into the esophagus are staged as gastric cancers.",
"     </li>",
"     <li>",
"      Redefinition of Tis as high-grade dysplasia, which includes all noninvasive neoplastic epithelia that was formerly called \"carcinoma in situ\", a diagnosis that is no longer used for columnar mucosa anywhere in the GI tract",
"     </li>",
"     <li>",
"      Subclassification of T4 disease based upon potential resectability of adjacent involved",
"      <span class=\"nowrap\">",
"       organs/structures",
"      </span>",
"     </li>",
"     <li>",
"      Subclassification of nodal (N) status according to the number of regional nodes containing metastases",
"     </li>",
"     <li>",
"      Reassignment of stage groupings using T, N, M categories as well as histologic grade of differentiation (G), and for SCCs, tumor location",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tumors arising in the cervical, thoracic esophagus, or abdominal esophagus, including those that arise within the cardia of the stomach within 5 cm of the EGJ (",
"    <a class=\"graphic graphic_table graphicRef68416 \" href=\"UTD.htm?28/10/28843\">",
"     table 4",
"    </a>",
"    ) share the same criteria for T stage designation. As with the prior staging criteria, pathologic classification (pTNM stages) following surgery that was preceded by chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiotherapy is designated by the prefix yp (ypTNM).",
"   </p>",
"   <p>",
"    While the newer AJCC staging system provides a better separation of prognostic groups for both histologies as determined by the T, N, and M categories at the time of initial diagnosis, it was based on pTNM data from patients whose esophageal cancers were treated by esophagectomy alone, without induction chemotherapy or radiotherapy. As a result, its prognostic utility in patients who have had preoperative chemoradiotherapy is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Regional lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another major change of the 2010 TNM staging system as compared to the 2002 classification is in the definition of regional nodes.",
"   </p>",
"   <p>",
"    In the earlier classification, the specific lymph node groups that were considered regional varied according to the anatomic compartment and location within the esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/14\">",
"     14",
"    </a>",
"    ]. The regional nodes for intrathoracic esophagus tumors included the upper periesophageal (above the azygos vein), subcarinal, and lower periesophageal (below the azygos vein) sites, while those for the abdominal esophagus were lower esophageal, diaphragmatic, pericardial, left gastric, and celiac. Involvement of more distant lymph nodes (eg, cervical or celiac axis nodes for intrathoracic tumors) had been considered distant metastasis (M1 disease).",
"   </p>",
"   <p>",
"    Data suggesting the prognostic importance of the number of involved lymph nodes rather than location in esophageal cancer (particularly in the surgical specimen after chemoradiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/11,15-22\">",
"     11,15-22",
"    </a>",
"    ]) led to a change in N stage classification with an emphasis on number of involved nodes rather than location in the 2010 edition (",
"    <a class=\"graphic graphic_table graphicRef62895 \" href=\"UTD.htm?13/38/13934\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"UTD.htm?4/24/4494\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Overview of the preoperative staging evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of an esophageal cancer is established, staging usually begins with a CT scan of the chest and upper abdomen to both evaluate the region of the primary tumor and to search for distant metastatic disease. However, CT is of limited value for locoregional tumor staging. Although it can accurately show enlarged nodes, sensitivity for celiac axis nodal disease is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/23\">",
"     23",
"    </a>",
"    ], and it is not consistently able to differentiate the depth of primary tumor invasion. In one study, local tumor staging was correctly predicted by CT in only 42 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/24\">",
"     24",
"    </a>",
"    ]. Endoscopic ultrasound (EUS) is more accurate and has replaced CT as the locoregional tumor staging modality of choice. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Locoregional staging with EUS'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Another disadvantage of CT is its limited sensitivity for small metastases (particularly within the peritoneum). PET scans are more sensitive than CT for detecting metastatic disease and are now widely used for preoperative staging in patients who lack evidence of distant disease on CT. In general, the addition of preoperative PET to the staging evaluation results in a change in management (usually avoidance of unnecessary surgery) in up to 20 percent of patients with esophageal cancer. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Evaluation for distant metastases'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Like CT, PET scans (with or without integrated CT) have low accuracy for staging locoregional disease extent, particularly nodal status [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/23\">",
"     23",
"    </a>",
"    ]. This may be due, at least in part, to high FDG uptake in the primary esophageal malignancy that obscures increased FDG uptake in the regional nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/25\">",
"     25",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    low sensitivity for small involved lymph nodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Locoregional staging with EUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasound (EUS) uses a high frequency ultrasound transducer to provide detailed images of esophageal masses and their relationship with the five-layered structure of the esophageal wall. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24597?source=see_link\">",
"     \"Endoscopic ultrasound: Anatomy of the normal esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EUS is the most accurate technique for locoregional staging of invasive esophageal cancer, with an overall accuracy of EUS for tumor (T) and node (N) staging of 80 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Staging accuracy may be less reliable in patients with early superficial esophageal cancer than in those with more advanced esophageal cancer. In a meta-analysis, the accuracy of EUS in the evaluation of superficial (T1, (",
"    <a class=\"graphic graphic_table graphicRef58757 \" href=\"UTD.htm?4/35/4668\">",
"     table 5",
"    </a>",
"    )) lesions was 67 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, for most patients, EUS provides the most accurate estimate of locoregional disease stage and assists with management decisions. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients who appear to have superficial disease that does not invade the muscularis mucosa and who are without evidence of suspicious lymph nodes may be amenable to nonsurgical therapy (eg, endoscopic mucosal resection). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20426?source=see_link\">",
"       \"Management of superficial esophageal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The demonstration of clinically suspicious lymph nodes by EUS may support the selection of induction chemoradiotherapy over surgery alone, particularly in a patient who appears to have T2 disease (",
"      <a class=\"graphic graphic_table graphicRef58757 \" href=\"UTD.htm?4/35/4668\">",
"       table 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link\">",
"       \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, EUS consistently provides better regional TNM tumor staging than CT, MRI, or PET scanning, particularly in detecting lymph node involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/23,31,32\">",
"     23,31,32",
"    </a>",
"    ]. The addition of fine needle aspiration to EUS increases the accuracy of the diagnosis of lymph node involvement. The role of EUS in staging of esophageal cancer, including those studies comparing the accuracy of EUS to CT, MRI, and PET is discussed in another topic review. What follows is a brief overview of EUS findings in patients with esophageal cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27208?source=see_link\">",
"     \"Endoscopic ultrasound in esophageal carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633030943\">",
"    <span class=\"h3\">",
"     T stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of EUS for T staging is 80 to 90 percent, although it may be less for stenotic tumors (see below). If the EUS identifies only mucosal (T1) disease, endoscopic mucosal resection is usually the next step to remove the tumor and precisely define the depth of invasion. The pathology result from the endoscopic mucosal resection (particularly the presence or absence of lymphovascular invasion) can then be used to guide therapeutic decisions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20426?source=see_link\">",
"     \"Management of superficial esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27208?source=see_link&amp;anchor=H4#H4\">",
"     \"Endoscopic ultrasound in esophageal carcinoma\", section on 'EUS for T staging of superficial tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    T2, T3, and T4 tumors are readily seen on endoscopy and EUS. They appear as strictures, ulcerations, or an exophytic masses (",
"    <a class=\"graphic graphic_picture graphicRef55542 \" href=\"UTD.htm?4/43/4799\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef78958 \" href=\"UTD.htm?9/15/9471\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    T2 tumors involve the muscularis propria but do not have transmural invasion through the esophageal wall. They appear as irregular hypoechoic masses involving the esophageal wall on EUS, leaving the muscularis intact as evidenced by a smooth contour of the mass and muscularis propria.",
"   </p>",
"   <p>",
"    T3 and T4 tumors are extraesophageal. Masses that extend into the adventitia are stage T3. T4 masses have invaded through the muscularis propria and adventitia to involve mediastinal structures such as the pericardium, aorta, bronchus, or pleura. EUS identifies T4 lesions by demonstrating tumor invasion into mediastinal structures.",
"   </p>",
"   <p>",
"    The presence of an irregular outer border suggests invasion through the wall of the esophagus. Measurement of maximal thickness of the esophageal mass can also predict extraesophageal extension. In one report, for example, T3-T4 tumors were significantly thicker than T1-T2 tumors (16 versus 8.2 mm) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/33\">",
"     33",
"    </a>",
"    ]. The thickness of the tumor was a more accurate predictor of staging (which was determined by esophageal resection) than disruption of the muscularis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17678943\">",
"    <span class=\"h4\">",
"     Stenotic tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A caveat for EUS staging of esophageal wall penetration (T-staging) is that the instrument cannot traverse a tumor-induced stenosis (which occurs in about 30 percent of cases). In these settings, EUS may understage the tumor, since the entire lesion and the celiac axis are not seen. It is controversial as to whether to dilate the esophagus for the purpose of a staging examination, since perforations have occurred. An alternative is to use miniature EUS probes, which are passed through the biopsy channel of an endoscope. However, these devices only provide a partial solution to the problem because of the limited depth of penetration (approximately 3 cm) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27208?source=see_link&amp;anchor=H5#H5\">",
"     \"Endoscopic ultrasound in esophageal carcinoma\", section on 'EUS for staging advanced tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633030954\">",
"    <span class=\"h3\">",
"     Regional nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS achieves nodal staging of esophageal cancer by imaging characteristics and by enabling fine needle aspiration biopsy (FNAB). Malignant lymph nodes appear as large (&gt;1 cm), rounded, hypoechoic structures with discrete borders that are often directly adjacent to an esophageal mass:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EUS has an accuracy of 80 percent for detecting disease spread to the cervical paraesophageal, right recurrent laryngeal, left paratracheal, upper and lower paraesophageal, infraaortic, infracarinal, and lower posterior mediastinal regions. Its sensitivity is highest for cervical and upper thoracic paraesophageal, infracarinal, left paratracheal, and recurrent laryngeal nodes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27208?source=see_link&amp;anchor=H7#H7\">",
"       \"Endoscopic ultrasound in esophageal carcinoma\", section on 'EUS for preoperative lymph node staging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The accuracy of EUS regional node staging can be further increased when nodes are aspirated, but this can only be performed in nodes that are accessible and in which the primary tumor is not in the pathway of the aspiration needle. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27208?source=see_link&amp;anchor=H8#H8\">",
"       \"Endoscopic ultrasound in esophageal carcinoma\", section on 'Endoscopic ultrasound-guided fine-needle aspiration biopsy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The finding of a malignant node in the celiac area remote from the primary tumor (ie, for SCCs or for lesions in the upper or middle thoracic esophagus, (",
"    <a class=\"graphic graphic_figure graphicRef76958 \" href=\"UTD.htm?4/36/4678\">",
"     figure 1",
"    </a>",
"    )) was previously considered to be a sign of unresectability and staged as M1a metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/14\">",
"     14",
"    </a>",
"    ]. Celiac nodal metastases are scored as regional nodal disease in the new 2010 edition of the TNM staging system, regardless of the primary tumor location or histology [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/4\">",
"     4",
"    </a>",
"    ]. Nevertheless, prognosis is poor in such cases, even if the primary tumor is located in the distal esophagus or EGJ [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'TNM staging criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     EUS restaging after neoadjuvant chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS has also been used to restage patients who have undergone preoperative chemotherapy or chemoradiotherapy. However, it is much less accurate in this setting (",
"    <a class=\"graphic graphic_table graphicRef64046 \" href=\"UTD.htm?21/7/21627\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/36-43\">",
"     36-43",
"    </a>",
"    ]. As an example, in one report, EUS correctly predicted a complete response to chemoradiotherapy (ie, no tumor in the surgical specimen) in only 3 of 17 patients (17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even a negative EUS and EUS-guided biopsy is an inadequate predictor of a pathologic complete response at the time of surgery. In one report, 69 percent of the 118 patients who had no tumor in the endoscopic biopsies had residual tumor in the surgical specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/37\">",
"     37",
"    </a>",
"    ]. Another prospective study of 80 patients with localized esophageal cancer found that endoscopy, rebiopsy and EUS were inadequate to evaluate response after chemoradiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data suggest that different techniques are needed to predict response of locoregional disease to preoperative therapy. Measuring the change in maximal cross-sectional area pre- and post-chemoradiotherapy may be a more useful measure to assess the response of esophageal cancer to preoperative chemoradiation, but this is not yet a standard approach [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Evaluation for distant metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common sites of distant metastases in patients with esophageal cancer are the liver, lungs, bone, and adrenal glands [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/47\">",
"     47",
"    </a>",
"    ]. Adenocarcinomas most frequently metastasize to intraabdominal sites (liver, peritoneum), while metastases from SCCs are usually intrathoracic. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Regional lymph nodes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    M staging is carried out with systemic imaging (CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PET scanning), EUS, and diagnostic laparoscopy. While relatively inexpensive, CT is limited in its ability to identify locally advanced (T4, (",
"    <a class=\"graphic graphic_table graphicRef58757 \" href=\"UTD.htm?4/35/4668\">",
"     table 5",
"    </a>",
"    )) disease, and subclinical distant metastatic disease, particularly in the peritoneal cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/23,48\">",
"     23,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EUS can visualize liver metastases &lt;1 cm or malignant ascites; EUS-guided FNA can provide a tissue diagnosis for either of these findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=see_link\">",
"     \"Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnostic laparoscopy is particularly helpful for evaluating the liver and intraabdominal space in patients with distal esophageal or esophagogastric junction (EGJ) cancers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     PET scans",
"    </span>",
"    &nbsp;&mdash;&nbsp;PET scanning with 18F-fluorodeoxyglucose is a noninvasive staging modality that is more sensitive than CT or EUS for the detection of distant metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/23,31,49-53\">",
"     23,31,49-53",
"    </a>",
"    ]. Small studies report a management change in up to 20 percent of patients because of the addition of PET to the preoperative assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/31,47,49-51,54,55\">",
"     31,47,49-51,54,55",
"    </a>",
"    ]. This reduces the number of patients who are found to have distant metastases at the time of surgical exploration (and who therefore underwent needless surgery).",
"   </p>",
"   <p>",
"    The benefit of PET in the preoperative locoregional staging evaluation was confirmed in a randomized trial conducted by the American College of Surgeons Oncology Group, in which 262 patients with nonmetastatic potentially resectable esophageal cancer after CT of the chest and abdomen were randomly assigned to PET or no PET [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/52\">",
"     52",
"    </a>",
"    ]. With the caveat that 22 percent of eligible patients did not undergo esophagectomy for a variety of reasons, PET after standard clinical staging identified biopsy-confirmed distant metastatic disease in nine patients (5 percent of cases) and unconfirmed evidence of M1 disease (which was accepted by the surgeon as evidence of metastases without biopsy confirmation) in 18 others. There were seven false-positive PET scans and seven false-negative cases where exploration after a negative PET revealed metastatic disease in the liver, peritoneum, or lung. An important limitation of the trial was that integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    was not used.",
"   </p>",
"   <p>",
"    Nevertheless, the improved sensitivity of PET for the detection of metastatic disease makes it",
"    <strong>",
"     potentially",
"    </strong>",
"    the most cost-effective method of identifying patients with occult metastases, for whom curative therapy should not be pursued [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/25,48,54,56\">",
"     25,48,54,56",
"    </a>",
"    ]. This hypothesis was directly tested in a decision analysis model that compared several different staging strategies and was conducted in parallel with a prospective clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/48,56\">",
"     48,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When compared with the staging strategy of CT plus",
"    <span class=\"nowrap\">",
"     EUS/FNA,",
"    </span>",
"    PET plus",
"    <span class=\"nowrap\">",
"     EUS/FNA",
"    </span>",
"    was slightly more expensive (by $4158 on average) and only associated with a one-month benefit in quality adjusted life years. Nevertheless, the marginal cost-effectiveness ratio of this strategy ($60,544 per QALY) compares favorably with other accepted medical treatments. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=see_link\">",
"     \"A short primer on cost-effectiveness analysis\"",
"    </a>",
"    .) The authors concluded that combined",
"    <span class=\"nowrap\">",
"     PET/EUS",
"    </span>",
"    represented the recommended preoperative staging procedures for esophageal cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Integrated PET/CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major drawback of PET scanning for the evaluation of the primary site and nodal metastases is its poor spatial resolution. This can make it difficult to localize the anatomic location of the FDG uptake.",
"   </p>",
"   <p>",
"    This limitation has been significantly reduced by the use of integrated PET-CT imaging, a technique in which both PET and CT are performed sequentially during a single visit on a hybrid",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scanner. The PET and CT images are then co-registered using fusion software, enabling the physiologic data obtained on PET to be localized according to the anatomic CT images.",
"   </p>",
"   <p>",
"    Few data are available to assess the contribution of integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    to the staging evaluation of esophageal cancer, and its role (compared to PET alone) is incompletely characterized [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Nevertheless, most institutions are now doing integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    rather than PET alone because of the better spatial resolution.",
"   </p>",
"   <p>",
"    Measurement of the SUV (standardized uptake value), which reflects the metabolic activity of the tumor, on",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    may also serve as a prognostic factor. In a meta-analysis of seven studies that evaluated the impact of SUV on overall survival, a high SUV predicted a worse survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/59\">",
"     59",
"    </a>",
"    ]. However, a large retrospective series, which was not included in the meta-analysis, did not find worse survival in patients with locally advanced esophageal cancer who had an initially high SUV [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/60\">",
"     60",
"    </a>",
"    ]. In fact, their results suggested a better response to preoperative chemoradiotherapy in this group. The value of FDG-PET as a predictive marker of response to neoadjuvant therapy remains uncertain, however [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A major issue is that the CT component of integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging has been performed in many institutions without the use of IV contrast material and in partial or complete expiration, precluding the optimal detection of small lung and liver metastases. Increasingly,",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is being carried out using IV contrast, but this practice is not widespread [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     PET restaging after initial induction therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another area in which integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    may be of clinical utility is in restaging after initial induction therapy, an approach that is increasingly being used in patients with locally advanced disease.",
"   </p>",
"   <p>",
"    Limited experience suggests that whole-body",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging detects distant metastases in approximately 8 percent of patients following induction chemoradiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/63\">",
"     63",
"    </a>",
"    ]. In many of these cases, the metastases have been located in sites (eg, skeletal muscle, subcutaneous soft tissue, brain, thyroid) that are not imaged well by conventional staging radiographic evaluation.",
"   </p>",
"   <p>",
"    In addition to detecting otherwise occult metastatic disease, post-induction therapy FDG PET provides information on metabolic response in the primary tumor that may be clinically useful in the selection of subsequent therapy. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early data from retrospective series suggest that postchemoradiotherapy FDG-PET scanning may serve to identify those patients for whom surgery might be avoided. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link&amp;anchor=H20504361#H20504361\">",
"       \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\", section on 'Utility of postinduction therapy PET scans'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other data suggest that responses observed on PET scans during induction chemotherapy has significant predictive and prognostic benefit. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39738?source=see_link&amp;anchor=H5353223#H5353223\">",
"       \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\", section on 'Use of PET and PET-CT during treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, PET-directed therapy for esophageal or EGJ cancer cannot yet be considered a standard approach for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The above data need to be confirmed and validated in prospective trials. An upcoming US cooperative group trial (CALGB 80803) will use the results of postinduction chemotherapy PET scan to determine the choice of the chemotherapy regimen during subsequent chemoradiotherapy, followed by surgery.",
"     </li>",
"     <li>",
"      The best way to measure metabolic response to induction chemotherapy or chemoradiotherapy in esophageal cancer has not been well established. The standard uptake value (SUV), a semiquantitative measure of FDG uptake, has low sensitivity and specificity [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Whether",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      outperforms CT or EUS for assessment of response to preoperative therapy is unclear; the available data are conflicting [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/39,65,66\">",
"       39,65,66",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Locoregional staging with EUS'",
"      </a>",
"      above.) Some series report accurate assessment of response to therapy and significant differences in prognosis according to the findings on a postchemoradiotherapy PET [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/67-73\">",
"       67-73",
"      </a>",
"      ], while others have found only a limited impact of PET in assessing response status (particularly complete versus small volume residual disease) and locoregional resectability [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/74-78\">",
"       74-78",
"      </a>",
"      ]. A major issue with",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      after induction therapy is the possibility of false-positive results due to treatment-related inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/69,77\">",
"       69,77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Until additional data is available, we order a postinduction therapy",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    no earlier than four weeks after the completion of induction therapy to assess for distant metastatic disease. If a new lesion is identified, a biopsy is performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Laparoscopy and thoracoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to limit aggressive treatment to patients with locally advanced disease, diagnostic laparoscopy is sometimes performed to detect occult intraperitoneal metastases in patients with distal esophageal and EGJ adenocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. Intraperitoneal metastases are notoriously difficult to diagnose noninvasively by either CT or PET.",
"   </p>",
"   <p>",
"    Thoracoscopic and laparoscopic staging procedures have also been examined for their potential to more accurately stage regional lymph nodes (particularly celiac and intrathoracic) as compared to EUS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. In a multi-institutional study conducted by the Cancer and Leukemia Group B, for example, noninvasive imaging (CT, MRI, EUS) incorrectly staged (either false negative lymph nodes or false positive metastatic disease as determined by",
"    <span class=\"nowrap\">",
"     thoracoscopy/laparoscopy)",
"    </span>",
"    in 50, 40, and 30 percent of patients, respectively, as assessed by thoracoscopic or laparoscopic staging [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/82\">",
"     82",
"    </a>",
"    ]. Positive lymph nodes were found in 43 patients and 16 of these cases were identified by",
"    <span class=\"nowrap\">",
"     thoracoscopy/laparoscopy",
"    </span>",
"    but not by imaging. Three patients had more advanced disease detected by laparoscopy. One had a T4 primary tumor detected by bronchoscopy, and two had second primary lung cancers and underwent no further nodal evaluation. The impact of better pretreatment nodal staging on treatment selection was not addressed. An important limitation of this study was that EUS was performed without FNA, thus limiting the accuracy of noninvasive imaging.",
"   </p>",
"   <p>",
"    Similar results were noted in another report of 26 patients, in whom laparoscopy and thoracoscopy appeared to be more accurate than EUS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/84\">",
"     84",
"    </a>",
"    ]. EUS suggested N0 disease in eight patients, while laparoscopy and thoracoscopy documented N1 disease in six of the eight. Laparoscopy and thoracoscopy also had the advantage of allowing evaluation of the thoracic and abdominal cavities for metastases. EUS revealed no distant metastases in any patient, but in four of 26 (15 percent) laparoscopy identified liver metastases.",
"   </p>",
"   <p>",
"    Taken together, these data support the view that invasive staging is more accurate than EUS or CT alone; however, no study has compared this approach with EUS plus PET scanning, which is superior to conventional imaging modalities for detecting distant metastases. As noted above, despite the lack of data, noninvasive staging with combined PET plus EUS-FNA has become a preferred staging algorithm based upon cost effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'PET scans'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The need for diagnostic laparoscopy for patients who appear to have potentially resectable distal esophageal and EGJ adenocarcinomas is controversial, and there is no consensus on this issue. While a few patients may avoid an unnecessary laparotomy and hospitalization, most patients will not have any abnormality found at time of laparoscopy. Whether the incidence of positive findings for these patients is sufficient to recommend its routine use remains controversial.",
"   </p>",
"   <p>",
"    Guidelines from the NCCN describe diagnostic laparoscopy as \"optional\" if there is no evidence of M1 disease, and tumor is at the EGJ [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/85\">",
"     85",
"    </a>",
"    ]. However, some clinicians advocate diagnostic laparoscopy for patients with adenocarcinomas arising within the intraabdominal portion of the esophagus or at the EGJ or if there is suspicion for intraperitoneal metastatic disease that cannot otherwise be confirmed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39738?source=see_link&amp;anchor=H3443822#H3443822\">",
"     \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\", section on 'Diagnostic laparoscopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34282?source=see_link\">",
"     \"Surgical oncologic principles for management of resectable esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another approach, laparoscopic ultrasound, may provide the benefits of both locoregional and intraperitoneal staging [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. In a study of 26 patients with gastric or esophageal cancers, primary tumor (T) and nodal (N) staging with laparoscopic ultrasound was comparable to results from EUS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/86\">",
"     86",
"    </a>",
"    ]. The accuracy of M staging for laparoscopic ultrasound was better than with laparoscopy alone or CT (89 versus 44 and 64 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative bronchoscopy with biopsy and brush cytology has been advocated by some (including the NCCN) as the last investigation in the staging workup for patients with locally advanced nonmetastatic tumors that are located at or above the level of the carina [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/85\">",
"     85",
"    </a>",
"    ]. In a study of 116 consecutive patients with potentially operable esophageal carcinoma, bronchoscopy was superior to CT and was the sole decisive procedure resulting in exclusion from surgery because of airway invasion in 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30106?source=see_link&amp;anchor=H5#H5\">",
"     \"Management of locally advanced unresectable esophageal cancer\", section on 'Bronchoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/17/9491?source=see_link\">",
"       \"Patient information: Esophageal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of an esophageal or esophagogastric junction (EGJ) cancer is usually established by endoscopic biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/5\">",
"       5",
"      </a>",
"      ]. Early cancers may appear as superficial plaques, nodules, or ulcerations (",
"      <a class=\"graphic graphic_picture graphicRef55091 \" href=\"UTD.htm?3/16/3343\">",
"       picture 1",
"      </a>",
"      ). Advanced lesions may appear as strictures (",
"      <a class=\"graphic graphic_picture graphicRef55542 \" href=\"UTD.htm?4/43/4799\">",
"       picture 2",
"      </a>",
"      ), ulcerated masses (",
"      <a class=\"graphic graphic_picture graphicRef78958 \" href=\"UTD.htm?9/15/9471\">",
"       picture 3",
"      </a>",
"      ), circumferential masses (",
"      <a class=\"graphic graphic_picture graphicRef67522 \" href=\"UTD.htm?43/25/44447\">",
"       picture 4",
"      </a>",
"      ), or large ulcerations. The endoscopic appearance of a large mucosal mass is frequently diagnostic of esophageal cancer. Biopsies confirm the diagnosis in more than 90 percent of cases (",
"      <a class=\"graphic graphic_picture graphicRef68324 \" href=\"UTD.htm?39/54/40807\">",
"       picture 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef63363 \" href=\"UTD.htm?37/60/38853\">",
"       picture 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The TNM staging system of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) for esophageal cancer is used universally [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/31\">",
"       31",
"      </a>",
"      ]. A major change between the 2002 and the 2010 editions was the development of separate stage groupings according to histology (",
"      <a class=\"graphic graphic_table graphicRef62895 \" href=\"UTD.htm?13/38/13934\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52078 \" href=\"UTD.htm?4/24/4494\">",
"       table 3",
"      </a>",
"      ). In addition, tumors at the EGJ and proximal 5 cm of the stomach that extend into the EGJ or esophagus as staged as esophageal cancers while all other tumors with an epicenter in the stomach &gt;5 cm from the EGJ, or those within 5 cm or the EGJ without extension into the esophagus are staged as gastric cancers. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'TNM staging criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the diagnosis of an esophageal cancer is established, staging usually begins with a CT scan to evaluate for the presence of metastatic disease. Patients without evidence of metastatic disease by CT undergo endoscopic ultrasonography (EUS), which uses a high frequency ultrasound transducer to provide detailed images of esophageal masses and their relationship with the five-layered structure of the esophageal wall. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Overview of the preoperative staging evaluation'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Integrated",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scans are useful to detect metastatic disease in patients who are otherwise believed to be surgical candidates after routine CT staging. However, suspicious PET findings should be confirmed before excluding a patient from surgical consideration. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Integrated PET/CT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of staging laparoscopy is controversial, and there is no consensus on this issue. While a few patients may avoid an unnecessary laparotomy and hospitalization, most patients will not have any abnormality found at laparoscopy.",
"      <br/>",
"      <br/>",
"      NCCN guidelines suggest that diagnostic laparoscopy is \"optional\" for patients with no evidence of metastatic disease and tumor location at the EGJ [",
"      <a class=\"abstract\" href=\"UTD.htm?7/45/7898/abstract/85\">",
"       85",
"      </a>",
"      ]. Other clinicians (including one of the authors [MG]) advocate diagnostic laparoscopy for patients with adenocarcinomas arising within the intraabdominal portion of the esophagus (",
"      <a class=\"graphic graphic_table graphicRef68416 \" href=\"UTD.htm?28/10/28843\">",
"       table 4",
"      </a>",
"      ) or at the EGJ, or if there is suspicion for intraperitoneal metastatic disease that cannot otherwise be confirmed. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Laparoscopy and thoracoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preoperative bronchoscopy with biopsy and brush cytology is indicated for patients with locally advanced nonmetastatic tumors that are located at or above the level of the carina. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Bronchoscopy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/1\">",
"      Younes M, Henson DE, Ertan A, Miller CC. Incidence and survival trends of esophageal carcinoma in the United States: racial and gender differences by histological type. Scand J Gastroenterol 2002; 37:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/2\">",
"      Daly JM, Karnell LH, Menck HR. National Cancer Data Base report on esophageal carcinoma. Cancer 1996; 78:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/3\">",
"      Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003; 95:1404.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.103.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/5\">",
"      Lightdale CJ. Esophageal cancer. American College of Gastroenterology. Am J Gastroenterol 1999; 94:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/6\">",
"      Yendamuri S, Swisher SG, Correa AM, et al. Esophageal tumor length is independently associated with long-term survival. Cancer 2009; 115:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/7\">",
"      Graham DY, Schwartz JT, Cain GD, Gyorkey F. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology 1982; 82:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/8\">",
"      Acosta MM, Boyce HW Jr. Chromoendoscopy--where is it useful? J Clin Gastroenterol 1998; 27:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/9\">",
"      Rice TW, Rusch VW, Ishwaran H, et al. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer 2010; 116:3763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/10\">",
"      R&uuml;diger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000; 232:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/11\">",
"      Rizk NP, Venkatraman E, Bains MS, et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol 2007; 25:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/12\">",
"      Barbour AP, Jones M, Gonen M, et al. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Ann Surg Oncol 2008; 15:2894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/13\">",
"      Nomura M, Shitara K, Kodaira T, et al. Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012; 82:946.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 6th, Greene FL, Page DL, Fleming ID, et al (Eds), Springer-Verlag, New York 2002. p.91.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/15\">",
"      Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005; 103:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/16\">",
"      Rohatgi P, Swisher SG, Correa AM, et al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 2005; 104:2365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/17\">",
"      Lin CS, Chang SC, Wei YH, et al. Prognostic variables in thoracic esophageal squamous cell carcinoma. Ann Thorac Surg 2009; 87:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/18\">",
"      Peyre CG, Hagen JA, DeMeester SR, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 2008; 248:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/19\">",
"      Zhang HL, Chen LQ, Liu RL, et al. The number of lymph node metastases influences survival and International Union Against Cancer tumor-node-metastasis classification for esophageal squamous cell carcinoma. Dis Esophagus 2010; 23:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/20\">",
"      Rizk N, Venkatraman E, Park B, et al. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg 2006; 132:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/21\">",
"      Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 2008; 247:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/22\">",
"      Bogoevski D, Onken F, Koenig A, et al. Is it time for a new TNM classification in esophageal carcinoma? Ann Surg 2008; 247:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/23\">",
"      van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 2008; 98:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/24\">",
"      Lowe VJ, Booya F, Fletcher JG, et al. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol 2005; 7:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/25\">",
"      Rice TW. Clinical staging of esophageal carcinoma. CT, EUS, and PET. Chest Surg Clin N Am 2000; 10:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/26\">",
"      R&ouml;sch T. Endosonographic staging of esophageal cancer: a review of literature results. Gastrointest Endosc Clin N Am 1995; 5:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/27\">",
"      Chandawarkar RY, Kakegawa T, Fujita H, et al. Endosonography for preoperative staging of specific nodal groups associated with esophageal cancer. World J Surg 1996; 20:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/28\">",
"      Young PE, Gentry AB, Acosta RD, et al. Endoscopic ultrasound does not accurately stage early adenocarcinoma or high-grade dysplasia of the esophagus. Clin Gastroenterol Hepatol 2010; 8:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/29\">",
"      Vazquez-Sequeiros E, Wiersema MJ, Clain JE, et al. Impact of lymph node staging on therapy of esophageal carcinoma. Gastroenterology 2003; 125:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/30\">",
"      Rice TW, Blackstone EH, Adelstein DJ, et al. Role of clinically determined depth of tumor invasion in the treatment of esophageal carcinoma. J Thorac Cardiovasc Surg 2003; 125:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/31\">",
"      Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000; 18:3202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/32\">",
"      Keswani RN, Early DS, Edmundowicz SA, et al. Routine positron emission tomography does not alter nodal staging in patients undergoing EUS-guided FNA for esophageal cancer. Gastrointest Endosc 2009; 69:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/33\">",
"      Brugge WR, Lee MJ, Carey RW, Mathisen DJ. Endoscopic ultrasound staging criteria for esophageal cancer. Gastrointest Endosc 1997; 45:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/34\">",
"      H&uuml;nerbein M, Ghadimi BM, Haensch W, Schlag PM. Transendoscopic ultrasound of esophageal and gastric cancer using miniaturized ultrasound catheter probes. Gastrointest Endosc 1998; 48:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/35\">",
"      Boonstra JJ, Koppert LB, Wijnhoven BP, et al. Chemotherapy followed by surgery in patients with carcinoma of the distal esophagus and celiac lymph node involvement. J Surg Oncol 2009; 100:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/36\">",
"      Zuccaro G Jr, Rice TW, Goldblum J, et al. Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer. Am J Gastroenterol 1999; 94:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/37\">",
"      Sarkaria IS, Rizk NP, Bains MS, et al. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg 2009; 249:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/38\">",
"      Schneider PM, Metzger R, Schaefer H, et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg 2008; 248:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/39\">",
"      Westerterp M, van Westreenen HL, Reitsma JB, et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy--systematic review. Radiology 2005; 236:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/40\">",
"      Laterza E, de Manzoni G, Guglielmi A, et al. Endoscopic ultrasonography in the staging of esophageal carcinoma after preoperative radiotherapy and chemotherapy. Ann Thorac Surg 1999; 67:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/41\">",
"      Bowrey DJ, Clark GW, Roberts SA, et al. Serial endoscopic ultrasound in the assessment of response to chemoradiotherapy for carcinoma of the esophagus. J Gastrointest Surg 1999; 3:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/42\">",
"      Giovannini M, Seitz JF, Thomas P, et al. Endoscopic ultrasonography for assessment of the response to combined radiation therapy and chemotherapy in patients with esophageal cancer. Endoscopy 1997; 29:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/43\">",
"      Kalha I, Kaw M, Fukami N, et al. The accuracy of endoscopic ultrasound for restaging esophageal carcinoma after chemoradiation therapy. Cancer 2004; 101:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/44\">",
"      Isenberg G, Chak A, Canto MI, et al. Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation. Gastrointest Endosc 1998; 48:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/45\">",
"      Chak A, Canto MI, Cooper GS, et al. Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients. Cancer 2000; 88:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/46\">",
"      Willis J, Cooper GS, Isenberg G, et al. Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma. Gastrointest Endosc 2002; 55:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/47\">",
"      Meltzer CC, Luketich JD, Friedman D, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med 2000; 25:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/48\">",
"      Romagnuolo J, Scott J, Hawes RH, et al. Helical CT versus EUS with fine needle aspiration for celiac nodal assessment in patients with esophageal cancer. Gastrointest Endosc 2002; 55:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/49\">",
"      Flanagan FL, Dehdashti F, Siegel BA, et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997; 168:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/50\">",
"      Block MI, Patterson GA, Sundaresan RS, et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997; 64:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/51\">",
"      Luketich JD, Friedman DM, Weigel TL, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999; 68:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/52\">",
"      Meyers BF, Downey RJ, Decker PA, et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg 2007; 133:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/53\">",
"      R&auml;s&auml;nen JV, Sihvo EI, Knuuti MJ, et al. Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 2003; 10:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/54\">",
"      van Westreenen HL, Heeren PA, van Dullemen HM, et al. Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. J Gastrointest Surg 2005; 9:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/55\">",
"      Wren SM, Stijns P, Srinivas S. Positron emission tomography in the initial staging of esophageal cancer. Arch Surg 2002; 137:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/56\">",
"      Wallace MB, Nietert PJ, Earle C, et al. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg 2002; 74:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/57\">",
"      Bruzzi JF, Truong MT, Macapinlac H, et al. Integrated CT-PET imaging of esophageal cancer: unexpected and unusual distribution of distant organ metastases. Curr Probl Diagn Radiol 2007; 36:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/58\">",
"      Erasmus JJ, Munden RF. The role of integrated computed tomography positron-emission tomography in esophageal cancer: staging and assessment of therapeutic response. Semin Radiat Oncol 2007; 17:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/59\">",
"      Pan L, Gu P, Huang G, et al. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2009; 21:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/60\">",
"      Rizk NP, Tang L, Adusumilli PS, et al. Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol 2009; 4:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/61\">",
"      Kwee RM. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. Radiology 2010; 254:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/62\">",
"      Mawlawi O, Erasmus JJ, Munden RF, et al. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. AJR Am J Roentgenol 2006; 186:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/63\">",
"      Bruzzi JF, Swisher SG, Truong MT, et al. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 2007; 109:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/64\">",
"      Roedl JB, Colen RR, Holalkere NS, et al. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol 2008; 89:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/65\">",
"      Cerfolio RJ, Bryant AS, Ohja B, et al. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 2005; 129:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/66\">",
"      Jones DR, Parker LA Jr, Detterbeck FC, Egan TM. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 1999; 85:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/67\">",
"      Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002; 13:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/68\">",
"      Kato H, Kuwano H, Nakajima M, et al. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 2002; 184:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/69\">",
"      Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19:3058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/70\">",
"      Song SY, Kim JH, Ryu JS, et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 2005; 63:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/71\">",
"      Levine EA, Farmer MR, Clark P, et al. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 2006; 243:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/72\">",
"      Patnana SV, Murthy SB, Xiao L, et al. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer 2010; 116:4487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/73\">",
"      Monjazeb AM, Riedlinger G, Aklilu M, et al. Outcomes of patients with esophageal cancer staged with [&sup1;F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol 2010; 28:4714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/74\">",
"      Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003; 21:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/75\">",
"      Vallb&ouml;hmer D, H&ouml;lscher AH, Dietlein M, et al. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2009; 250:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/76\">",
"      McLoughlin JM, Melis M, Siegel EM, et al. Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer? J Am Coll Surg 2008; 206:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/77\">",
"      Wieder HA, Br&uuml;cher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004; 22:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/78\">",
"      Konski AA, Cheng JD, Goldberg M, et al. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. Int J Radiat Oncol Biol Phys 2007; 69:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/79\">",
"      Kaushik N, Khalid A, Brody D, et al. Endoscopic ultrasound compared with laparoscopy for staging esophageal cancer. Ann Thorac Surg 2007; 83:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/80\">",
"      Yau KK, Siu WT, Cheung HY, et al. Immediate preoperative laparoscopic staging for squamous cell carcinoma of the esophagus. Surg Endosc 2006; 20:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/81\">",
"      Bryan RT, Cruickshank NR, Needham SJ, et al. Laparoscopic peritoneal lavage in staging gastric and oesophageal cancer. Eur J Surg Oncol 2001; 27:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/82\">",
"      Krasna MJ, Reed CE, Nedzwiecki D, et al. CALGB 9380: a prospective trial of the feasibility of thoracoscopy/laparoscopy in staging esophageal cancer. Ann Thorac Surg 2001; 71:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/83\">",
"      Krasna MJ, Jiao X, Mao YS, et al. Thoracoscopy/laparoscopy in the staging of esophageal cancer: Maryland experience. Surg Laparosc Endosc Percutan Tech 2002; 12:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/84\">",
"      Luketich JD, Schauer P, Landreneau R, et al. Minimally invasive surgical staging is superior to endoscopic ultrasound in detecting lymph node metastases in esophageal cancer. J Thorac Cardiovasc Surg 1997; 114:817.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/86\">",
"      Finch MD, John TG, Garden OJ, et al. Laparoscopic ultrasonography for staging gastroesophageal cancer. Surgery 1997; 121:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/87\">",
"      Wakelin SJ, Deans C, Crofts TJ, et al. A comparison of computerised tomography, laparoscopic ultrasound and endoscopic ultrasound in the preoperative staging of oesophago-gastric carcinoma. Eur J Radiol 2002; 41:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/45/7898/abstract/88\">",
"      Riedel M, Hauck RW, Stein HJ, et al. Preoperative bronchoscopic assessment of airway invasion by esophageal cancer: a prospective study. Chest 1998; 113:687.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2502 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-AD1D6AEAC5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_45_7898=[""].join("\n");
var outline_f7_45_7898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - In vivo staining",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREOPERATIVE STAGING EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TNM staging criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Regional lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Overview of the preoperative staging evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Locoregional staging with EUS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H633030943\">",
"      - T stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17678943\">",
"      Stenotic tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H633030954\">",
"      - Regional nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - EUS restaging after neoadjuvant chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Evaluation for distant metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - PET scans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Integrated PET/CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - PET restaging after initial induction therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Laparoscopy and thoracoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2502\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2502|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/36/4678\" title=\"figure 1\">",
"      AJCC diagram of the esophageal anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2502|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/16/3343\" title=\"picture 1\">",
"      Early esoph ca endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/43/4799\" title=\"picture 2\">",
"      Malignant stricture EGD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/15/9471\" title=\"picture 3\">",
"      Ulcerating esoph CA EGD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/25/44447\" title=\"picture 4\">",
"      Cicumferential ES CA EGD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/54/40807\" title=\"picture 5\">",
"      Esoph CA squamous Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/60/38853\" title=\"picture 6\">",
"      Esoph adenocarcinoma Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2502|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/11/6331\" title=\"table 1\">",
"      Epidemiology of esophageal CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/38/13934\" title=\"table 2\">",
"      TNM staging esoph SCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/24/4494\" title=\"table 3\">",
"      TNM staging esoph adenoCA including EGJ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/10/28843\" title=\"table 4\">",
"      Esoph CA site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/35/4668\" title=\"table 5\">",
"      T stage esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/7/21627\" title=\"table 6\">",
"      Accuracy EUS post chemo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=related_link\">",
"      A short primer on cost-effectiveness analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44202?source=related_link\">",
"      Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=related_link\">",
"      Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27208?source=related_link\">",
"      Endoscopic ultrasound in esophageal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=related_link\">",
"      Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24597?source=related_link\">",
"      Endoscopic ultrasound: Anatomy of the normal esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=related_link\">",
"      Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30106?source=related_link\">",
"      Management of locally advanced unresectable esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20426?source=related_link\">",
"      Management of superficial esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39738?source=related_link\">",
"      Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/17/9491?source=related_link\">",
"      Patient information: Esophageal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=related_link\">",
"      Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34282?source=related_link\">",
"      Surgical oncologic principles for management of resectable esophageal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_45_7899="GI bleeding after TIPS";
var content_f7_45_7899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of gastrointestinal bleeding after TIPS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Continued variceal hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Persistent gastric varices",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Associated with spontaneous splenorenal collaterals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Associated with massive splenomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Stent dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Retractions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Kinking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Displacement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemobilia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TIPS: transjugular intrahepatic portosystemic shunt.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Sanyal AJ. Semin Gastrointest Dis 1997; 8:188.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_45_7899=[""].join("\n");
var outline_f7_45_7899=null;
var title_f7_45_7900="Cutan react multitarg TKI";
var content_f7_45_7900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cutaneous reactions associated with small molecule tyrosine kinase (TK) inhibitors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup width=\"90%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drugs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reported cutaneous effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imatinib",
"       </td>",
"       <td>",
"        Edema, hair repigmentation, hypopigmentation, lichenoid eruption, morbilliform eruption, photosensitization, exacerbation of psoriasis, pruritus, Stevens-Johnson syndrome, xerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dasatinib",
"       </td>",
"       <td>",
"        Acne, HFSR, alopecia, hyperhidrosis, morbilliform eruption, pruritus, urticaria, xerosis, stomatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nilotinib",
"       </td>",
"       <td>",
"        Alopecia, morbilliform eruption, pruritus, xerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bosutinib",
"       </td>",
"       <td>",
"        Acne, allergic dermatitis, erythema, folliculitis, maculopapular rash, pruritic rash, skin exfoliation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sorafenib",
"       </td>",
"       <td>",
"        HFSR, edema, flushing, stomatitis (mucositis), subungual splinter hemorrhages, squamous hyperproliferation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sunitinib",
"       </td>",
"       <td>",
"        HFSR, bullous dermatosis, edema, hair depigmentation, yellow skin discoloration, stomatitis (mucositis), periungual erythema, subungual splinter hemorrhages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pazopanib",
"       </td>",
"       <td>",
"        Change in hair color, skin hypopigmentation, alopecia, rash, palmar-plantar erythrodysesthesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vandetanib",
"       </td>",
"       <td>",
"        Rash, acne, dry skin, dermatitis, pruritus, photosensitivity, HFSR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Regorafenib",
"       </td>",
"       <td>",
"        HFSR, rash, desquamation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ponatinib",
"       </td>",
"       <td>",
"        Rash, acneiform eruption, dry skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cabozantinib",
"       </td>",
"       <td>",
"        HFSR, stomatitis, dry mouth",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HFSR: hand-foot skin reaction.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_45_7900=[""].join("\n");
var outline_f7_45_7900=null;
var title_f7_45_7901="Static tests adrenal insufficiency";
var content_f7_45_7901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal values for blood and urinary steroid hormone levels (unstimulated)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Normal values*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Serum cortisol&bull;",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        micrograms/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Premature infants (day 4)",
"       </td>",
"       <td>",
"        26 to 28 weeks",
"       </td>",
"       <td colspan=\"2\">",
"        1&nbsp;to 11 (6.0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        31&nbsp;to 35 weeks",
"       </td>",
"       <td colspan=\"2\">",
"        2.5&nbsp;to 9.1 (6.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Full-term infants",
"       </td>",
"       <td>",
"        3 days",
"       </td>",
"       <td colspan=\"2\">",
"        1.7&nbsp;to 14 (6.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7 days",
"       </td>",
"       <td colspan=\"2\">",
"        2&nbsp;to 11 (4.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        31 days&nbsp;to 11 months",
"       </td>",
"       <td colspan=\"2\">",
"        2.8&nbsp;to 23 (9.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Children",
"       </td>",
"       <td>",
"        12 months&nbsp;to 15 years (8:00 AM)",
"       </td>",
"       <td colspan=\"2\">",
"        3&nbsp;to 21 (9.8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Adults",
"       </td>",
"       <td>",
"        8:00 AM",
"       </td>",
"       <td colspan=\"2\">",
"        8&nbsp;to 19 (11.0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4:00 PM",
"       </td>",
"       <td colspan=\"2\">",
"        4&nbsp;to 11 (5.9)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Urinary 17-hydroxycorticosteroids (17-OHCS)",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        mg/g creatinine",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        mg/24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Prepubertal children",
"       </td>",
"       <td>",
"        1&nbsp;to 4 years",
"       </td>",
"       <td>",
"        1.7&nbsp;to 6.4 (4.1)",
"       </td>",
"       <td>",
"        0.2&nbsp;to 2.5 (0.8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5&nbsp;to 9 years",
"       </td>",
"       <td>",
"        2.2&nbsp;to 6.0 (3.5)",
"       </td>",
"       <td>",
"        0.5&nbsp;to 2.5 (1.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Pubertal children and adults",
"       </td>",
"       <td>",
"        Male",
"       </td>",
"       <td>",
"        2.4&nbsp;to 4.3 (3.2)",
"       </td>",
"       <td>",
"        3&nbsp;to 10 (6.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female",
"       </td>",
"       <td>",
"        1.6&nbsp;to 3.6 (2.3)",
"       </td>",
"       <td>",
"        2&nbsp;to 6 (2.8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Urinary free cortisol",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        micrograms/g creatinine",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        micrograms/24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prepubertal children",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        7&nbsp;to 25 (15)",
"       </td>",
"       <td>",
"        3&nbsp;to 9 (5.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Adults",
"       </td>",
"       <td>",
"        Male",
"       </td>",
"       <td>",
"        7&nbsp;to 45 (21)",
"       </td>",
"       <td>",
"        11&nbsp;to 84 (40)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female",
"       </td>",
"       <td>",
"        9&nbsp;to 32 (19)",
"       </td>",
"       <td>",
"        10&nbsp;to 34 (20)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy",
"       </td>",
"       <td>",
"        14&nbsp;to 59 (38)",
"       </td>",
"       <td>",
"        16&nbsp;to 60 (47)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Normal ranges and means (in parentheses) are based on reference ranges from Esoterix Laboratories, Calabasas Hills, California, and are used with permission. In other laboratories, plasma rather than serum cortisol may be measured, but the reference ranges are similar.",
"     <br>",
"      &bull; Stress (physiological or psychological) may cause elevation of cortisol levels above the reference range.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_45_7901=[""].join("\n");
var outline_f7_45_7901=null;
var title_f7_45_7902="Exercise in HF";
var content_f7_45_7902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Impaired hemodynamic response to exercise in HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 227px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peak VO2 achieved with exercise in normal subjects and those with chronic heart failure (HF) in relation to peak leg blood flow and cardiac output (CO). These parameters were linearly related in both groups, an expected finding since peak VO2 is determined in part by tissue perfusion. However, when compared to normals, patients with HF had lower levels of oxygen consumption, leg blood flow, and cardiac output.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Sullivan MJ, Knight JD, Higginbotham MB, Cobb FR. Circulation 1989; 80:769.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_45_7902=[""].join("\n");
var outline_f7_45_7902=null;
var title_f7_45_7903="Superior sulcus CT";
var content_f7_45_7903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superior sulcus tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan confirms the tumor and demonstrates chest wall invasion with partial rib destruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_45_7903=[""].join("\n");
var outline_f7_45_7903=null;
        